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Selective disruption of protein-protein interactions by small molecules is important 
for probing the structure and dynamic aspects of the cellular network. It can also provide 
new therapeutic targets. -Catenin of the canonical Wnt signaling pathway uses the same 
positively charged groove to bind with T-cell factor (Tcf), cadherin, and adenomatous 
polyposis Coli (APC). The extravagant formation of -catenin/Tcf interactions drives the 
initiation and progression of many cancers and fibroses, while -catenin/cadherin and -
catenin/APC interactions are essential for cell–cell adhesion and -catenin degradation. In 
this study, a selective binding site that can differentiate -catenin/Tcf, -catenin/cadherin 
and -catenin/APC interactions was identified by alanine scanning and biochemical assays.  
In Chapter 2, a new peptidomimetic strategy was used to design selective small-
molecule inhibitors for -catenin/Tcf interactions. A potent inhibitor was discovered to 
bind with -catenin and completely disrupt -catenin/Tcf interactions. It also exhibits dual 
selectivity for -catenin/Tcf over -catenin/cadherin and -catenin/APC interactions in 
both biochemical and cell-based assays. The study provides a proof of concept for 
designing selective inhibitors of -catenin/Tcf interactions. 
To develop a more drug-like compound, Chapter 3 focused on the modification of 
the inhibitors discovered in Chapter 2. The replacement of the peptide bond with a benzene 
ring brought up an interesting off-target outcome.  
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Each year in the United States, almost 150,000 patients are diagnosed with 
colorectal cancer, causing more than 55,000 deaths.1 Current therapy for colon cancer 
includes rarely curative surgical resection and traditional cytotoxic agents (chemotherapy), 
which also have very limited effects.2 Thus, it is important to develop new treatments 
taking the pathogenic molecular lesions into consideration. 
 
1.1 History of Wnt Signaling Pathway 
The Wnt signaling pathway was discovered over 30 years ago, but it can be traced 
to as early as the 1930s when mouse models of cancer and oncogenic retroviruses were 
studied.3 In 1936, Bittner and Korteweg separately reported that some laboratory mice are 
more prone to acquire breast cancer, and the disease is often transmitted to their off-springs 
through milk.4-5 This tumor-generating factor in the milk was not isolated until 1962 and 
was discovered to be a retrovirus—Mouse Mammary Tumor Virus (MMTV).6 The studies 
of oncogenic retroviruses led to the discovery of viral oncogenes such as Src, Myc and 
Ras.7 From the 1980s to the 1990s, numerous new discoveries were made to elucidate the 
relationship between these proto-oncogenes and cancer. A timeline for the history of int1, 
wingless genes and some components of the Wnt signaling pathway is shown in Table 1.1.   
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Table 1.1. Timeline of the discovery of the int1 and wnt genes. 
Year Event Authors 
1976 Wingless gene was identified. Sharma and Chopra8 
1980 Segment polarity genes were defined (Wingless, 
Armadillo, and Arrow). 
Nusslein-Volhard and 
Wieschaus9 
1982 Int1 gene was identified. Nusse and Varmus10 
1984 Structure and sequence of the int1 gene were 
disclosed. 
Van Ooyen and Nusse11 
1984 Int2 was discovered. Dickson et al.12 
1985 Proto-oncogenes were discovered. Bishop and Varmus13 
1985 cDNA of the int1 gene was elucidated-no 
homology with other genes at that time. 
Fung et al. 14 
1985 Human int1 is 99% identical to that of the mouse 
homolog. 
Van Ooyen et al.15 
1986 Overexpression of int1 rarely leads to the 
formation of cells that can turn into tumor. 
Brown et al.16 
1987 Int1 was found close to wingless and played a role 
in segmentation. 
Rijsewijk et al.17 
1987 Wingless gene cloned was identical to the 
Drosophila int1 clone. 
Baker et al.18 
1987 Int3 was discovered. Gallahan and Callahan19 
1988 Expression of the int1 transgene under MMTV 
transcriptional regulator led to cancer in mice. 
Tsukamoto et al.20 
1989 β-Catenin was found to interact with E-cadherin. Ozawa et al.21 
1989 Int1 is an organizer and embryonic inducer. McMahon and Moon22 
1990 Int4 was discovered. Roelink et al.23 
1990 A large family of genes of int1 was identified; int 
gene nomenclature became inadequate. 
Gavin et al.24 
1990 β-Catenin was characterized. Takeichi25 
1990 Adenomatous Polyposis Coli (APC) was 
discovered. 
Groden et al. 26 
Kinzler et al.27 
1990 APC and β-catenin were involved in regulating 
adhesion between cells. 
Peifer and Wieschaus28 
1991 Wnt was given as a new name to int1, wingless, 
and their related genes. 
Nusse et al.29 
1992 Int1 mutation phenomena are the consequences of 
Wnt gene mutations. 
Nusse and Varmus30 
1992 Wnt/Wingless is a Glycogen Synthase Kinase 3 
(GSK3) inhibitor. 
Siegfried et al. 31 
1993 APC was found interacting with β-catenin. Rubinfeld et al.32 
1993 β-Catenin is involved in Wnt/Wingless signaling. Peifer et al.33 
1994 Increased level of stabilized β-catenin was found 
in Wnt-activated cells. 
Peifer et al.34 




By 1995, an outline of the Wnt signaling pathway was generated, but there were 
still missing pieces in this network (Figure 1.1).  In the 1990s, as more components were 
found on both upstream and downstream sides of the pathway, this signaling map started 
to connect (Table 1.2, Figure 1.1).  Amongst the interactions, the discoveries of the β-
catenin/T-cell factor (Tcf) interactions closed gaps between the Wnt signaling pathway and 
cancers.3 Numerous genes are now known to have Tcf binding sites and therefore become 
transcriptional targets for the Wnt signaling pathway, and some of these genes such as c-
myc are known to cause cancer.36 
 
 









Table 1.2. Wnt components discovered after 1995. 
Year Event Authors 
1995 β-Catenin was found in cell nucleus and cell 
membrane 
Funayama et al.37 
1996 GSK3 was found in a complex with β-catenin and 
APC 
Rubinfeld et al.38 
1996 Tcf/Lef1 could interact with  β-catenin Molenaar et al.39 
1996 Wingless protein can bind to Frizzled; transfection 
of Frizzled genes activates Wnt signaling 
Bhanot et al.40 
1997 FRP contains Wnt receptor domains and can bind to 
Wnt proteins 
Finch et al.41 
Leyns et al.42 
Rattner et al.43 
1997 Wingless signaling is mediated by TCF/Lef1 Riese et al.44 
1998 Axin together with APC and GSK3 participates in 
the β-catenin destruction complex 
Behrens et al45. 
Ikeda et al.46 
2000 Lipoprotein receptor-related protein (LRP) is a co-
receptor for Wnt, adjacent to Frizzled in the cell 
membrane 
Pinson et al.47 
Tamai et al.48 
2001 LRP-6 is a receptor for Dickkopf proteins Mao et al.49 
   
5 
 
1.2 Cancer and Wnt Pathway 
The canonical Wnt signaling pathway has been proven to play a crucial role in cell 
proliferation, differentiation, and survival.50 The role of Wnt1 in cancer was described in 
the mouse model of mammary and colon cancer as early as 1982.10, 51 The direct connection 
between the Wnt pathway and human disease was first reported in the 1990s. The signaling 
pathway is regulated by Wnt ligands such as the APC-Axin complex and β-catenin. In 
colorectal and other cancers, these complexes are often found disrupted,52-56 resulting in 
the stabilization of β-catenin, a multifunctional protein and a key mediator of the canonical 
Wnt pathway (Figure 1.2).  
 
. 




In the absence of a Wnt signal, β-catenin is degraded by the destruction complex in 
the cytoplasm. APC and axin together facilitate the phosphorylation of β-catenin by casein 
kinase 1α (CK1α) and glycogen synthase kinase 3β (GSK3β) at regularly spaced N-
terminal Ser/Thr residues. Phosphorylated β-catenin is then ubiquitinated by β-transducin 
repeats containing proteins (β-TRCP) leading to proteasomal degradation, maintaining a 
low level of free β-catenin to bind with Tcf proteins. Hence Tcf can interact with co-
repressors such as Groucho and prevent target gene expression.  
However, when the Wnt signaling is turned on, fizzled/low-density lipoprotein 
receptor-related protein (Fz/LRP) receptors are engaged by Wnt proteins, and Axin is 
recruited to the phosphorylated tail of LRP. This interaction inhibits the ubiquitination of 
β-catenin and therefore inhibits the degradation of phosphorylated β-catenin. As newly 
synthesized β-catenin cannot be degraded, it accumulates in the cell and translocates to the 
nucleus to form a complex with Tcf. The β-catenin/Tcf complex recruits transcriptional co-
activators (CBP, Brg-1, Cdc73, and BCL9) and results in the expression of Wnt target 
genes, such as c-myc and cyclin D1.50, 57-58 It was found that both of these genes contribute 
to the development of cancers.36, 59-62 Past research also showed that β-catenin-Tcf complex 
(present in all of the nuclei of Wnt-related types of cancer) leads to chronic activation of a 
genetic program promoting cancer formation by stimulating cell growth and blocking 
apoptosis.63 Disruption of the complex formation in colon cancer cells was proven to block 
the target gene’s activation and to inhibit their in vitro growth.61-62 Therefore, it is expected 
that drugs designed to disrupt this β-catenin/Tcf interaction will have great potential for 




1.3 Wnt Singling Pathway as Drug Target 
Ever since the late 1990s, there has been significant interest in the development of 
effective Wnt pathway inhibitors in the pharmaceutical and biotechnology fields.53-55 
Methods such as high-throughput screening (HTS) and rational drug design have already 
identified some inhibitors, after nonsteroidal anti-inflammatory drugs showed no 
promising application in the chemoprevention or treatment of Wnt-related cancers.57, 64-65  
Inhibitors of the upstream sites are less desirable because they can cause cross-
regulatory effects on the -catenin-independent Wnt pathways or perturb the function of 
β-catenin in cell-cell adhesion. Therefore, it would be advantageous to identify inhibitors 
for the downstream sites of the canonical Wnt signaling pathway. The formation of the β-
catenin/Tcf complex in the cell nucleus is the penultimate step of canonical Wnt signaling. 
Transcriptional overactivation of canonical Wnt target genes is solely dependent on the 
formation of this complex. The deletion of the -catenin gene can significantly reduce the 
growth of cancer cells.66 Overexpression of dominant-negative Tcf,62 or the use of 
siRNAs67 and inducible shRNAs68 against β-catenin can markedly decrease -catenin-
dependent gene expression and diminish the growth of many cancer cells in vitro and in 
vivo. Also, β-catenin knockdown by inducible shRNA abolishes cloning efficiency and the 
in vivo leukemogenic potential of MLL Leukemic stem cells.69 Therefore, selective 
inhibition of -catenin/Tcf protein-protein interactions (PPIs) is an appealing therapeutic 
target. Moreover, it is important that the inhibitor binds to co-activator -catenin rather 
than transcriptional factor Tcf, because Tcf is essential for the other signaling pathways, 
while -catenin is specific for canonical Wnt signaling.70  
It is known that protein-protein interfaces tend to be flat, featureless and large 
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(typically 1500−3000 Å2),71-72 and the surfaces of protein often display complex dynamical 
behavior, all of which greatly complicate the process of inhibitor design. In addition, the 
dissociation constant (Kd) of the β-catenin/Tcf complex is 7–10 nM73-74 and much lower 
than those of the β-catenin/cadherin (Kd: 41–82 nM)75 and β-catenin/APC (Kd: 0.6–3.1 μM 
for APC-R3, the APC repeat with the highest binding affinity) complexes,76-77 which 
further complicates the design of selective β-catenin/Tcf inhibitors, making the disruption 
of β-catenin/Tcf interactions a “mission impossible”.57, 78 
 
1.4 Previously Identified Small Molecule Inhibitors 
Lepourcelet et al. reported six small-molecule inhibitors of -catenin/Tcf PPIs 
through high-throughput screening in 2004.2 Surface plasmon resonance (SPR) assay and 
enzyme-linked immunosorbent assay (ELISA) were used in their primary screening to 
filter out six compounds from 7000 natural compounds. These compounds can all inhibit 
-catenin/Tcf interaction with a low micromolar IC50 (Figure 1.3).  
 
Figure 1.3.  Inhibitors identified by HTS. IC50 values were measured in ELISA assay. 
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These compounds behave differently in their ability to inhibit Wnt signaling 
pathway in vivo. The three inhibitors from fungal derivatives PKF115–584, PKF118-310, 
and CGP049090 exhibit exceptional potency in inhibiting β-catenin-regulated transcription 
(CRT), colon cancer cell proliferation and β-catenin mediated axis duplication in Xenopus 
embryos. The exact mechanisms of how these inhibitors interfere with the target interaction 
were unclear. However, strong interference with β-catenin/APC interactions were observed 
for these compounds, suggesting that β-catenin was likely the target of the interaction. 
In 2006, Trosset et al. reported a small molecule inhibitor PNU74654, identified 
through virtual screening and medium-throughput biophysical (NMR and ITC) assays 
(Figure 1.4).79 The Isothermal Titration Calorimetry (ITC) experiments confirmed that the 
small molecule binds to β-catenin with a Kd of 450 nM. They hypothesized that the 
compound is likely to bind to the K435/R469 “hot spot” area on the β-catenin. However, 
no actual experimental support was given to verify the binding mode.  
Tian et al. reported an organocopper inhibitor, BC21 (Figure 1.5), from virtual 
screening and luciferase reporter assays.80 Its inhibitory activity against -catenin/Tcf 
interactions was confirmed by the fluorescence polarization (FP) assay. BC21 also exhibits 
direct interruption of β-catenin/Tcf4 interaction and down-regulates the Wnt target genes, 
resulting in cancer cell death. They proposed that the binding site for BC21 was the pocket 
around K435 but had no experimental evidence to support this assignment. 
More recently, Gonsalves et al. identified three small molecule inhibitors (iCRT3, 
iCRT5, and iCRT14) out of 14,977 compounds using high-throughput screening (Figure 
1.6).81 The HTS methods employed an Axin-specific dsRNA to address the selectivity for 




Figure 1.4. The structure of PNU74654. The Kd value was determined by ITC. 
 
 
Figure 1.5. The structure of BC21. 
 
 





inhibited the expression of Wnt target genes and the growth of colorectal cancers in vitro 
and in vivo through direct inhibition of β-catenin/Tcf4 interactions. Although in silico 
studies suggested over 20 druggable pockets on the β-catenin surface, the pocket lined by 
K435 and R469 was considered the most important binding site for the iCRT compounds, 
because these two residues are crucial for stabilizing the interaction for β-catenin/Tcf4.82  
The druggability of these hit compounds was questionable as the conjugated 
quinone substructure in PKF115–584 and CGP049090, and the rhodanine substructure in 
iCRT5 and iCRT14 have been identified as frequent hits.83 Moreover, the exact binding 
modes of these HTS hits remain unknown and hence have prohibited their optimization. 
Additionally, the selectivity of these inhibitors for -catenin/Tcf over -catenin/E-cadherin 
and -catenin/APC interactions was low,84 thus lowering the likelihood of therapeutic use.  
Grossmann et al. reported that a hydrocarbon-stapled Axin α-helix, aStAx-35, can 
inhibit β-catenin/Tcf interactions by binding with the Axin-binding site of -catenin.85 
However, as Axin is the scaffolding protein for β-catenin phosphorylation, the β-
catenin/Axin interactions maintain a low level of free β-catenin in the cytoplasm. The use 
of these hydrocarbon-stapled peptides has the risk of elevating the concentrations of free 
β-catenin in normal cells, potentially promoting more β-catenin entering the cell nucleus 
and binding with Tcf. Therefore, it is important to find inhibitors that specifically target 
the β-catenin/Tcf interaction and leave the other two interactions unaffected. 
 
1.5 Ji Laboratory Assay Development 
In the Ji laboratory, efforts have been made to design and synthesize small molecule 
inhibitors of β-catenin/Tcf interactions. Homogeneous high-throughput fluorescence 
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polarization (FP) and AlphaScreen assays were first established for inhibitors of β-
catenin/Tcf PPIs.86  
The FP assay (Figure 1.7) used C-terminal fluorescein-labeled human Tcf4 
(residues 7-51) and N-terminal His6-tagged human β-catenin (residues 138-686).86 When 
the fluorescence tracer binds to the target protein, it will emit a strong FP signal. As the 
inhibitors disrupt the PPIs, the FP signal that is emitted will have a low polarization. 
AlphaScreen is a bead-based technique. It is similar to the time-resolved 
fluorescence resonance energy transfer (TR-FRET) technique and can provide orthogonal 
results with respect to the FP assay. In the AlphaScreen assay, the streptavidin-coated 
donor beads and nickel-chelate acceptor beads are brought together through C-terminus 
biotinylated human Tcf4 (residue 7−51) and N-terminus His6-tagged human β-catenin 
(residues 138−686) interaction (Figure 1.8). Upon excitation by 680 nm laser light, the 
donor beads convert ambient oxygen to a singlet state. The lifetime of singlet oxygen is 
only a few microseconds,87 and can only get to the acceptor beads if it is within 200 nm. If 
the PPIs are disrupted, the singlet oxygen can no longer reach the acceptor beads. Therefore 
no signal can be observed. 
These two assays can exclusively evaluate the inhibitors ability to disrupt the 
protein-protein interaction complex. Previously identified inhibitors were re-evaluated 
using the FP assay. The results are shown in Table 1.3. The IC50’s of the known inhibitors 
are reported as discovered by their source articles. 
PKF115-584, CGP049090, PKF118-310, and PNU74654 were purchased through 
commercial sources, and the iCRT compounds were synthesized in the Ji lab. The synthetic 














Table 1.3. The binding affinity (Ki) of the known inhibitors measured in the Ji lab.88  
Compound 




PKF115-584 17.78 ± 2.13 3200 
CGP049090 35.56 ± 4.43 8700 
PKF118-310 5.82 ± 0.24 800 
PNU74654 180.99 ± 0.68 ND 
iCRT3 364.71 ± 6.32 8.2 
iCRT5 80.34 ± 4.17 18 










Figure 1.10. Synthesis of iCRT5. 
 
 





Synthesis of iCRT3. Key intermediate 4,5-dimethyloxazole (1.6) was synthesized 
using a Dakin-West reaction in excellent yields.89-90 Selective halogenation on the 4-methyl 
group was achieved by treating 1.6 with one equivalent of NBS in acetonitrile at room 
temperature.91 Treating 1.11 with NaH at 0˚C and brominated oxazole 1.8 gave the iCRT3 
in 10% overall yield. 
Synthesis of iCRT5. The Knoevenagel condensation92 between vanillin aldehyde  
1.12 and rhodanine 1.13 was carried out using a reported method to afford the adduct 
1.14.93 Alkylation on the sulfur (1.16) is favored over nitrogen. Lower temperature together 
with a hard counter ion (Na+) yielded slightly more of the desired N-alkylated product 1.17. 
Attempts to hydrolyze the ethyl ester in 1.17 under basic conditions resulted in a complete 
decomposition of the rhodanine. In contrast, 1.17 was very tolerant of harsh acidic 
condition (12 M aqueous HCl and trifluoroacetic acid), yielding iCRT5 in 46% overall 
yield.  
Synthesis of iCRT14. The two key intermediates for the synthesis of iCRT14 
pyrrole-3-carbaldehyde (1.21) and 3-phenylthiazolidine-2,4-dione (1.25) were synthesized 
in satisfactory yields according to reported methods.94-95 Exposure of 1.21 and 1.25 to 
Knoevenagel condensations condition generated iCRT14 with a 10% overall yield. 
 
1.6 “Hot Spot” Based Design 
It was reported that not all interfaces between the two proteins are equally important 
for PPIs.96  Small subsets of residues on protein surface contribute to most of the free 
energy of binding,97 termed as “hot spots,” which can serve as the starting point for 
inhibitor design. Although Tcf and β-catenin have a large protein-protein contacting 
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surface (≥2800 Å2 versus typical 1500-3000 Å2), three hot spots on β-catenin for binding 
to Tcf were revealed by crystallographic and biochemical analyses,66, 82, 98-100 shown in 
Figure 1.12.88 Hot spot 1 (K435/K508 binding to D16/E17 of Tcf4) and 2 (K312/K345 
binding E24/E29 of Tcf4)99, 101 are charge-charge interactions, while the third one is a 
hydrophobic pocket that consists of F253, I256, I293, A295 and I296, interacting with the 
hydrophobic residues (V44 and L48) on Tcf4.  
It has been evident that K435 is the most important “hot spot” for T-cell factor (Tcf) 
binding.74, 98, 100, 102-103 The D16A mutation of human Tcf4 results in a complete loss of its 
ability to bind to β-catenin.100, 102 Additionally, the D19A or E20A mutation of mouse Lef-
1 (corresponding to D16 and E17 of human Tcf4, respectively) prevents nuclear 
translocation of β-catenin,82 and the simultaneous mutation of D19A and E20A results in 
a protein unable to bind to β-catenin.  
 
Figure 1.12.88 Structure of the -catenin/Tcf complex (PDB id: 2GL778).  
A. Armadillo repeats 5-9 of -catenin binds to Tcf.  -Catenin is shown as a surface model 
(green), and Tcf is shown as a ribbon (purple).  
B. “Hot spots” 1 and 2. -Catenin: surface model (gray), and Tcf: stick model.  “Hot spot” 
1: K435 and K508 of -catenin.  “Hot spot” 2: K312 and K345 of -catenin.   
C. “Hot spot” 3: F253, I256, F293, A295 and I296 of -catenin. 
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Yu et al. used alanine scanning combined with SPR experiments to evaluate the 
contribution of each hot spot (Table 1.4). The studies confirmed that hot spot 1 (D16/E17 
on Tcf4) was the most important, as Tcf4 completely lost the ability to bind to β-catenin 
after the mutation. 
The SPR study strongly indicated that mimicking D16/E17 was a rational starting 
point and feasible approach to designing small molecule inhibitors for -catenin/Tcf PPIs. 
Therefore, a small–molecule inhibitor UU-01 (Figure 1.13) was designed and synthesized 
for the β-catenin/Tcf4 interaction by mimicking the D16/E17 residues of Tcf4 and 
bioisosteric replacement strategy.88 The Ki was determined by competitive FP assay to be 
3.14 ± 0.48 μM.86, 88 
 
Table 1.4. SPR study of β-catenin with wild-type and mutant Tcf4 peptides.88 
Entry Tcf4 peptides Kd (nM) 
1 Residues 7-15 4.71 
2 Residues 7-15, D16A, E17A >100,000 
3 Residues 7-15, E24A, E29A 28 









However, though UU-01 showed excellent inhibitory activity towards -
catenin/Tcf4 interaction, its selectivity towards -catenin/APC and -catenin/E-cadherin 




The Wnt signaling pathway has become an important target for designing drugs for 
cancer therapy. This work focused on the design of a selective inhibitor for -catenin/Tcf4 
PPIs using a peptidomimetic strategy. The peptidomimetic strategy faces challenges when 
designing small-molecule PPIs inhibitors due to the large protein−protein surface and the 
noncontiguous distribution of hot spots.71 Peptides derived from short contiguous 
sequences at the protein−protein interface have been shown to be poor chemical starting 
points for disrupting PPIs. The current peptidomimetic strategies, however, strive to mimic 
protein hot spot residues88, 104 or protein secondary structures,105 including α-helix, β-sheet, 
and β-turn. In this work, we hypothesized that a peptidomimetic strategy could be used to 
generate new potent inhibitors through the exploration of new pockets/new binding 
elements that are adjacent to a hot spot but not employed by β-catenin/Tcf4 PPIs. 
 
1.8 Methods and Experiments 
1.8.1 Chemistry 
All experiments were conducted under anhydrous conditions under an argon 
atmosphere, using flame-dried apparatus and employing standard techniques in handling 
air-sensitive materials.  Dichloromethane (CH2Cl2), acetonitrile (CH3CN), tetrahydrofuran 
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(THF), dimethylformamide (DMF) were degassed with nitrogen and passed through JC 
Meyer solvent systems.  All reagents were purchased from Sigma-Aldrich and used as 
received.  Aqueous solutions of sodium bicarbonate (NaHCO3), sodium chloride (brine), 
and ammonium chloride (NH4Cl) were saturated.  Analytical thin layer chromatography 
was visualized by ultraviolet light. Flash chromatography was performed on SilicaFlash@ 
F60 silica gel (230–400 mesh).  1H NMR spectra were recorded using a Varian Unity Inova 
500 (500 MHz) or a Varian Unity Inova 300 (300 MHz).  13C NMR spectra were recorded 
using a Varian Unity Inova 500 (125 MHz) or Varian Unity Inova 300 (75 MHz).  The 1H 
and 13C NMR spectra were referenced to the residual solvent signals (7.26 ppm for 1H and 
77.0 ppm for 13C in CDCl3; 2.50 ppm for 1H and 39.5 ppm for 13C in DMSO-d6).  All 
melting points were determined on a Büchi M560 melting point apparatus and uncorrected.  
Low (MS) and high (HRMS) mass spectra were determined on a Micromass Quattro II 
(ESI/APCI-TOF) at the University of Utah, Department of Chemistry Mass Spectrometry 
Facility. 
 
1.8.2 Synthetic Routes, Procedures and Characterizations 
 
(S)-Methyl 2-(4-ethylbenzamido) propanoate (1.4). To a stirred solution of 4-
ethylbenzoyl chloride (0.786 g, 4.7 mmol) in 10 mL dichloromethane was added (S)-
methyl 2-aminopropanoate hydrochloride (0.700 g, 5 mmol) and 1.4 mL Et3N (10 mmol). 
The reaction was stirred at rt overnight. The mixture was poured into 20 mL 1 M HCl (aq), 
and extracted with ethyl acetate (2 × 15 mL). The organic layers were combined and 
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washed with saturated NaHCO3 (aq) (2 × 20 mL) and brine (2 × 20 mL), then dried and 
evaporated to afford 0.968 g product as a white solid (92%). 1H NMR (300 MHz, 
Chloroform-d) δ 7.75 (m, 2H), 7.28 (m, 2H), 6.72 (d, J = 6.4 Hz, 1H), 4.82 (p, J = 7.2 Hz, 
1H), 3.81 (s, 3H), 2.71 (q, J = 7.6 Hz, 2H), 1.54 (d, J = 7.1Hz, 3H), 1.26 (t, J = 7.6 Hz, 
3H). 13C NMR (125MHz, CDCl3) δ 174.0, 166.9, 148.7, 131.5, 128.3, 127.4, 52.8, 48.6, 
29.0, 18.9, 15.5. MS (ESI) m/z = 236.4 [M + H]+. 
 
(S)-2-(4-Ethylbenzamido) propanoic acid (1.5). To a stirred solution of 1.4 
(0.968 g, 4.34 mmol) in 5 mL of MeOH was added 5 mL 1M NaOH. The reaction was 
heated to reflux for 5 h. The reaction mixture was poured into 15 mL of 1M NaOH and 
washed with dichloromethane (2 × 10 mL). Then the aqueous layer was acidified with 1 M 
HCl (aq) to pH = 3, and extracted with ethyl acetate (3 × 15 mL). The organic layer was 
combined and dried then concentrated in vacuo to yield pure product as white solid (0.797 
g, 81%). 1H NMR (300 MHz, Chloroform-d) δ 7.78 – 7.67 (m, 2H), 7.32 – 7.22 (m, 2H), 
6.70 (d, J = 6.9 Hz, 1H), 4.79 (p, J = 7.1 Hz, 1H), 2.70 (q, J = 7.6 Hz, 2H), 1.58 (d, J = 7.2 
Hz, 3H), 1.24 (t, J = 7.6 Hz, 3H). 13C NMR (75 MHz, CDCl3) δ 176.1, 149.2, 130.8, 128.4, 
127.4, 49.0, 29.0, 18.3, 15.5. MS (ESI) m/z = 222.6 [M + H]+. 
 
4-Ethyl-N-(3-oxobutan-2-yl) benzamide (1.6). To a stirred solution of 1.5 (0.72 
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g, 3.25mmol) in 7.5 mL pyridine was added 0.72 mL acetic anhydride. The reaction was 
heated to reflux for 2.5 h. The mixture was dissolved in 30 mL of ethyl acetate and washed 
with 1M HCl (aq) (2 × 20 mL), 10% Na2CO3 (aq) (2 × 20 mL) and brine (2 × 20 mL), then 
dried and purified by silica gel column chromatography (hexanes : ethyl acetate = 1 : 1) to 
afford 0.552 g product as a white solid (77%). 1H NMR (300 MHz, Chloroform-d) δ 7.79 
– 7.70 (m, 2H), 7.33 – 7.22 (m, 2H), 7.02 (d, J = 6.4 Hz, 1H), 4.81 (p, J = 7.0 Hz, 1H), 
2.71 (q, J = 7.6 Hz, 2H), 2.30 (s, 3H), 1.50 (d, J = 7.2 Hz, 3H), 1.26 (t, J = 7.6 Hz, 3H).  
13C NMR (75 MHz, CDCl3) δ 207.2, 148.7, 131.6, 128.3, 127.3, 55.2, 29.0, 26.9, 18.0, 
15.6. MS (ESI) m/z = 220.5 [M + H]+. 
 
2-(4-Ethylphenyl)-4,5-dimethyloxazole (1.7). To a stirred solution of 1.6 (0.552 
g, 2.5 mmol) in 1.5 mL acetic anhydride was added 1 mL concentrated H2SO4. The reaction 
was heated to reflux for 2.5 h. Upon completion, the mixture was poured into 30 mL 1M 
NaOH and extracted with ethyl acetate (2 × 20 mL). The organic layers were combined 
and washed with 10% Na2CO3 (aq) (2 × 30 mL) and brine (2 × 30 mL) dried. The solvent 
evaporated in vacuo to afford 0.432 g product as a white solid (86%). 1H NMR (300 MHz, 
Chloroform-d) δ 7.94 – 7.80 (m, 2H), 7.29 – 7.20 (m, 2H), 2.68 (q, J = 7.6 Hz, 2H), 2.30 
(d, J = 0.9 Hz, 3H), 2.15 (q, J = 0.9 Hz, 3H), 1.25 (t, J = 7.6 Hz, 3H). 13C NMR (75 MHz, 
CDCl3) δ 159.6, 146.3, 143.2, 131.9, 128.4, 126.1, 125.6, 29.0, 15.6, 11.5, 10.3. MS (ESI) 




4-(Bromomethyl)-2-(4-ethylphenyl)-5-methyloxazole (1.8). To a stirred solution 
of 1.7 (0.419 g, 2.08 mmol) in 4 mL MeCN at rt was added NBS (0.407 g, 2.29 mmol). 
The reaction was stirred at rt for 1.5 h. Then the reaction mixture was poured into 20 mL 
1M HCl (aq), and then extracted with ethyl acetate (2 × 15 mL). The organic layers were 
combined and washed with 10% Na2CO3 (aq) (2 × 30 mL) and brine (30 mL), then 
concentrated under reduced pressure. The residue was purified by chromatography 
(hexanes : ethyl acetate = 4 : 1) to afford 0.546 g product as a white solid (0.546 g, 85%). 
1H NMR (300 MHz, Chloroform-d) δ 7.98 – 7.86 (m, 2H), 7.31 – 7.08 (m, 2H), 4.44 (s, 
2H), 2.69 (q, J = 7.6 Hz, 2H), 2.39 (s, 3H), 1.26 (t, J = 7.6 Hz, 3H). 13C NMR (75 MHz, 
CDCl3) δ 159.8, 147.0, 128.5, 126.5, 124.9, 29.1, 24.2, 15.5, 10.7. MS (ESI) m/z = 280.5 
[M + H]+. 
 
2-Mercapto-N-phenethylacetamide (1.11). To a stirred solution of 0.7 mL 
thioglycolic acid in 5 mL methanol was added 0.2 g 4-methylbenzenesulfonic acid. The 
reaction was heated to reflux overnight. After TLC showed no thioglycolic acid left, the 
reaction was cooled to rt and 1.26 mL 2-phenylethanamine was added. The reaction was 
stirred at rt overnight. Then the reaction was concentrated under reduced pressure and the 
residue was purified by column chromatography (hexanes: ethyl acetate = 1 : 4, Rf = 0.3) 
to afford 0.7 g product as a white solid. 1H NMR (500 MHz, Chloroform-d) δ 7.31 (t, J = 
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7.8 Hz, 2H), 7.26 – 7.19 (m, 3H), 6.53 (s, 1H), 3.57 (q, J = 6.8 Hz, 2H), 3.33 (s, 2H), 2.87 
(t, J = 7.0 Hz, 3H). 13C NMR (75 MHz, CDCl3) δ 168.5, 138.9, 129.0, 128.9, 126.8, 42.7, 
41.4, 35.7. MS (ESI) m/z = 196.5 [M + H]+. 
 
2-{{[2-(4-Ethylphenyl)-5-methyloxazol-4-yl] methyl}thio}-N-
phenethylacetamide (iCRT3). To a stirred solution of 1.11 (0.12 g, 0.615 mmol) at -15 ˚C 
was added 0.03 g NaH (60%, 0.74 mmol) proportionally. After 30 min, 1.8 (0.21 g, 0.74 
mmol) was added. The reaction was allowed to warm to rt slowly and stirred overnight. 
After the reaction was complete (monitored by TLC), the solvent was evaporated and the 
residue was purified by column chromatography (hexanes : ethyl acetate = 7 : 3 to 1 : 1) to 
afford 60 mg product as a pale yellow solid (25%). 1H NMR (300 MHz, Chloroform-d) δ 
7.87 (d, J = 8.4 Hz, 2H), 7.36 (s, 1H), 7.30 – 7.15 (m, 5H), 7.14 – 7.06 (m, 2H), 3.55 – 3.43 
(m, 4H), 3.20 (s, 2H), 2.78 (t, J = 7.2 Hz, 2H), 2.70 (q, J = 7.5 Hz, 2H), 2.32 (s, 3H), 1.27 
(t, J = 7.6 Hz, 3H). 13C NMR (75 MHz, CDCl3) δ 168.9, 160.3, 147.1, 145.3, 138.9, 132.3, 
128.9, 128.8, 128.6, 126.7, 126.3, 124.9, 41.1, 35.7, 35.5, 29.1, 27.4, 15.6, 10.5. HRMS 
(ESI, CH3OH) C23H27N2O2S Calc.: 395.1793, Found: 395.1795. 
 
(Z)-5-(3,4-dimethoxybenzylidene)-2-thioxothiazolidin-4-one (1.14). To a stirred 
solution of 0.66 g Rhodanine (5 mmol) and 0.83 g methyl vanillin aldehyde (5 mmol) in 
20 mL EtOH was added 0.15 mmol piperidine. The reaction was heated to reflux overnight. 
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Yellow solid was formed. The reaction was cooled in an ice bath. The solid was filtered 
and the filter cake was washed with 5 mL cold EtOH and 10 mL hexanes. The solid was 
dried in the oven for 30 min to afford the 1.396 g product as a yellow solid (99%).1H NMR 
(500 MHz, DMSO-d6) δ 7.59 (d, J = 3.6 Hz, 1H), 7.20 – 7.13 (m, 2H), 7.11 (d, J = 8.3 Hz, 
1H), 3.82 (s, 3H), 3.80 (s, 3H). 13C NMR (126 MHz, DMSO) δ 151.9, 149.7, 133.0, 126.3, 
125.3, 123.0, 114.1, 112.9, 95.0, 56.4, 56.2. MS (ESI) m/z = 282.7 [M + H]+. 
 
Ethyl (Z)-4-(5-(3,4-dimethoxybenzylidene)-4-oxo-2-thioxothiazolidin-3-
yl)butanoate (1.17). At -10˚C, to a stirred solution of 1.379 g 1.14 (4.9 mmol) in 50 mL 
DMF was added 0.23 g NaH slowly (5.8 mmol). The reaction was stirred at -10˚C for 0.5 
h and 0.84 mL ethyl 4-bromobutanoate (5.4 mmol) was added. The reaction was allowed 
to warm to the rt over 2 h and left to react overnight. Upon completion, the reaction mixture 
was poured into 100 mL 1 M HCl (aq) and extracted with ethyl acetate (50 mL × 2). The 
organic layers were combined and concentrated in vacuo. The residue was purified by 
column chromatography to afford 0.48 g 1.17 as a yellow solid (25%) and 0.35 g 1.16 as 
an orange sold (18%). 1H NMR (500 MHz, Chloroform-d) δ 7.67 (s, 1H), 7.14 (dd, J = 8.4, 
2.1 Hz, 1H), 7.03 – 6.93 (m, 2H), 4.20 (t, J = 7.1 Hz, 2H), 4.14 (q, J = 7.2 Hz, 2H), 3.95 
(s, 3H), 3.95 (s, 3H), 2.39 (t, J = 7.4 Hz, 3H), 2.07 (p, J = 7.3 Hz, 3H), 1.26 (t, J = 7.1 Hz, 
3H). 13C NMR (125 MHz, CDCl3) δ 193.5, 172.7, 168.1, 151.8, 149.8, 133.8, 126.5, 125.9, 






yl)thio)butanoate (1.16). 1H NMR (300 MHz, Chloroform-d) δ 7.82 (s, 1H), 7.15 (ddd, J 
= 8.4, 2.2, 0.6 Hz, 2H), 7.01 (d, J = 2.1 Hz, 2H), 6.94 (d, J = 8.5 Hz, 1H), 4.14 (q, J = 7.1 
Hz, 2H), 3.94 (d, J = 1.1 Hz, 9H), 3.53 – 3.41 (m, 2H), 2.47 (t, J = 7.2 Hz, 3H), 2.15 (p, J 
= 7.2 Hz, 3H), 1.26 (t, J = 7.1 Hz, 3H). 13C NMR (75 MHz, CDCl3) δ 172.7, 151.7, 149.6, 
136.5, 126.7, 125.5, 123.8, 112.6, 111.6, 60.9, 56.3, 56.2, 33.0, 32.9, 24.7, 14.4. 
 
(Z)-4-(5-(3,4-dimethoxybenzylidene)-4-oxo-2-thioxothiazolidin-3-yl)butanoic 
acid (iCRT5). To a mixture of 3 mL concentrated HCl (aq) and 3 mL trifluoroacetic acid 
was added 100 mg 1.17. The reaction was heated to reflux overnight. Upon completion, 
the reaction was cool in an ice bath, the pH was adjusted to 4 by adding 2 M NaOH (aq). 
The mixture was then extracted with ethyl aceate (2 × 10 mL). The organic layers were 
combined and washed with brine (2 × 20 mL), dried and concentrated in vacuo to afford 
92 mg product as a yellow solid. (99%). 1H NMR (500 MHz, Chloroform-d) δ 8.59 (s, 2H), 
7.66 (s, 1H), 7.12 (dt, J = 8.3, 2.0 Hz, 1H), 6.99 – 6.92 (m, 2H), 4.18 (t, J = 7.0 Hz, 2H), 
3.94 (s, 2H), 3.93 (s, 2H), 2.44 (t, J = 7.3 Hz, 2H), 2.10 – 2.00 (m, 2H). 13C NMR (126 
MHz, CDCl3) δ 193.4, 178.1, 168.4, 151.9, 149.7, 134.2, 126.4, 126.0, 120.0, 112.7, 111.7, 





3-(2,5-Dimethyl-1H-pyrrol-1-yl)pyridine (1.20).  To a stirred solution of 0.94 g 
3-amino pyridine (10 mmol) in 1.4 mL 2,5-hexadione (12 mmol) at rt was added 0.25 g 
iodine crystals.  The reaction was stirred at rt for 24 h. Upon completion, the reaction 
mixture was diluted in 50 mL ethyl acetate. The solution was washed with 50 mL 5% 
Na2S2O3 (aq). The organic layer was then concentrated in vacuo. The residue was purified 
with column chromatography (hexanes : ethyl acetate = 8:2) to yield 1.02 g product as 
colorless oil (59%). 1H NMR (300 MHz, Chloroform-d) δ 8.66 (dd, J = 4.9, 1.5 Hz, 1H), 
8.54 (d, J = 2.5 Hz, 1H), 7.59 (dt, J = 8.1, 2.0 Hz, 1H), 7.44 (dd, J = 8.0, 4.8 Hz, 1H), 5.95 
(s, 2H), 2.05 (s, 6H). 13C NMR (75 MHz, CDCl3) δ 149.6, 149.0, 135.7, 129.1, 123.9, 106.8, 
13.2. MS (ESI) m/z = 172.9. [M + H]+. 
 
2,5-Dimethyl-1-(pyridin-3-yl)-1H-pyrrole-3-carbaldehyde (1.21). To a stirred 
solution of 1.01 g 1.20 (5.87 mmol) in 20 mL toluene was added 0.45 mL DMF (5.87 mmol) 
and 0.55 mL POCl3 (5.87 mmol). The reaction was heated to reflux for 3.5 h. Upon 
completion, the reaction mixture was cooled to rt. Saturated NaOAc (aq) (20 mL) was 
added and stirred for 20 min. K2CO3 (2 g) was added to the mixture and the mixture was 
extracted with dichloromethane (2 × 30 mL). The organic layers were combined and 
concentrated in vacuo. The residue was purified by column chromatography to afford 1.02 
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g product as colorless oil (87%). 1H NMR (300 MHz, Chloroform-d) δ 9.89 (s, 1H), 8.75 
(dd, J = 4.7, 1.7 Hz, 1H), 8.53 (dd, J = 2.5, 0.8 Hz, 1H), 7.59 (ddd, J = 8.0, 2.5, 1.6 Hz, 
1H), 7.50 (ddd, J = 8.1, 4.8, 0.8 Hz, 1H), 6.42 (q, J = 1.1 Hz, 1H), 2.29 (s, 3H), 2.00 (d, J 
= 1.0 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 174.0, 166.9, 148.7, 131.5, 128.3, 127.3, 
52.8, 48.6, 29.0, 19.0, 15.5. MS (ESI) m/z = 201.2 [M + H]+. 
 
1,3-Diphenylthiourea (1.23). At 0˚C, 1 mL aniline (11 mmol) was added to 1.5 
mL isothiocyanatobenzene dropwise with stirring. White solid was formed and the reaction 
became too thick to stir. The solids were recrystallized from hot ethanol to afford 2.23 g 
product as tabular crystal (89%). m.p. 152.2-154.5˚C. 1H NMR (300 MHz, DMSO-d6) δ 
9.77 (s, 2H), 7.49 – 7.42 (m, 4H), 7.36 – 7.24 (m, 4H), 7.14 – 7.04 (m, 2H). 13C NMR (75 
MHz, DMSO) δ 180.2, 140.1, 129.1, 125.1, 124.3. MS (ESI) m/z = 229.4 [M + H]+. 
 
(E)-3-Phenyl-2-(phenylimino)thiazolidin-4-one (1.24). To a stirred solution of 
1.12 g 1.23 (4.9 mmol) in 10 mL ethanol was added 0.46 g monochloro-acetic acid (4.9 
mmol). The reaction as heated to reflux overnight. The reaction was then cooled in an ice 
bath, and white crystals were formed. The mixture was filtered and the solid was washed 
with cold ethanol to afford 0.527 g product as a white solid (40%). 1H NMR (300 MHz, 
Chloroform-d) δ 7.53 (t, J = 7.5 Hz, 2H), 7.48 – 7.36 (m, 3H), 7.36 – 7.28 (m, 2H), 7.12 (t, 




3-Phenylthiazolidine-2,4-dione (1.25). To a stirred solution of 0.527 g 1.24 (1.96 
mmol) in 10 mL ethanol was added 1.5 mL concentrated HCl (aq). The reaction was heated 
to reflux for 5 h. The reaction was cooled in an ice bath and white precipitate formed. The 
mixture was filtered and the solid was washed with cold water and hexanes to afford 0.201 
product as a white solid (53%). 1H NMR (500 MHz, Chloroform-d) δ 7.54 – 7.46 (m, 2H), 
7.49 – 7.38 (m, 1H), 7.29 – 7.22 (m, 2H), 4.12 (s, 2H). 13C NMR (126 MHz, CDCl3) δ 
170.9, 132.9, 129.7, 129.6, 127.4, 34.1. MS (ESI) m/z = 193.9 [M + H]+. 
 
(Z)-5-((2,5-Dimethyl-1-(pyridin-3-yl)-1H-pyrrol-3-yl)methylene)-3-
phenylthiazolidine-2,4-dione (iCRT14).  To a stirred solution of 0.1 g 1.21 (0.5 mmol) 
and 0.101 g 1.25 (0.524 mmol) in 5 mL ethanol was added 2 drops of piperindine. The 
reaction was heated to reflux for 2 h. Upon completion, the reaction was cooled to rt and 
the solvent was concentrated in vacuo. The residue was purified by column 
chromatography to yield 0.103 g product as a white solid (55%). 1H NMR (300 MHz, 
Chloroform-d) δ 8.73 (dd, J = 4.7, 1.6 Hz, 1H), 8.53 (dd, J = 2.5, 0.8 Hz, 1H), 7.95 (d, J = 
0.5 Hz, 1H), 7.58 (ddd, J = 8.1, 2.5, 1.6 Hz, 1H), 7.55 – 7.38 (m, 4H), 7.38 – 7.29 (m, 2H), 
6.33 – 6.28 (m, 1H), 2.18 (s, 3H), 2.06 (d, J = 1.0 Hz, 3H), 1.25 (t, J = 7.1 Hz, 1H). 13C 
NMR (75 MHz, CDCl3) δ 168.2, 166.3, 150.3, 149.2, 136.5, 135.6, 134.4, 133.4, 132.3, 
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129.5, 129.2, 128.3, 127.7, 124.4, 116.5, 114.0, 106.4, 13.1, 11.5. HRMS (ESI, CH3OH) 
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TARGETING THE TCF4 GANDE BINDING SITE TO SELECTIVELY DISRUPT 
β–CATENIN/T-CELL FACTOR PROTEIN-PROTEIN INTERACTIONS 
USING A PEPTIDOMIMETIC STRATEGY  
 
2.1 Introduction 
In the postgenomic era, a myriad of functional proteins have been characterized. 
Inside of the cell, there is a complex network of protein-protein interactions (PPIs). The 
protein tends to use the same interface to interact with the various other proteins in different 
organelles or cellular environments. Under pathological conditions, PPIs lose the 
compartmental constraint, and unexpected PPIs take place, often leading to disease. One 
challenge of biomedical research is to design a small molecule to modulate a specific 
protein-protein interface while leaving the other related PPIs unaffected. The selective 
disruption of β-catenin/Tcf PPIs, a key downstream effector of the canonical Wnt signaling 
pathway, represents such a case. 
The canonical Wnt signaling pathway plays a fundamental role in directing cell 
proliferation, differentiation, and survival.1 β -Catenin is the key mediator of this signaling 
pathway. The mutations in the regulatory genes of the canonical Wnt signaling pathway, 
such as those that encode Adenomatous Polyposis Coli (APC), Axin, and/or the N-terminal 
phosphorylation sites of β-catenin, result in the stabilization of β-catenin and an increased
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level of nuclear β-catenin. Nuclear β-catenin forms a complex with T-cell factor 
(Tcf)/lymphoid enhancer factor (Lef) to induce the overexpression of cell proliferation, 
migration, and survival genes, such as cyclin D1, c-myc, and survivin. Canonical Wnt 
signaling can also be activated through epigenetic silencing of Wnt antagonist genes or the 
autocrine activation of Wnt ligands, frizzled (Fz), and disheveled (Dvl). The 
hyperactivation of the canonical Wnt signaling pathway is strongly implicated in the 
initiation and progression of many cancers and fibrosis. In addition, canonical Wnt 
signaling is aberrantly over-activated in cancer stem cells, which drive tumor growth, seed 
metastases, and cause cancer recurrence after remission.2-4 Significant efforts have been 
made to identify inhibitors of the canonical Wnt signaling pathway.5-7 Inhibitors of the 
upstream sites are less desirable because they can cause cross-regulatory effects on the β-
catenin independent Wnt pathways or perturb the function of β-catenin in cell-cell adhesion. 
Thus, it would be better to identify inhibitors for the downstream sites of the canonical Wnt 
signaling pathway. The formation of the β-catenin/Tcf complex in the cell nucleus is the 
penultimate step of canonical Wnt signaling. Transcriptional over-activation of canonical 
Wnt target genes is solely dependent on the formation of this complex. Therefore, selective 
inhibition of β-catenin/Tcf PPIs represents an appealing therapeutic target. It is important 
that the inhibitor binds to coactivator β-catenin rather than transcriptional factor Tcf, 
because Tcf is essential for the other signaling pathways,8 while β-catenin is specific for 
canonical Wnt signaling. 
The crystal structures of β-catenin in complexes with Xenopus Tcf3,9 human 
Tcf4,10-12 mouse Lef1,13 E-cadherin,14 and APC15-16 have been solved. A comparison of 
these structures reveals that β-catenin uses the same armadillo repeats to bind Tcf (human 
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Tcf4 residues 7−51), cadherin (human E-cadherin residues 819−873), and APC (residues 
1477−1519 of human APC 20-amino acid repeat 3, APC-R3). The binding modes of Tcf, 
cadherin, and APC in this region are identical. Biochemical analyses confirm that the 
binding modes of Tcf, cadherin, and APC to β-catenin are mutually exclusive.17-20 
Selectivity becomes a major challenge when designing inhibitors for β-catenin/Tcf 
interactions. The inhibitor cannot block the β-catenin/cadherin interaction because this 
interaction is essential for the integrity of epithelial junctions. The blockage of this protein-
protein complex alters cell-cell adhesion and impairs the functions of normal stem cells. 
The inhibitor cannot block the β-catenin/APC interaction either because this interaction is 
critical for β-catenin degradation. The blockage of this protein-protein complex leads to a 
larger pool of free β-catenin, and more β-catenin enters the cell nuclei to over-activate the 
transcription of Wnt target genes, thereby promoting new cancer formation. In addition, 
the dissociation constant (Kd) of the β-catenin/Tcf complex is 7−10 nM13, 21 and much 
lower than those of the β-catenin/cadherin (Kd: 41−82 nM)20 and β-catenin/APC (Kd: 
0.6−3.1 μM for APC-R3, the APC repeat with the highest binding affinity) complexes,15, 
21 which further complicates the design of selective β-catenin/Tcf inhibitors. The disruption 
of β-catenin/Tcf interactions has been thought undruggable for these reasons.5, 12  
Although extensive high-throughput screening (HTS) has been performed to 
identify small-molecule inhibitors for β-catenin/Tcf PPIs, only four examples have been 
reported (Figure 2.1).22-25 However, the exact binding modes of these HTS hits remain 
unknown and hence have prohibited their optimization. The selectivity of these inhibitors 
for β-catenin/Tcf over β-catenin/E-cadherin and β-catenin/APC interactions was low.26 
Hydrocarbon-stapled Axin α-helix, aStAx-35, was identified to bind to the Axin-binding  
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Figure 2.1 Chemical structures of known β-catenin/Tcf inhibitors. 
 
site of β-catenin and inhibit β-catenin/Tcf interactions.27 Axin is the scaffolding protein for 
β-catenin phosphorylation. β-Catenin/Axin interactions maintain a low level of free β-
catenin in the cytoplasm. The use of these hydrocarbon-stapled peptides has the potential 
to elevate the concentrations of β-catenin in normal cells. Yu et al. reported a rational 
design of small molecule inhibitor UU-01 by bioisostere replacement.28  
In this study, we demonstrated that targeting the Tcf4 G13ANDE17 binding site can 
selectively inhibit β-catenin/Tcf PPIs. Small-molecule inhibitors with excellent cell-based 
activity and high selectivity for β-catenin/Tcf over β-catenin/cadherin were identified. 
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2.2 Results and Discussion 
2.2.1 Identification of a Selective Binding Site for β-Catenin/Tcf over  
β-Catenin/E-Cadherin and β-Catenin/APC Interactions 
A careful inspection of the crystal structures of β-catenin reveals that the binding 
modes of the sequences flanking Tcf4 D16, E-cadherin D830, and APC-R3 D1486 have 
subtle but critical differences. A kink between armadillo repeats 9 and 10 of β-catenin 
forms a binding site (Figure 2.2, hot spot 126). Tcf4 G13ANDE17 binds to this site. There 
are four well-defined pockets for the Tcf4 G13ANDE17 binding site: pocket A is lined with 
C429, N430, K435, H470, S473, and R474; pocket B is deep and lined with V511, C573, 
L539, I569, I507, and the side chain carbons of K508; pocket C is a surface pocket defined 
by L519 and I579; and pocket D is another surface pocket that is lined with C466, E462, 
L506, A509, and the side chain carbons of K508. Pockets A and B are connected to pocket 
C. Pockets B and D are connected by K508 and R469. 
 
 
Figure 2.2. Pockets A–D of the Tcf GANDE binding site. Tcf4 G13ANDE17 is shown 
yellow as the reference.  
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Residue K435 in pocket A forms a salt bridge with D16 of human Tcf4, D830 of 
human E-cadherin, and D1486 of human APC-R3. This interaction is essential for 
anchoring Tcf/Lef,9, 11, 18, 21, 29-31 cadherin,9, 30 and APC13, 32 in place. However, the binding 
modes adjacent to this salt bridge are different among the three protein–protein complexes. 
Tcf4 E17 forms a salt bridge with β-catenin K508. β-Catenin K508A or Tcf4 E17A 
mutation significantly decreases the β-catenin/Tcf affinity.18, 21, 28, 30 Our previous study 
demonstrated that Tcf4 D16E17 alone could effectively disrupt β-catenin/Tcf interactions 
with a Ki value of 396.59 μM.28 The mimicking of Tcf4 D16E17 by bioisostere replacement 
generated a potent β-catenin/Tcf inhibitor, UU-01, with a Ki value of 3.14 μM.  
On the other hand, the residues in E-cadherin and APC-R3 that correspond to Tcf4 
E17 are S831 and T1487, respectively. These two residues do not form a direct bonding 
with β-catenin. The backbone amide of Tcf4 A14 forms an H-bond with the side chain 
carboxamide of N516. Deletion experiments show that the sequences N-flanking the 
conserved Asp is critical for Tcf/Lef binding to -catenin, including G13–T20 of human 
Lef1,31 and G8–A14 of Tcf4.11, 29-30 Table 2.1 listed the key binding segments of Lef1 
(Q9UJU2), Tcf4 (Q9NQB0), E-cadherin (P12830), and APC-R3(P25054). The N-terminal 
flanking amino acids are shown.  and  are the hydrophobic and aromatic residues, 
respectively. The sequences that bind to the Tcf4 G13ANDE17 binding site are shown in the 
rectangular red box.  
The residues in E-cadherin and APC-R3 that correspond to Tcf4 G13AN15 do not 
bond directly with β-catenin. The FP competitive inhibition assay was performed to 
evaluate the importance of the corresponding sequences of Tcf, cadherin, and APC, as 
shown in Table 2.2. Tcf4 peptide (residues 7–51) has an IC50 value of 1.09 nM.28 Under 
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Table 2.1 Sequences of human Lef1, Tcf4, E-cadherin and APC-R3. 
          DXΘΘXΦXXE   
hLef1 13 GDPELCATDEMIPFKDEGD 31 
hTcf4 8 GGDDLGANDELISFKDEGE 26 
hE-cadherin 820 TDPTAPPYDSLLVFDYEGS 838 




Table 2.2 Inhibitory activities of Tcf, cadherin, and APC sequences. 
Peptides IC50, nM 
Tcf (7-51) 1.09 ± 0.04 
Tcf (7-51, D16A, E17A) >200,000 
Tcf (18-51) >200,000 
E-cadherin (819-873) 94.66 ± 3.90 
E-cadherin (819-873, p826YDS829/A826AAA829) 943.7 ± 2.9 
APC-R3 (1482-1511) 2690 ± 120 




the same assay, Tcf4 peptide (residues 7–51, D16A/E17A)28 or a truncated Tcf4 peptide 
(residues 18–51) did not disrupt β-catenin/Tcf4 interactions even at a concentration of > 
200 μM. In contrast, the simultaneous mutation of four residues, P826YDS829 of human E-
cadherin (residues 819–873) into alanine, only leads to a 10-fold increase in the IC50 value. 
The mutation of four residues, D1484ADT1487 of human APC-R3 (residues 1477–1519) into 
alanine, causes a 30-fold increase in the IC50 value. The FP saturation binding assay was 
also performed for E-cadherin (819–873) and E-cadherin mutant (819–873, 
P826YDS829/A826AAA829). The Kd values of E-cadherin and the E-cadherin 
P826YDS829/A826AAA829 mutation are 80.40 ± 1.1 and 832.1 ± 14.4 nM, respectively. As a 
comparison, the Kd value of human Tcf4 D16A/E17A is > 100 μM, while the Kd value of 
native human Tcf4 is 4.71 nM.28 Based on these results, we proposed that targeting the Tcf 
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G13ANDE17 binding site by mimicking the binding mode of Tcf4 G13ANDE17 would lead 
to the generation of selective small-molecule inhibitors specific for -catenin/Tcf 
interactions. 
 
2.2.2 Peptidomimetic Strategy to Design Small-Molecule Inhibitors 
Pockets A, B, and C of the Tcf GANDE binding site were characterized by 
SiteMap33 and multiple copy simultaneous search (MCSS).34 SiteMap uses a GRID-based 
method to define the binding site, calculate hydrophobicity, and determine the orientations 
of H-bond donors and acceptors. The SiteMap analysis indicates that the hydrophobic 
region is mainly located in pocket B, as the yellow region shown in Figure 2.3a. The 
molecular interaction fields (MIFs) of H-bond donors are primarily from the side chains of 
K508, R469, K435, S473, R474, R515, R612, and the backbone amide of N430. The MIFs 
of H-bond acceptors were determined by the side chains of N516, E571, H578, S473, and 
the backbone carbonyl of K508 (Figure 2.4).  
 
 
Figure 2.3.  Analysis of the Tcf4 G13ANDE17 binding site. Pocket A, B, C and D are 
indicated. a. Results of hydrophobic SiteMap analysis. b. Representative MCSS-
minimized positions of hydrophobic aromatic fragments, benzene (yellow), and indole 




Figure 2.4.  Results of H-bonding SiteMap analysis.  The β-catenin residues are shown 
green.  The residues contribute to the SiteMap contours are colored atom type.  a. H-bond 




Ten aromatic, aliphatic, polar and charged functional groups that are commonly 
found in bioactive small molecules were used in an MCSS analysis (Table 2.3). The 
minima having the second and third most favorable interaction energies with benzene and 
indole, respectively, located in pocket B (Figure 2.3b), where they form hydrophobic 
interactions with V511 and I569. The minima with the third most favorable interaction 
energy benzene and the second most favorable interaction energy with indole are located 
in the arginine channel formed by R474 and R515, where favorable cation–π interactions 
were observed. In pocket C, benzene (minimum No. 5) and indole (minimum No. 4) form 
cation–π interactions with R612 and R582 and are stabilized by H578 and I569. In pocket 
D, benzene (minimum No. 6) and indole (minimum No. 5) are stabilized by R469, A509, 
C466, and L506.  
The MCSS results for the aliphatic apolar fragments, cyclohexane, propane, and 
isobutane, are described in Figure 2.5. The region displaying the most favorable interaction 
energies with cyclohexane and isobutane are located in pocket B lined by V511, I569,  
49 
 








Range of Ubinda  for  
minima (kcal/mol) 
Selected minima 
From to Ubind; Pocket Residues involved 
Benzene 2500 19 –1.96 –9.94 No.2: –8.19; B V511, I569 
     No.3: –7.88; C R474, R515 
     No.5: –5.94; C R612 
     No.6: –5.71; D R469, A509, C466, 
L506 
Indole 5000 187 –3.46 –17.54 No.2: –14.74; C R474, R515 
     No.3: –14.35; B V511, I569 
     No.4: –13.92; C R612, R582, H578, 
I579 
     No.5: –12.85; D R469, K508, A509, 
C466 
Cyclohexane 5000 19 –0.01 –4.57 No.1: –4.57; B K508, V511, I569, 
G512 
     No.2: –3.80; A K435, H470, R474, 
C429 
     No.3: –2.50; D A509, K508, C466 
     No.4: –2.11; C L519, N516, R515, 
S473 
     No.6: –2.11; B N516, R515, G512, 
R469 
Propane 5000 54 –1.54 –8.65 No.1: –8.65; A K435, H470, C429, 
S473 
     No.2: –8.59; B K508, V511, I569, 
G512 
     No.4: –7.38; D A509, K508, C466 
     No.6: –7.20; B N516, R515, S473, 
R469 
Isobutane 5000 49 –1.02 –10.77 No.1: –9.67; B K508, V511, I569, 
G512 
     No.2: –9.38; A K435, H470, C429, 
S473 
     No.3: –8.42; B N516, R515, R469, 
S473 
     No.5: –8.27; D A509, K508, C466 
     No.6: –8.06; C L519, N516, R515, 
I579 
Dimethyl ether 5000 42 –2.95 –16.08 No.1: –16.08; A K435 
     No.3: –12.89; C R612 
     No.4: –12.84; D R469 
     No.6: –10.71; B K508 
     No.7: –10.68; B K515 
Methanol 5000 47 –2.40 –21.79 No.9: –13.06; C N516 
N-Methylacetamide 5000 108 –1.84 –25.86 No.1: –25.86; A K435, C429, R474 
     No.3: –25.09; D R469, E462, A509 
     No.4: –24.31; C N516, R474, L519 
     No.6: –18.40; C R612, I579 
     No.7: –17.68; B K508 
Acetate anion 5000 21 –10.76 –61.04 No.1: –61.04; A K435, N430 
     No.3: –48.82; D R469 
     No.4: –45.72; B K508 
     No.5: –44.34; C R474 
Methylammonium 5000 20 –0.29 –40.57 No.5: –25.76; B N516, G512 
aUbind, the binding energy of a given functional group in each minimized replica obtained from the MCSS 
calculation, is defined as Ubind = Uprotein–group + Ugroup − Ugroup0, where Uprotein–group represents the nonbonded 
interactions between β-catenin and the given functional group.  Ugroup represents the internal energy of the 
functional group within the complex, and Ugroup0 represents the internal energy of the isolated functional 




Figure 2.5.  Representative MCSS-minimized positions of aliphatic fragments in the Tcf 
GANDE-binding site of β-catenin (PDB id, 2GL7). Cyclohexane, propane, and isobutane 
are shown yellow, green, and magenta, respectively. β-Catenin is shown as a space-filled 




G512, and the side chain carbons of K508. The polar functional groups, dimethyl ether, 
methanol, and N-methylacetamide, were used to explore the H-bond capacity in these 
pockets (Figure 2.6). The polar functional groups, methanol and N-methyl acetamide, 
contain H-bond donors. The lowest energy minima of methanol (minimum No. 9) and N-
methylacetamide (minim No. 4) as H-bond donors form H-bonds with the side chain 
carbonyl oxygen of N516, mimicking the H-bond between backbone amide bond of Tcf4 
A14 and side chain carbonyl oxygen of β-catenin N516. 
Based on the results of the above SiteMap and MCSS analyses, a peptidomimetic 
strategy was employed to design new β-catenin/Tcf inhibitors. The G13ANDE17 sequence 
of human Tcf4 was used as the starting template. As the previous studies indicated that 
D16 and E17 of human Tcf4 were critical for Tcf to bind with β-catenin, these two residues 
were kept in the new inhibitors. The MCSS analysis shows that indole can be located in 




Figure 2.6.  Representative MCSS-minimized positions of polar fragments in the Tcf 
GANDE binding site of β-catenin (PDB id, 2GL7).  β-Catenin is shown as the cyan stick 
model, and the fragments are shown as the stick–and–ball model.  a. Polar fragments, 
dimethyl ether (yellow), methanol (blue), and N-methyl acetamide (green) in the active site. 




conformation of Tcf4 G13ANDE17, which leads to the deletion of residues Gly-Ala. The 
electron-rich indole ring was used to form cation-π interactions with the arginine channel. 
The commercially available hydrophobic D- and L- amino acids identified from SciFinder 
search were used to replace Asn to explore hydrophobic pocket B. AutoDock 4.235 was 
employed to predict the binding mode of new compounds.  
Compound 2.12 in Figure 2.7a was selected as the first designed compound for 
synthesis. The predicted binding mode of 2.12 with β-catenin is shown in Figure 2.7b. The 
AutoDock model indicated that the O-methyltyrosine moiety of 2.12 points towards 
hydrophobic pocket B, while indole ring can form cation-π interactions with R515 
(parallel) and R474 (T-shaped). The N-H of indole can form a H-bond with the side chain 
carbonyl of N516. The indole can also interact with \hydrophobic pocket C. The predicted 
binding mode of the designed compound matches the proposed key binding elements.   
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Figure 2.7.  Structure-based design of new inhibitors based on Tcf4 G13ANDE17. a. 
Structural evolution from 2.11 to 2.12. b. AutoDock predicted conformation of 2.12 (gray).  





Synthesis of compound 2.12 is shown in Figure 2.8. The Glu-Asp dipeptide was 
synthesized through standard peptide coupling reactions (Figure 2.8a). The methoxy 
tyrosine 2.21 was synthesized by a direct alkylation of the phenolic hydroxyl group of Boc-
protected tyrosine, followed by the deprotection of the Boc group to yield the desired 
hydrochloride salts (Figure 2.8b). The 2-(5-chloro-1H-indol-2-yl)acetic acid 2.25 was 
prepared through an intermolecular Wittig reaction using a modified procedure (Figure 
2.8c).36  Figure 2.8d shows the coupling of the fragments followed by deprotection of all 
the tert-butyl ester and Boc groups in one step to yield compound 2.12. 
Three dipeptides 2.31-2.33 were synthesized as shown in Figure 2.9 using standard 
peptide coupling procedures. Together with other intermediates and known inhibitors, they 




Figure 2.8. Synthesis of 2.12. 
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Figure 2.9 Synthesis of dipeptide derivatives. 
 
The FP competitive inhibition assay results of compounds are shown in Table 2.4. 
Compound 2.12 exhibits a Ki value of 5.74 ± 0.76 μM and can completely disrupt the large 
and tight β-catenin/Tcf PPIs. Compared to 2.11 (Ki = 290.4 ± 1.3 μM), compound 2.12 is 
50-fold more potent, indicating the success of the design. Fragments 2.26 and 2.31-2.33 
exhibited some inhibitory activities but much were less potent than 2.12. The FP assay also 
demonstrated that 2.12 was more potent than known inhibitors KF115–584, CGP049090, 
PNU74654, iCRT3, iCRT5, and iCRT14 and comparable to PKF115–310 and UU-01. 
 
Table 2.4. The FP assay results of synthesized inhibitors and known inhibitors. 
Entry Ki ± SD (μM) Compounds28 Ki ± SD (μM) 
2.11 290.4 ± 1.3 PKF115-584 17.8 ± 2.1 
2.12 5.7 ± 0.8 CGP049090 35.6 ± 4.4 
2.31 343.0 ± 2.0 PKF118-310 5.8 ± 0.2 
2.32 396.6 ± 2.2 PNU74645 181.0 ± 0.7 
2.33 119.7 ± 1.2 iCRT3 364.7 ± 6.3 
2.26 140.8 ± 1.9 iCRT5 80.3 ± 4.2 




2.2.3 Exploration of the Arginine Channel and Pocket B 
Additional structural modification involved the exploration of the structure-activity 
relationship (SAR) for the indole moiety of 2.12. Compounds 2.34-2.40 were designed 
(Figure 2.10).  
Compounds 2.34-2.35 were synthesized using a method that was similar to the 
synthesis of 2.12 as shown in Figure 2.11. They were designed to study the effects of the 
substitutions on the indole ring. Compounds 2.36-2.40 were synthesized using standard 
peptide coupling procedures (Figure 2.12 and 2.13) from commercially available starting 
materials.  
The FP competitive inhibition assay results are shown in Figure 2.14. The Ki of 
2.12 is lower than those of 2.34 and 2.35, indicating chlorine is a better substituent. The 
importance of the indole moiety of 2.12 was further evaluated by the synthesis of 3,4-
disubstituted benzacetamide derivatives, 2.36 and 2.37. The AutoDock study shows that 
2.36 and 2.37 do not have an -NH to form an H-bond with the side chain carbonyl of N516 
and have weaker cation-π interactions with R474 and R515 due to fewer π-electrons. In 
accordance with our expectation, the Ki values of 2.36 and 2.37 were over 60-fold higher 
than 2.12, indicating the importance of the H-bond and cation–π interactions for binding. 
Compounds 2.38–2.40 were used to investigate the optimum connectivity for the indole 
ring. In good agreement with the docking results, substitutions at 2-position of the indole 
ring (2.34 and 2.38) yielded a better inhibitor than those at 3-position (2.39 and 2.40). 
Compared to 2.12, a relatively flexible 2-substituted side chain, as in 2.34, can significantly 
increase the inhibitory activities because the indole can stay comfortably in the arginine 




Figure 2.10. Compounds to explore Pocket C.  
 
 








Figure 2.12. Synthesis of compound 2.36-2.37. 
 
 






Figure 2.14. FP competitive inhibition assay results of 2.34-2.40. 
 
The deep and narrow hydrophobic pocket B was explored using substituted tyrosine 
derivatives and the other unnatural amino acids. Compounds 2.62-2.67 were designed and 
synthesized (Figure 2.15). The commercially available fragments were prepared and 
coupled with the 2-indole acetic acid and dipeptide as shown in Figure 2.16. 
The FP assay results of 2.62-2.67 are shown in Figure 2.17. Compound 2.62 has 
the lowest inhibitory activities in this series presumably coming from the over-sized 
isopropyl group for pocket B. The phenyl group of 2.63 and the cyclohexyl group of 2.64 
only stay at the entrance of pocket B, exhibiting higher Ki values than 2.12. On the other 
hand, as expected, more hydrophobic derivatives (compound 2.65-2.67) have better 
inhibitory activities. Among this series, 2.66 exhibits the highest inhibitory activity for β-
catenin/Tcf PPIs (Ki = 1.36 ± 0.12 μM). It is over 210-fold more potent than 2.11 and 
represents one of the most potent inhibitors discovered to date. 
The activities of the inhibitors were also evaluated using AlphaScreen assay37 by 
Dr. Min Zhang (Table 2.5). The Ki of 2.66 in the AlphaScreen assay is 1.32 ± 0.56 μM, 
which more potent than known inhibitors CGP049090 and PKF118–310 (Ki determined in 
the parallel assays).  
Entry Ki ± SD (μM) 
2.34 45.5 ± 1.2 
2.35 13.2 ± 1.2 
2.36 333.5 ± 1.1 
2.37 305.1 ± 1.9 
2.38 51.4 ± 1.1 
2.39 60.9 ± 1.1 




Figure 2.15. Compounds to explore pocket B. 
 
 




Figure 2.17. FP competitive inhibition assay results of 2.62-2.67. 
 
 
Table 2.5. AlphaScreen Ki values of 2.12, 2.65-2.67 and two known inhibitors. 
Entry Ki ± SD (μM) Compounds Ki ± SD (μM) 
2.12 4.9 ± 0.8 CGP049090 5.9 ± 0.9 
2.65 3.7 ± 0.6 PKF118-310 3.6 ± 0.7 
2.66 1.3 ± 0.6 iCRT14 37.0 ± 0.8 
2.67 10.9 ± 0.9   
 
  
Entry Ki ± SD (μM) 
2.62 16.7 ± 1.1 
2.63 11.9 ± 0.9 
2.64 10.6 ± 0.7 
2.65 4.3 ± 0.6 
2.66 1.4 ± 0.1 
2.67 6.5 ± 1.3 
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2.2.4 Binding Mode Verification Using Isothermal Titration Calorimetry  
(ITC) and Site-Directed Mutagenesis Studies 
Figure 2.18 shows the AutoDock predicted binding mode of 2.66 with β-catenin. 
Firstly, to verify the inhibitor binds to β-catenin instead of Tcf, ITC experiments were 
performed. Figure 2.19 confirmed this 2.66 binds to wild-type β-catenin with a Ki value of 
0.418 μM, but not Tcf (Figure 2.19). 
The binding mode of 2.66 with -catenin was further evaluated by site-directed 
mutagenesis studies. Mutated proteins (hydrophobic pocket B: V511S and V511S/I569S; 
arginine channel pocket C: R474A, R515A and R474A/R515A) were made in the Ji 
laboratory by Dr. Min Zhang and were verified not affecting -catenin/Tcf binding.38  The 
Ki values of 2.12, 1.65 and 2.66 for wild-type -catenin/Tcf and mutant -catenin/Tcf 
interactions were determined by FP assays (Table 2.6).  
 
 





Figure 2.19. ITC studies to determine the binding affinity of compound 2.66 with human 
-catenin (residues 138–686) and human Tcf (residues 7–51). a. -Catenin/2.66 binding 
experiment. b. Tcf /2.66 binding experiment. 
 
Table 2.6. Site-directed mutagenesis studies and the FP assay to evaluate the binding 
mode of 2.12, 2.65, and 2.66. 
 Ki, μM 
β-catenin              2.12            2.65          2.66 
Wild type      5.74 ± 0.76     4.30 ± 0.59   1.32 ± 0.56 
V511S    32.47 ± 2.08   25.98 ± 0.80   5.68 ± 0.78 
V511S/I569S  135.2   ± 2.1   83.69 ± 1.64 36.72 ± 0.77 
R474A    44.00 ± 1.80   23.28 ± 1.71 11.05 ± 1.24 
R515A 35.94    ± 1.04   37.30 ± 0.90   4.69 ± 0.75 





The mutants in pocket B turned the hydrophobic pocket to a hydrophilic one, which 
resulted in a more than 20-fold decrease in Ki values for all three compounds, confirming 
that the hydrophobic interactions were essential for the small molecules to bind. 
R474 and R515 of the arginine channel were mutated to alanine. The deletion of 
two guanidino groups of R474 and R5151 leads to a drastic reduction of the inhibitory 
activity (greater than 50-fold change for 2.12 and 2.66), suggesting that the inhibitors 
indeed interact with the guanidino groups to bind to the protein.   
Additionally, we tried to evaluate the binding affinities of 2.66 with mutant β-
catenin proteins with the ITC studies, but unfortunately, the heat generation was too low 
to be accurately determined, which insinuated that the inhibitor lost its binding affinity 
with mutant proteins. Therefore, with the result from above site-directed mutagenesis 
studies, we are confident that the designed small molecule inhibitors are utilizing the 
interactions as proposed. 
 
2.2.5 Inhibitor Selectivity Studies 
The selectivity assay was established by Dr. Min Zhang using FP to quantify the 
inhibitor selectivity between β-catenin/Tcf, β-catenin/E-cadherin, and β-catenin/APC 
interactions.26 The results are shown in Table 2.7. The selectivities of 2.66 for -
catenin/Tcf over β-catenin/E-cadherin interactions and -catenin/APC interactions are 
more than 175- and 63-fold, respectively. To our best knowledge, compound 2.66 is the 









Table 2.7   The FP selectivity assay to determine inhibitor selectivity of the potent 
small–molecule -catenin/Tcf inhibitors. 










PKF115–584 17.78 ± 2.13 13.04 ± 0.31 53.85 ± 0.08 0.7 3.0 
CGP049090 35.56 ± 4.40 14.39 ± 0.32 62.49 ± 0.05 0.4 1.8 
PKF118–310 5.82 ± 0.24 13.30 ± 0.11 171.3 ± 0.1 2.3 29.4 
UU-01 3.14 ± 0.48 103.6   ± 0.4 176.0 ± 0.1 33.0 56.0 
2.12 5.74 ± 0.76 136.0   ± 4.2 77.21 ± 1.75 23.7 13.5 
2.65 4.30 ± 0.59 158.0   ± 2.3 115.0 ± 2.9 36.8 26.7 





2.2.6 Cell-based Studies 
All cell-based studies were designed and performed in the Ji laboratory by Dr. Min 
Zhang. The Wnt-responsive luciferase reporter assay was performed using two cell lines, 
Wnt-activated human embryonic kidney cell (HEK) 293 and colorectal cancer cell SW480. 
HEK293 cells were co-transfected with β-catenin plasmid and TOPFlash (luciferase 
reporter gene with wild-type Tcf4 binding sites) or FOPFlash (luciferase reporter gene with 
mutant Tcf4 binding sites). SW480 cells were only transfected with TOPFlash or FOPFlash 
because this cell type itself harbors deletion APC and has highly elevated β-catenin. A 
known inhibitor of the canonical Wnt signaling pathway, quercetin (Figure 2.20),39 was 
used as a reference in the cell-based assays. 
Compound 2.78 (Figure 2.21), an ethyl ester derivative of 2.66, was synthesized 
for the cell-based assays since it was hard for 2.66 to pass through the cell membrane with 
two carboxylic acid groups. To our delight, compound 2.78 exhibited better inhibitory 
activity than 2.66 with IC50 values of 28.73 ± 3.09 and 37.57 ± 3.23 μM in luciferase 
reporter assays for SW480 and Wnt-activated HEK293 cells, while not reducing the 
FOPFlash luciferase activities (Figure 2.22), which is consistent with the specificity of this 
inhibition. 
The downregulation of 2.78 to the Wnt signaling pathway was evaluated by real-
time PCR study (Figure 2.23). AXIN2 and LGR5 are the specific targets of the canonical 
Wnt signaling pathway. Cyclin D1 and c-myc are two important target genes of canonical 
Wnt signaling that promote tumorigenesis. Compound 2.78 down-regulated the 











Figure 2.21. Wnt-responsive luciferase reporter assays for 2.66, 2.78 and quercetin. 
 
 
Figure 2.22. FOPFlash luciferase reporter assay results of 2.78. 
 
 
 IC50, μM 
Entry SW480 HEK293 
2.66 231.9 ± 3.2 n.d. 
2.78 28.7 ± 3.1 37.6 ± 3.2 




Figure 2.23. Quantitative real-time PCR study to determine the changes in mRNA 
expression of AXIN2, LGR5, cyclin D1, and c-myc in response to different concentrations 




The protein expression levels of cyclin D1, c-myc, and β-catenin in SW480 cells 
were also examined by the Western blot analysis (Figure 2.24). The protein expression 
levels of cyclin D1 and c-myc were significantly reduced after the treatment of 2.78.  The 
protein expression level of β-catenin was not affected by the treatment of 2.78, indicating 
that 2.78 does not inhibit the upstream sites of canonical Wnt signaling. 
Co-immunoprecipitation experiments were performed to evaluate inhibitor 
selectivity in colorectal cancer cell HCT116. As shown in Figure 2.25, compound 2.78 
inhibited β-catenin/Tcf PPIs in a dose-dependent manner but had no effect on β-catenin/E-
cadherin and β-catenin/APC PPIs at the highest examined concentration.  
Compound 2.78 also inhibited the growth of colorectal cancer cells with the IC50 





Figure 2.24. Western blot analysis to monitor the changes of protein expression of c-myc, 
cyclin D1, and β-catenin in response to different concentrations of 2.78. β-Tublin was used 




Figure 2.25. Co-immunoprecipitation experiments to evaluate inhibitor selectivity of 2.78 
for β-catenin/Tcf over β-catenin/E-cadherin and β-catenin/APC interactions. IP, 




SW480, HT29, and HCT116, respectively (Table 2.8).  This compound exhibited a much 
higher IC50 value of 84.02 ± 3.62 μM for normal cell HEK293, again demonstrating the 
selectivity of this inhibitor.  
 
2.3 Conclusion 
The discovery of small-molecule inhibitors that selectively disrupt one protein-
protein interface not only provides a class of new therapeutic targets but also greatly 
facilitates our understanding of the structure and dynamic aspects of cellular networks. In 
this chapter, alanine scanning and the FP assays were used to identify a selective binding 
site that is crucial for β-catenin/Tcf interactions but much less important for β-
catenin/cadherin and β-catenin/APC interactions. A new peptidomimetic strategy 
incorporating SiteMap and MCSS was used to explore new pockets/new binding elements 
adjacent to the hot spot. Hydrophobic pocket B and the positively charged arginine channel 
(pocket C) were employed to design new potent and selective inhibitors. After three rounds 
of structural optimization, compound 2.66 was identified as the best hit (Figure 2.26). Site-
directed mutagenesis and structure−activity relationship studies were performed to 
evaluate the binding mode of 2.66. 
Compound 2.66 has a Kd value of 0.418 μM for binding to β-catenin and a Ki value 
of 1.36 μM to completely disrupt β-catenin/Tcf interactions. It also exhibits dual selectivity 
for β-catenin/Tcf over β-catenin/E-cadherin and β-catenin/APC interactions. Compound 
2.78, an ethyl ester derivative of 2.66, can effectively pass the cell membrane and inhibit 
canonical Wnt signaling and the growth of colorectal cancer cells. This compound provides 
an excellent starting point to generating more potent and selective inhibitors specific for β-  
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Table 2.8 MTs assay to monitor the effects of 2.66, 2.78, and quercetin on the growth of 
colorectal cancer cells. n.d., not determined. 
 IC50, μM 
Entry SW480 HT29 HCT116 HEK293 
2.66 152.6 ± 3.7 130.4 ± 4.9 87.30 ± 6.07 n.d. 
2.78 10.77   ± 1.18 11.01  ± 1.15 28.83 ± 1.26 84.02 ± 3.62 









catenin/Tcf interactions. Furthermore, we envision that further modification of 2.66 with a 
focus on pockets B and C will lead to new inhibitors with better selectivity along with 
higher inhibitor potency. 
 
2.4 Methods and Experiments 
2.4.1 Protein Structure for Computer Modeling 
The crystallographic coordinates for human β-catenin (PDB id, 2GL7, 2.60 Å 
resolution, Rcryst = 0.223) were obtained from the Research Collaboratory for Structural 
Bioinformatics (RCSB) protein database.  All computational work was performed on Linux 
Red Hat 6.2 Workstations.  The preparation of the crystal structure and molecular modeling 
were achieved with the commercially available Accelrys Discovery Studio 3.0 
(http://accelrys.com/), Schrodinger (http://www.schrodinger.com/) and SYBYL-X 2.0 
(http://www.tripos.com) software packages.  The missing side chains of β-catenin were 
added in SYBYL X2.0.  The protonation states of the residues were set to pH 7.0 when 
adding the hydrogens.  The AMBER 7 force field 99 within SYBYL X2.0 was used to 
optimize the orientation of hydrogen atoms and the missing side chains of the protein and 
structural waters.  After the protein structure was optimized.  Chains B (Tcf4), C (BCL9), 
D (the second monomer of β-catenin), E (the second monomer of Tcf4), F (the second 
monomer of BCL9), and solvent molecules were removed, leaving only one monomer of 
β-catenin for further calculation.  The residues in the Tcf4 G13ANDE17 binding site of β-
catenin include G422, S425–N426, T428–N430, K435, E462–P463, I465–C466, R469–
H470, S473–R474, Q482, L506–A509, V511–G512, R515–N516, L519, L536, L539, 





2.4.2 Fragment Docking using MCSS 
The functional groups chosen for the MCSS analysis were benzene, indole, 
cyclohexane, propane, isobutane, dimethyl ether, methanol, trans-N-methyl-acetamide, 
acetate anion, and methylammonium cation. The binding site area in the MCSS simulation 
was defined to include all the residues of the Tcf4 G13ANDE17 binding site. 2500–5000 
Replicas of a given functional group were randomly distributed inside the binding site (The 
distance threshold between fragment and protein was set to 0.9 Å) and then simultaneously 
and independently energy minimized. A distance-dependent dielectric model was used to 
approximate the solvent. Default iteration profile and energy thresholds were used. Pairs 
of molecules were considered to be identical if the rmsd between them was less than 0.2 
Å. The minima with the binding energy lower than 0 kcal/mol were retrieved in the 
analysis. All of the calculations were performed using the CHARMM force field and 
Momany and Rone partial charge.40 At the end of the MCSS run, energy minima within 
2.0 Å rmsd of each other were considered as one cluster, and the copy in each cluster with 
the lowest energy was selected as cluster representative. 
 
2.4.3 Ligand Docking using AutoDock 4.235  
In AutoDock studies, only the polar hydrogen atoms remained on the protein 
structure, and Kollman united atom charges were assigned. The 3D structures of the ligands 
were built, and the partial atomic charges were calculated using the Gasteiger–Marsili 
method.  The rotatable bonds in the ligands were defined using AutoTors, which also united 
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the nonpolar hydrogens and partial atomic charges to the bonded carbon atoms. The grid 
maps were calculated using AutoGrid. The AutoDock area was defined to include all the 
residues of the Tcf4 G13ANDE17 binding site, and the grid spacing was set to 0.375 Å. 
Docking was performed using the Lamarckian genetic algorithm, and the pseudo-Solis and 
Wets method were applied to the local search. Each docking experiment was performed 
100 times, yielding 100 docked conformations. Other settings were the standard default 
parameters. All of the ligands followed the same docking protocol. The results of the 
docking experiments were evaluated by the auxiliary clustering analysis and a visual 
inspection to match the proposed binding elements. 
 
2.4.4 FP Competitive Inhibition Assay26, 37 
Experiments were performed in 96-well Microfluor 2 black plates on a Synergy 2 
plate reader (Biotek). The polarization was measured at room temperature with an 
excitation wavelength at 485 nm and an emission wavelength at 535 nm. The FP 
experiments were performed in an assay buffer of 137 mM NaCl, 2.7 mM KCl, 10 mM 
Na2HPO4, 2 mM KH2PO4, 100 μg/mL of bovine gamma globulin, and 0.01% Triton-X 
100. The final reaction volume was set to 100 μL. For the β-catenin/Tcf assay, 10 nM of 
β-catenin (residues 142–686) was incubated with 2.5 nM of C-terminally fluorescein-
labeled human Tcf4 (residues 7–51) for 30 min at 4 °C, and then different concentrations 
of the tested peptides and compounds in assay buffer were added. The negative control 
(equiv to 0% inhibition) refers to 2.5 nM Tcf4 fluorescence tracer and 10 nM β-catenin in 
assay buffer without the tested compound. The positive control (equiv to 100% inhibition) 
refers to only 2.5 nM Tcf4 fluorescence tracer in assay buffer. For the β-catenin/cadherin 
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assay, 150 nM human β-catenin (residues 138−686) was incubated with 5 nM of C-
terminally fluorescent-labeled human E-cadherin (residues 819−873) in assay buffer for 30 
min at 4 °C. The negative control refers to 5 nM E-cadherin fluorescence tracer and 150 
nM β-catenin in assay buffer with no inhibitor presenting. The positive control refers to 5 
nM E-cadherin fluorescence tracer in assay buffer. For the β-catenin/APC-R3 assay, 2000 
nM human β-catenin (residues 138−686) was incubated with 5 nM of C-terminally 
fluorescent-labeled human APC-R3 (residues 1477−1519) in assay buffer for 30 min at 4 
°C. The negative control refers to 5 nM APC-R3 fluorescence tracer and 2000 nM β-catenin 
in assay buffer without the tested compound.  The positive control refers to 5 nM APC-R3 
fluorescence tracer in assay buffer. Each assay plate was covered black and gently mixed 
on an orbital shaker at 4 °C for 2.5 h to reach equilibrium before the polarization values 
were read. The background of the tested inhibitors was corrected by subtracting the raw 
intensity values of the sample background well (all components except probe) from the 
raw intensity values of the corresponding test wells (all components). The IC50 values were 
determined by GraphPad Prism 5.0. The Ki values were derived from the IC50 values.26 All 
of the experiments were performed in triplicate and carried out in the presence of 1% 
DMSO for small-molecule inhibitors. The results were expressed as mean ± standard 
deviation. The Tcf/cadherin selectivity ratios were calculated based on the respective Ki 
value of β-catenin/E-cadherin interactions over that of β-catenin/Tcf4 interactions. The 
Tcf/APC selectivity ratios were calculated based on the respective Ki value of β-





2.4.5 AlphaScreen Assay 
Experiments were performed in white opaque 384-well plates from PerkinElmer 
(Waltham, MA), and the samples were read on a Synergy 2 plate reader (Biotek, Winooski, 
VT) with a sensitivity setting of 200 using AlphaScreen protocol with excitation at 680 nm 
and emission at 570 nm.   All dilutions were made in 1 × assay buffer containing 25 mM 
HEPES (pH 7.4), 100 mM NaCl and 0.1% BSA to minimize nonspecific interactions.   In 
the AlphaScreen competitive inhibition assay, 20 nM of N-terminal His6-tagged β-catenin 
(residues 142-686) was incubated with 5 nM of C-terminal biotinylated Tcf4 45-mer 
(residues 7-51) for 30 min at 4 °C, and then different concentrations of the tested inhibitors 
in the assay buffer were added to make a final volume of 20 μL.  The mixture was incubated 
at 4 °C for 2 h.   Donor and acceptor beads were added to a final concentration of 10 μg/mL 
in 25 μL of assay buffer.  The mixture was incubated at 4 °C for 1 h. The IC50 value was 
determined by nonlinear least-square analysis of GraphPad Prism 5.0.  The Ki values were 
derived from the IC50 values by a reported method.41  Experiments were performed in 
triplicate and carried out in the presence of 1 % DMSO. 
 
2.4.6 ITC Experiments 
ITC measurements were performed at 30 °C using a VP-ITC (Microcal, GE 
Healthcare Life Sciences).  The concentrations of 2.66 and β-catenin were set to 80 μM 
and 8 μM, respectively, in a buffer of 20 mM HEPES, pH 7.5, 200 mM NaCl, 1mM TCEP, 
0.01% Triton X-100, and 8% glycerol.  Each titration experiment was initiated by a 2 μL 
injection, followed by 30–35 injections with 8 μL per injection.  Blank titrations, which 
were carried out by injecting the compound into the buffer, were subtracted from each data 
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set.  The association constant KA, enthalpy change (ΔH), and stoichiometry N were 
obtained from fitting the data using the Origin software package (Microcal).  The Kd, the 
free energy change ΔG, and the entropy change ΔS were obtained from the basic 
thermodynamic relationships Kd = KA–1, ΔG = –RTlnKA, and ΔG = ΔH − TΔS. 
 
2.4.7 Site-Directed Mutagenesis Studies 
β-Catenin mutants V511S, V511S/I569S, R474A, R515A, and R474A/R515A 
were generated using the overlapping PCR technique. The template for the mutagenesis 
reactions was the full-length wild-type β-catenin in pET-28a. KOD hot start DNA 
polymerase (Novagen) was used for all the experiments. Mutants were confirmed by direct 
sequencing (Core facility, University of Utah). The templates used for β-catenin double 
mutation were V511S for V511S/I569S and R474A for R474A/R515A, respectively. The 
double mutants were again confirmed by direct sequencing. Following the confirmation of 
the sequence, β-catenin mutants were cloned into a pET-28 vector and transformed into E. 
coli BL21 DE3.  
 
2.4.8 Cell Transfection and Luciferase Assay 
FuGENE6 (Promega) 96 well plate format was used for the transfection of HEK293 
and SW480 cells according to the manufacturer’s instructions.  HEK293 cells were 
cotransfected with 45 ng of TOPFlash or FOPFlash reporter gene, 135 ng pcDNA3.1–β-
catenin and 20 ng pCMV-RL normalization reporter gene.  SW480 cells were cotransfected 
with 60 ng of TOPFlash or FOPFlash reporter gene and 40 ng pCMV-RL normalization 
reporter.  Cells were cultured in DMEM and 10% FBS at 37 °C for 24 h and the different 
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concentrations of inhibitors or DMSO were then added. After 24 h, the luciferase reporter 
activity was measured using the Dual-Glo system (Promega).  Normalized luciferase 
activity in response to treatment with small-molecule compounds was compared with that 
obtained from cells treated with DMSO.  Experiments were performed in triplicate. 
 
2.4.9 Quantitative Real-Time PCR Analysis 
SW480 cells at 1 × 106/mL were treated with different concentrations of inhibitor 
for 24 h. Total RNAs were extracted with TRIzol (15596026, Life Technologies), and the 
cDNA was synthesized with the superscript III first-strand kit (18080-051, Invitrogen). 
Quantitative PCR (qPCR) was performed using the iQTM SYBR green supermix kit (170-
8880, BIO-RAD) on an iQ5 multicolor real-time PCR reaction system (BIO-RAD). The 
threshold cycle (CT) values were normalized to that of internal reference GAPDH. The 
primer pairs for human GAPDH were forward: 5-GAAGGTGAAGGTCGGAGTC-3, and 
reverse: 5-GAAGATGGTGATGGGATTTC-3, for human AXIN2 forward: 5-
AGTGTGAGGTCCACGGAAAC-3 and reverse: 5-CTTCACACTGCGATGCATTT-3, 
for human LGR5 forward: 5-TGCTGGCTGGTGTGGATGCG-3 and reverse: 5-
GCCAGCAGGGCACAGAGCAA-3, for human c-myc forward: 5-
CTTCTCTCCGTCCTCGGATTCT-3 and reverse: 5-
GAAGGTGATCCAGACTCTGACCTT-3, and for human cyclin D1 forward: 5-
ACAAACAGATCATCCGCAAACAC-3, and reverse: 5-





2.4.10 Western Blotting 
SW480 cells at 1 × 106 cells/mL were treated with different concentrations of 
inhibitor for 24 h. Cell were lysed in buffer containing 50 mM Tris (pH 7.4), 150 mM 
NaCl, 1% Nonidet P-40, 0.5% sodium deoxycholate, 0.1% SDS, and protease inhibitors. 
After centrifugation at 12,000 rpm for 20 min at 4 °C, the supernatant was loaded onto an 
8% SDS-polyacrylamide gel for electrophoretic analysis. Separated proteins were 
transferred onto nitrocellulose membranes for immunoblot analysis. IRDye 680LT goat 
anti-mouse IgG (827-11080, LiCOR) or IRDye 800CW goat anti-rabbit IgG (827-08365, 
LiCOR) was used as the secondary antibodies. The images were detected by the Odyssey 
Infrared Imaging System (LiCOR). Experiments were performed in duplicate. 
 
2.4.11 Co-immunoprecipitation Assay 
HCT116 cells at 1 × 106/mL were treated with different concentrations of inhibitor 
for 24 h. Cells were lysed in buffer containing 50 mM Tris, pH 7.4, 150 mM NaCl, 1% 
Nonidet P-40, 2 mM EDTA, and protease inhibitors. The lysates were preadsorbed to A/G 
plus agarose (sc-2003, Santa Cruz Biotechnology, Inc.) at 4 °C for 1 h. Preadsorbed lysates 
were incubated with a specific primary antibody overnight at 4 °C. A/G plus agarose was 
then added to the lysates mixture and incubated for 3 h. The beads were washed 5 times 
with the lysis buffer at 4 °C. The bound protein was eluted by boiling in the SDS sample 
buffer and loaded onto 8% SDS-polyacrylamide gel for electrophoretic analysis. Separated 
proteins were transferred onto nitrocellulose membranes for immunoblot analysis. IRDye 
680LT goat anti-mouse IgG (827-11080, LiCOR) was used as the secondary antibody. The 
images were detected by the Odyssey Infrared Imaging System (LiCOR). Experiments 
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were performed in duplicate. 
 
2.4.12 MT's Cell Viability Assay 
Colorectal cancer cell lines, SW480, HT29, and HCT116, and normal cell HEK293 
were seeded in 96 well plates at 4 × 103 cells/well, maintained overnight at 37 °C, and 
incubated in the presence of inhibitor at various concentrations.  Cell viability was 
monitored after 72 h using a freshly prepared mixture of 1 part phenazine methosulfate 
(PMS, Sigma) solution (0.92 mg/mL) and 19 parts 3-(4,5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTs, Promega) solution (2 
mg/mL).  Cells were incubated in 10 μL of this solution at 37 °C for 3 h and A490 was 
measured.  The effect of each compound is expressed as the concentration required to 




All experiments were conducted under anhydrous conditions in an atmosphere of 
argon, using flame-dried apparatus and employing standard techniques in handling air-
sensitive materials.  Dichloromethane (CH2Cl2), acetonitrile (CH3CN), tetrahydrofuran 
(THF), dimethylformamide (DMF) were degassed with nitrogen and passed through JC 
Meyer solvent systems.  All reagents were purchased from Sigma-Aldrich and used as 
received.  Aqueous solutions of sodium bicarbonate (NaHCO3), sodium chloride (brine), 
and ammonium chloride (NH4Cl) were saturated.  Analytical thin layer chromatography 
was visualized by ultraviolet light. Flash chromatography was performed on SilicaFlash@ 
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F60 silica gel (230–400 mesh).  1H NMR spectra were recorded using a Varian Unity Inova 
500 (500 MHz) or a Varian Unity Inova 300 (300 MHz).  13C NMR spectra were recorded 
using a Varian Unity Inova 500 (125 MHz) or Varian Unity Inova 300 (75 MHz).  The 1H 
and 13C NMR spectra were referenced to the residual solvent signals (7.26 ppm for 1H and 
77.0 ppm for 13C in CDCl3; 2.50 ppm for 1H and 39.5 ppm for 13C in DMSO-d6).  All 
melting points were determined on a Büchi M560 melting point apparatus and uncorrected.  
Low (MS) and high (HRMS) mass spectra were determined on a Micromass Quattro II 
(ESI/APCI-TOF) at the University of Utah, Department of Chemistry Mass Spectrometry 
Facility. 
 
2.4.14 Synthetic Routes, Procedures and Characterizations 
 
5-(tert-Butyl) 1-methyl (((9H-fluoren-9-yl)methoxy)carbonyl)-L-glutamate 
(2.14). To a stirred solution of 4.25 g Fmoc-Glu(OtBu)-OH (10 mmol) in 40 mL DMF at 
room temperature, was added 1.40 g K2CO3 (10 mmol) and 0.75 mL CH3I (12 mmol). The 
reaction was kept at room temperature for 4 h. Upon completion, the reaction mixture was 
poured into 100 mL 1 M HCl (aq) and extracted with ethyl acetate (3 × 50 mL). The organic 
layers were combined and washed successively by saturated NaHCO3 (aq), 5% Na2S2O3 
(aq) and brine (100 mL each). The solvent was evaporated and in vacuo and the residue 
was purified by flash column chromatography (haxanes : ethyl acetate = 7:3) to yield 4.3 
g product as colorless oil (98%). 1H NMR (300 MHz, Chloroform-d) δ 7.77 (d, J = 7.5 Hz, 
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1H), 7.60 (dd, J = 7.6, 3.3 Hz, 2H), 7.40 (td, J = 7.4, 0.6 Hz, 1H), 7.32 (td, J = 7.7, 1.0 Hz, 
1H), 5.50 (d, J = 8.2 Hz, 1H), 4.48 – 4.32 (m, 3H), 4.22 (t, J = 7.0 Hz, 1H), 3.76 (s, 3H), 
2.33 (q, J = 7.4, 6.9 Hz, 2H), 2.28 – 2.07 (m, 1H), 1.98 (tt, J = 13.5, 6.2 Hz, 1H), 1.45 (s, 
9H). 13C NMR (75 MHz, CDCl3) δ 172.8, 172.3, 156.2, 144.1, 143.9, 141.5, 127.9, 127.3, 
125.3, 120.2, 81.1, 67.3, 53.7, 52.8, 47.4, 31.6, 28.3, 27.7. 
General procedure for deprotection of Fmoc-protected amine.  At 0 ˚C, to a 
stirred solution of Fmoc protected 53 in anhydrous dichloromethane (40 mL), equal volume 
of diethyl amine (40 mL) was added dropwise over 30 min. The reaction was kept at 0 ˚C 
for 4-6 h until TLC showed no starting material left. Upon completion, 20 mL anhydrous 
toluene was added to the reaction, and the mixture was evaporated under reduced pressure. 
The residue was purified by flash column chromatography (hexanes : ethyl acetate : 
methanol = 5:5:0 to 2:8:0.05) to afford the desired amine.   
 
(S)-5-tert-Butyl 1-methyl 2-((S)-2-amino-4-(tert-butoxy)-4-oxobutanamido) 
pentanedioate (2.15).  White solid, 65%.  1H NMR (500 MHz, Chloroform-d) δ 3.65 (s, 
3H), 3.40 (dd, J = 8.2, 5.3 Hz, 1H), 2.36 – 2.24 (m, 2H), 1.96 (dtd, J = 13.2, 7.6, 5.4 Hz, 
1H), 1.78 – 1.66 (m, 1H), 1.37 (d, J = 1.6 Hz, 9H). 13C NMR (126 MHz, Chloroform-d) δ 





glutamate hydrochloride (2.18). White solid, 85%.  1H NMR (300 MHz, Chloroform-d) 
δ 7.90 (d, J = 8.4 Hz, 1H), 4.55 (td, J = 8.4, 5.0 Hz, 1H), 3.71 (s, 3H), 3.62 (dd, J = 7.8, 3.8 
Hz, 1H), 2.75 (dd, J = 16.8, 3.8 Hz, 1H), 2.56 (dd, J = 16.8, 7.9 Hz, 1H), 2.27 (ddd, J = 
7.6, 6.8, 3.6 Hz, 2H), 2.20 – 2.03 (m, 1H), 1.90 (dtd, J = 13.8, 8.3, 6.2 Hz, 1H), 1.41 (s, 
9H), 1.40 (s, 9H). 13C NMR (75 MHz, CDCl3) δ 173.8, 172.5, 172.2, 171.4, 81.4, 80.8, 
52.6, 52.2, 51.6, 40.6, 31.5, 28.3, 28.3, 27.8. 
 
(S)-4-((S)-2-Acetamido-3-carboxypropanamido)-5-methoxy-5-oxopentanoic 
acid (2.31). To a stirred solution of 2.18 (0.219 g, 0.515 mmol) in 20 mL dichloromethane 
at 0 ˚C was added acetyl chloride (37 µL, 0.52 mmol) and triethyl amine (145 µL, 1.1 
mmol).  The reaction was kept at 0 ˚C for 3 h until TLC showed no starting material.  The 
solvent was evaporated under reduced pressure.  Resulting solids were broken up in 20 mL 
1 M HCl (aq), and then extracted with ethyl acetate (2 × 15 mL).  Organic layers were 
combined and washed with NaHCO3 (aq) and brine successively, and then dried over 
Na2SO4.  The solvent was evaporated under reduced pressure to afford 0.21 g 2.30 as white 
syrup (95%).  Deprotection of the tert-Butyl esters followed the general procedure to yield 
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2.31 as white solid with quantitative yield.  1H NMR (400 MHz, DMSO) δ ppm 8.77 (d, 
1H, J = 4 Hz), 8.53 (d, 1H, J = 8 Hz), 4.59 (m. 1H), 4.26 (m, 1H), 3.62 (s, 3H), 2.62 (dd, 
1H, J = 4.7 Hz, J = 16.5 Hz), 2.46 (dd, 1H, J = 8.6 Hz, J = 16.5 Hz), 2.28 (m, 2H), 1.96 
(m, 1H), 1.80 (m, 4H).  13C NMR (100 MHz, DMSO) δ ppm 174.2, 172.5, 172.0, 171.6, 
169.8, 52.3, 51.8, 49.7, 36.7, 30.2, 26.4, 23.0.  HRMS (ESI) m/e calcd. for C12H17N2O8 [M 
– H]– 317.0990, found 317.0987. 
 
(S)-3-Carboxy-1-(((S)-4-carboxy-1-methoxy-1-oxobutan-2-yl) amino)-1-
oxopropan-2-aminium 2,2,2-trifluoroacetate (2.33).  White syrup; quantitative.  1H 
NMR (500 MHz, DMSO) δ ppm 8.81 (d, 1H, J = 7 Hz), 8.19 (s, 3H), 4.33 (q, 1H, J = 8.2 
Hz, J = 15.5 Hz), 4.11 (s, 1H), 3.62 (s, 3H), 2.81 (dd, 1H, J = 1.8 Hz, J = 18.3 Hz), 2.70 
(dd, 1H, J = 8.8 Hz, J = 17.8 Hz), 2.29 (m, 2H), 1.99 (m, 1H), 1.79 (m, 1H).  13C NMR 
(125 MHz, DMSO) δ ppm 174.2, 172.2, 171.5, 168.7, 52.8, 52.2, 49.4, 36.0, 30.3, 26.6.  
HRMS (ESI) m/e calcd. for C10H17N2O7 [M – CF3COO]+ 277.1030, found 277.1021. 
 
(2-Amino-5-chlorobenzyl) triphenylphosphonium chloride (2.23).  To a stirred 
solution of 3.15 g 5-chloro-2-amino benzyl alcohol (20 mmol), 5.25 g triphenylphosphine 
(20 mmol), and 5 g molecular sieves (4 Å) in 100 mL acetonitrile at reflux, was added 1.67 
mL of 12 M HCl (aq) dropwise.  A precipitate was formed, and the mixture was further 
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refluxed for 4 h until TLC showed no starting material.  The reaction mixture was cooled 
in an ice bath allowing full precipitation.  Solids were filtered. The filter cake was washed 
with ice cold acetonitrile (2 × 5 mL), hexanes (2 × 20 mL) to give 7.89 g product as light 
orange-pink solids (90%), which was pure enough to use for the next step without further 
purification. 
 
Ethyl 2-(5-chloro-1H-indol-2-yl) acetate (2.24).  At room temperature, 4.4 g 2.23 
(10 mmol) was suspended in 100 mL anhydrous dichloromethane.  Then 1.54 mL ethyl 3-
chloro-3-oxopropanoate (1.1 equiv) was added dropwise.  The reaction was stirred at room 
temperature overnight.  Upon completion, solvent was removed under reduced pressure to 
afford crude product, which was used without further purification.  The generated (5-
chloro-2-(3-ethoxy-3-oxopropanamido) benzyl) triphenyl phosphonium chloride (5.5 g, 10 
mmol) was suspended in 150 mL anhydrous toluene under the protection of argon.  The 
solution was heated to reflux for 15 min, and then 1.68 g t-BuOK (15 mmol) was added in 
small portions over 15 min.  The reaction was further heated to reflux for another 30 min.  
Upon completion, the reaction was cooled to room temperature, and then filtered through 
a Celite plug.  The resulting dark yellow-green filtrate was then concentrated under reduced 
pressure, and the residue was then purified by column chromatography (ethyl acetate : 
hexanes = 2:8) to afford 1.3 g product as a light orange solid (54% over 2 steps). 1H NMR 
(300 MHz, Chloroform-d) δ ppm 8.84 (s, 1H), 7.51 (d, 1H, J = 2.0 Hz), 7.21 (td, 1H, J = 
0.6 Hz, J = 8.6 Hz), 7.09 (dd, 1H, J = 2.0 Hz, J = 8.6 Hz), 6.29 (dd, 1H, J = 0.9 Hz, J = 
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2.0 Hz), 4.23 (q, 1H, J = 7.2 Hz), 3.81 (d, 1H, J = 0.7 Hz), 1.31 (t, 1H, J = 7.2 Hz). 13C 
NMR (75 MHz, CDCl3) δ ppm 170.8, 134.9, 132.4, 129.5, 125.6, 122.1, 119.7, 112.0, 
101.7, 61.8, 34.0, 14.4. MS (ESI) m/e = 238.2 [M + H]+. 
 
2-(5-Chloro-1H-indol-2-yl) acetic acid (2.25).  To a stirred solution of 0.237 g 
23a (1 mmol) in 10 mL THF was added 10 mL 2 M LiOH (aq).  The reaction was brought 
to reflux for 6 h.  Upon completion, the reaction mixture was poured into 30 mL 1 M NaOH 
(aq), and then washed with dichloromethane (2 × 20 mL).  The aqueous layer was acidified 
to pH ~4 by adding 2 M HCl (aq).  A white precipitate was formed and extracted with ethyl 
acetate (2 × 30 mL).  Organic layers were combined and washed with brine and dried over 
Na2SO4.  Solvent was evaporated under reduced pressure to afford 0.201 g title compound 
as a light brown solid (96%).  1H NMR (500 MHz) 12.54 (s, 1H), 11.20 (s, 1H), 7.47 (s, 
1H), 7.31 (d, 1H, J = 8.6 Hz), 7.01 (m, 1H), 6.25 (d, 1H, J = 0.6 Hz), 3.74 (s, 1H).  13C 
NMR (125 MHz) 172.0, 135.3, 135.2, 129.9, 123.9, 121.1, 119.2, 113.0, 101.1, 34.5.  MS 
(ESI) m/e = 208.1 [M − H]+. 
 
Ethyl 2-(1H-indol-2-yl) acetate (2.43a).  The same procedure as 2.25.  Light 
brown oil; yield, 33% for four steps. 1H NMR (300 MHz, Chloroform-d) δ ppm 8.75 (s, 
1H), 7.64 (d, 1H, J = 7.5 Hz), 7.36 (d, 1H, J = 8.0 Hz), 7.24 (dd, 1H, J = 1.3 Hz, J = 7.1 
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Hz), 7.20 (t, 1H, J = 1.8 Hz), 7.16 (dd, 1H, J = 1.2 Hz, J = 7.1 Hz), 6.42 (d, 1H, J = 1.1 
Hz), 4.27 (q, 2H, J = 7.1 Hz), 3.85 (s, 2H), 1.35 (t, 3H, J = 7.2 Hz).  13C NMR (75 MHz, 
CDCl3) δ ppm 171.0, 136.6, 130.9, 128.5, 121.9, 120.4, 120.1, 111.2, 102.1, 61.7, 34.3, 
14.5.  MS (ESI) m/e = 204.1 [M + H]+. 
 
Methyl 2-(5-bromo-1H-indol-2-yl) acetate (2.43b).  The same procedure as 2.25.  
Light yellow oil; yield, 36% for four steps. 1H NMR (300 MHz, Chloroform-d) δ ppm 8.75 
(s, 1H), 7.50 (d, 1H, J = 1.9 Hz), 7.24 (d, 1H, J = 8.7 Hz), 7.10 (dd, 1H, J = 2.0 Hz, J = 
8.6 Hz), 6.28 (dd, 1H, J = 0.9 Hz, J = 1.9 Hz), 3.83 (s, 2H), 3.76 (s, 3H).  13C NMR (75 
MHz, CDCl3) δ ppm 171.1, 134.8, 132.1, 129.4, 125.6, 122.2, 119.7, 112.0, 101.8, 52.7, 
33.8.  MS (ESI) m/e = 268.1 [M + H]+. 
General procedure of alkylation of tyrosine.  To a stirred solution of 0.295 g 
Boc-Tyr-OMe (1 mmol) in 15 mL acetone was added 0.15 g K2CO3 and 5 equiv of alkyl 
iodide.  The reaction was heated to reflux overnight for MeI and 3 d for i-PrI.  Upon 
completion, the reaction mixture was poured into 30 mL 1 M HCl (aq) and extracted with 
ethyl acetate (2 × 20 mL).  Organic layers were combined and washed successively by 
saturated NaHCO3 (aq), 5% Na2S2O3 (aq), and brine.  The organic layer was concentrated 
under reduced pressure, and the residue was purified by column chromatography to afford 




Boc-L-Tyr(OMe)-OMe (2.20).  Colorless oil; yield, 92–95%. 1H NMR (300 MHz, 
Chloroform-d) δ ppm 7.03 (d, 2H, J = 8.6 Hz), 6.82 (d, 2H, J = 8.7 Hz), 4.96 (d, 1H, J = 
8.0 Hz), 4.53 (dd, 1H, J = 6.0 Hz, J = 14.2 Hz), 3.78 (s, 3H), 3.71 (s, 3H), 3.02 (m, 2H), 
1.41 (s, 9H).  13C NMR (75 MHz, CDCl3) δ ppm 172.6, 158.8, 155.3, 130.5, 128.1, 114.2, 
80.1, 55.4, 54.7, 52.4, 37.7, 28.5. MS (ESI) m/e = 310.2 [M + H]+. 
 
Boc-L-Tyr(OiPr)-OMe (2.68).  Colorless oil; yield, 70–77%.  1H NMR (500 MHz, 
Chloroform-d) δ ppm 6.99 (d, 2H, J = 8.2 Hz), 6.78 (d, 2H, J = 8.5 Hz), 4.99 (d, 1H, J = 
7.6 Hz), 4.48 (m, 2H), 3.68 (s, 3H), 2.99 (ddd, 2H, J = 6.0 Hz, J = 14.0 Hz, J = 28.0 Hz), 
1.39 (s, 9H), 1.29 (d, 6H, J = 6.1 Hz).  13C NMR (125 MHz, CDCl3) δ ppm 172.6, 157.1, 
155.3, 130.5, 127.9, 116.1, 80.0, 70.0, 54.7, 52.3, 37.6, 28.5, 22.3. MS (ESI) m/e = 338.3 
[M + H]+. 
General procedure for formation of methyl ester.  At 0 ˚C, to a stirred solution 
of carboxylic acid (1 equiv) and K2CO3 (1.2 equiv) in DMF was added MeI (1.5 equiv). 
The reaction was allowed to warm to room temperature.  Upon completion, the reaction 
mixture was poured into 50 mL 2 M HCl (aq), and then extracted with ethyl acetate (2 × 
30 mL).  The organic layers were combined and washed with NaHCO3 (aq), 5% Na2S2O3 
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(aq), and brine.  Solvent was removed under reduced pressure.  Column chromatography 
was used to purify the product if needed. 
 
Boc-L-Phe(4-Cl)-OMe (2.74d).  Colorless oil; yield, 97%.  1H NMR (500 MHz, 
Chloroform-d) δ ppm 7.26 (d, 2H, J = 8.2 Hz), 7.05 (d, 2H, J = 8.1 Hz), 4.97 (d, 1H, J = 
6.9 Hz), 4.57 (dd, 1H, J = 6.2 Hz, J = 13.2 Hz), 3.71 (s, 3H), 3.10 (dd, 1H, J = 5.6 Hz, J 
= 13.8 Hz), 3.00 (dd, 1H, J = 6.0 Hz, J = 13.9 Hz), 1.42 (s, 9H).  13C NMR (125 MHz, 
CDCl3) δ ppm 173.2, 172.3, 134.8, 130.8, 128.9, 95.0, 80.3, 54.5, 52.5, 38.0, 28.5. 
 
Boc-L-(2-Nal)-OMe (2.74e).  Pale yellow oil; yield, 92%. 1H NMR (500 MHz, 
Chloroform-d) δ ppm 7.80 (m, 3H), 7.59 (s, 1H), 7.46 (m, 2H), 7.26 (m, 1H), 5.00 (d, 1H, 
J = 8.4 Hz), 4.67 (dd, 1H, J = 5.9 Hz, J = 13.6 Hz), 3.72 (s, 3H), 3.29 (dd, 1H, J = 5.9 Hz, 
J = 13.7 Hz), 3.21 (dd, 1H, J = 6.2 Hz, J = 13.9 Hz), 1.40 (s, 9H).  13C NMR (125 MHz, 
CDCl3) δ ppm 172.6, 155.3, 133.8, 133.6, 132.7, 128.5, 128.3, 127.9, 127.8, 127.5, 126.4, 
125.9, 80.2, 54.7, 52.5, 38.7, 28.5. 
General procedure for deprotection of Boc-protected amine.  At 0 ˚C, to a 
solution of the Boc-protected amine in anhydrous dichloromethane (0.1 M, 20 mL) was 
added dropwise 20 mL 4 M HCl in dioxane.  The reaction was kept at 0 ˚C for 10-12 h 
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until TLC showed no starting material left.  Upon completion, the solvent was removed 
under reduced pressure to afford the desired amine as HCl salt.  The amine was used 
directly without further purification. 
General peptide coupling procedure.  At 0 ˚C, to a suspension of carboxylic acid 
(1 equiv), amine (HCl salt, 1 equiv), EDC•HCl (1.2 equiv), and HOAt (1 equiv) in 
anhydrous dichloromethane was added triethylamine (2.5 equiv) dropwise.  A clear yellow 
solution was formed.  The reaction was kept at 0 ˚C for 4-5 h until TLC showed no starting 
material left.  The reaction was concentrated under reduced pressure.  Residue was broken 
up in ethyl acetate and ice-cold 2 M HCl (aq).  The organic layer was washed with equal 
volume of saturated NaHCO3 (aq) and brine.  The organic layer was dried over Na2SO4 
and then evaporated under reduced pressure.  Column chromatography was used to purify 
the final product if necessary. 
 
5-(tert-Butyl) 1-methyl ((S)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-
4-(tert-butoxy)-4-oxobutanoyl)-L-glutamate (2.17). 1H NMR (300 MHz, Chloroform-d) 
δ 7.71 (d, J = 7.5 Hz, 1H), 7.56 (d, J = 7.4 Hz, 2H), 7.41 – 7.29 (m, 2H), 7.27 (t, J = 6.6 
Hz, 2H), 6.07 (d, J = 8.7 Hz, 1H), 4.56 (td, J = 8.2, 4.8 Hz, 1H), 4.38 (d, J = 7.1 Hz, 2H), 
4.19 (t, J = 7.1 Hz, 1H), 3.68 (s, 3H), 2.92 (dd, J = 17.3, 4.5 Hz, 1H), 2.60 (dd, J = 17.2, 
6.3 Hz, 1H), 2.39 – 2.23 (m, 2H), 2.12 (d, J = 5.0 Hz, 0H), 1.93 (ddd, J = 12.7, 8.5, 6.2 Hz, 
1H), 1.42 (s, 9H), 1.39 (s, 9H). 13C NMR (75 MHz, CDCl3) δ 172.3, 172.1, 170.8, 156.2, 
143.8, 141.5, 127.9, 127.3, 125.3, 120.2, 82.1, 80.9, 77.8, 77.4, 77.0, 67.5, 52.7, 52.1, 51.3, 
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47.3, 37.8, 31.4, 28.2, 27.4. 
 
(S)-Methyl 2-(2-(5-chloro-1H-indol-2-yl) acetamido)-3-(4-methoxyphenyl) 
propanoate (2.26).  Light orange solid; yield, 93%; m.p. 138.6-140.5˚C.  1H NMR (300 
MHz, Chloroform-d) δ ppm 9.07 (s, 1H), 7.51 (d, 1H, J = 2.0 Hz), 7.21 (d, 1H, J = 8.6 
Hz), 7.11 (dd, 1H, J = 2.0 Hz, J = 8.6 Hz), 6.73 (d, 2H, J = 8.7 Hz), 6.54 (d, 2H, J = 8.7 
Hz), 6.29 (t, 1H, J = 6.9 Hz), 6.23 (d, 1H, J = 1.3 Hz), 4.80 (td, 1H, J = 5.7 Hz, J = 7.9 
Hz), 3.72 (s, 3H), 3.68 (s, 3H), 3.64 (s, 2H), 3.01 (dd, 1H, J = 5.7 Hz, J = 14.2 Hz), 2.94 
(dd, 1H, J = 6.1 Hz, J = 14.2 Hz).  13C NMR (75 MHz, CDCl3) δ ppm 172.1, 169.4, 158.9, 
135.0, 133.2, 130.2, 129.6, 127.2, 125.6, 122.3, 119.7, 114.1, 112.2, 101.8, 55.4, 53.5, 52.7, 
36.8, 36.2.  MS (ESI) m/e = 401.2 [M + H]+. 
 
  (S)-Methyl 2-(2-(5-chloro-1H-indol-2-yl) acetamido)-3-(4-isopropoxyphenyl) 
propanoate (2.75a).  Light orange solid; yield, 87%.  1H NMR (300 MHz, Chloroform-d) 
δ ppm 9.19 (s, 1H), 7.51 (d, 1H, J = 2.0 Hz), 7.21 (d, 1H, J = 8.6 Hz), 7.11 (dd, 1H, J = 
2.0 Hz, J = 8.6 Hz), 6.70 (d, 2H, J = 8.6 Hz), 6.51 (d, 2H, J = 8.6 Hz), 6.36 (d, 1H, J = 
7.8 Hz), 6.23 (d, 1H, J = 1.2 Hz), 4.79 (td, 1H, J = 5.7 Hz, J = 7.8 Hz), 4.36 (sept., 1H, J 
= 6.0 Hz), 3.71 (s, 3H), 3.64 (d, 2H, J = 1.5 Hz), 2.99 (dd, 1H, J = 5.3 Hz, J = 13.9 Hz), 
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2.93 (dd, 1H, J = 5.8 Hz, J = 14.0 Hz), 1.30 (d, 3H, J = 3.5 Hz), 1.28 (d, 3H, J = 3.6 Hz).  
13C NMR (75 MHz, CDCl3) δ ppm 172.1, 169.5, 157.2, 135.0, 133.3, 130.3, 129.6, 126.9, 
125.6, 122.3, 119.7, 116.0, 112.2, 101.8, 70.0, 53.5, 52.7, 36.8, 36.3, 22.3, 22.2. 
 
(S)-Methyl 2-(2-(5-chloro-1H-indol-2-yl) acetamido)-3-(naphthalen-2-yl) 
propanoate (2.75e).  Orange solid; yield, 91%.  1H NMR (500 MHz, Chloroform-d) δ ppm 
8.80 (s, 1H), 7.74 (d, 1H, J = 8.3 Hz), 7.56 (d, 1H, J = 8.4 Hz), 7.46 (m, 4H), 7.33 (s, 1H), 
7.12 (s, 1H), 7.10 (s, 1H), 7.01 (d, 1H, J = 8.4 Hz), 6.26 (d, 1H, J = 7.6 Hz), 6.16 (s, 1H), 
4.93 (dd, 1H, J = 6.1 Hz, J = 13.2 Hz), 3.74 (s, 3H), 3.60 (s, 2H), 3.27 (dd, 1H, J = 5.4 
Hz, J = 13.9 Hz), 3.16 (dd, 1H, J = 6.3 Hz, J = 13.9 Hz).  13C NMR (125 MHz, CDCl3) δ 
ppm 172.0, 169.4, 134.9, 133.5, 132.9, 132.6, 129.5, 128.6, 128.2, 127.9, 127.7, 127.1, 
126.5, 126.161, 125.7, 122.3, 119.8, 112.1, 101.7, 53.4, 52.8, 37.8, 36.2. 
General procedure for formation of N-Boc protected indole.  At room 
temperature, 1 equiv of indole compound was dissolved in anhydrous dichloromethane.  
Then 1.5 equiv of Boc2O was added to the solution, followed by 0.1 equiv of DMAP.  After 
10-30 min, the reaction was confirmed to reach completion.  The solvent was removed 
under reduced pressure, and the residue was purified by column chromatography (hexanes 
: ethyl acetate = 9:1).  At 0 ˚C, to a solution of methyl ester in THF (0.1 M, 5 mL) was 
added dropwise 5 mL 2 M LiOH (aq).  The reaction was kept at 0 ˚C for 2 h until TLC 
showed no starting material left.  The reaction mixture was poured into 20 mL 2 M HCl 
(aq) and extracted with 20 mL ethyl acetate. The organic layer was then washed with 20 
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mL brine and dried over Na2SO4.  Solvent was removed under reduced pressure to afford 
the desired carboxylic acid, which was used without further purification. 
 
(S)-tert-Butyl 2-(2-((1-methoxy-3-(4-methoxyphenyl)-1-oxopropan-2-yl) 
amino)-2-oxoethyl)-1H-indole-1-carboxylate (2.27).  Light yellow oil; yield, 86%.  1H 
NMR (500 MHz, Chloroform-d) δ ppm 8.13 (d, 1H, J = 8.4 Hz), 7.50 (d, 1H, J = 7.8 Hz), 
7.32 (t, 1H, J = 7.8 Hz), 7.24 (t, 1H, J = 8.1 Hz), 6.72 (d, 2H, J = 8.6 Hz), 6.53 (s, 1H), 
6.46 (d, 2H, J = 8.6 Hz), 6.33 (d, 1H, J = 7.9 Hz), 4.82 (td, 1H, J = 5.5 Hz, J = 7.8 Hz), 
3.97 (dd, 1H, J = 15.8 Hz, J = 36.3 Hz), 3.67 (s, 3H), 3.65 (s, 3H), 2.97 (dd, 1H, J = 5.6 
Hz, J = 14.0 Hz), 2.93 (dd, 1H, J = 5.6 Hz, J = 14.0 Hz), 1.63 (s, 9H).  13C NMR (125 
MHz, CDCl3) δ ppm 171.9, 169.1, 158.7, 150.8, 136.8, 134.0, 130.2, 129.1, 127.5, 124.5, 
123.2, 120.7, 116.1, 114.0, 111.4, 85.2, 55.3, 53.2, 52.4, 38.3, 37.0, 28.3. 
 
 (S)-tert-Butyl 5-bromo-2-(2-((1-methoxy-3-(4-methoxyphenyl)-1-oxopropan-
2-yl) amino)-2-oxoethyl)-1H-indole-1-carboxylate (2.46b).  Light yellow oil; yield, 
92%.  1H NMR (500 MHz, Chloroform-d) δ ppm 7.98 (d, 1H, J = 8.9 Hz), 7.61 (d, 1H, J 
= 1.7 Hz), 7.40 (dd, 1H, J = 1.8 Hz, J = 8.9 Hz), 6.74 (d, 2H, J = 8.4 Hz), 6.49 (d, 2H, J 
= 8.4 Hz), 6.44 (s, 1H), 6.22 (d, 1H, J = 7.7 Hz), 4.81 (td, 1H, J = 5.5 Hz, J = 7.7 Hz), 
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3.94 (q, 2H, J = 15.9 Hz), 3.68 (s, 3H), 2.97 (dd, 1H, J = 5.8 Hz, J = 14.3 Hz), 2.93 (dd, 
1H, J = 5.8 Hz, J = 14.2 Hz), 1.62 (s, 9H).  13C NMR (125 MHz, CDCl3) δ ppm 171.8, 
168.7, 158.7, 150.3, 135.5, 135.3, 130.7, 130.2, 127.5, 127.2, 123.2, 117.5, 116.494, 114.1, 
110.3, 85.7, 55.3, 53.2, 52.5, 38.2, 37.0, 28.3. 
 
(S)-tert-Butyl 5-chloro-2-(2-((3-(4-isopropoxyphenyl)-1-methoxy-1-oxopropan 
-2-yl) amino)-2-oxoethyl)-1H-indole-1-carboxylate (2.76a).  Light yellow oil; yield, 
96%. 1H NMR (300 MHz, Chloroform-d) δ ppm 8.04 (d, 1H, J = 8.9 Hz), 7.46 (d, 1H, J = 
1.9 Hz), 7.26 (dd, 1H, J = 2.3 Hz, J = 8.7 Hz), 6.71 (d, 2H, J = 8.4 Hz), 6.46 (m, 3H), 6.19 
(d, 1H, J = 8.1 Hz), 4.82 (td, 1H, J = 5.6 Hz, J = 8.2 Hz), 4.33 (sept, 1H, J = 6.0 Hz), 3.95 
(dd, 2H, J = 15.9 Hz, J = 20.7 Hz), 3.68 (s, 3H), 2.98 (dd, 1H, J = 5.3 Hz, J = 13.9 Hz), 
2.90 (dd, 1H, J = 5.6 Hz, J = 14.0 Hz), 1.63 (s, 9H), 1.28 (s, 3H), 1.26 (s, 3H).  13C NMR 
(75 MHz, CDCl3) δ ppm 171.9, 168.7, 157.1, 150.3, 135.4, 135.2, 130.2, 130.2, 128.8, 




yl) amino)-2-oxoethyl)-1H-indole-1-carboxylate (2.76d). Yellow oil; yield, 95%.  1H 
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NMR (300 MHz, Chloroform-d) δ ppm 7.97 (d, 1H, J = 8.9 Hz), 7.46 (d, 1H, J = 2.0 Hz), 
7.27 (dd, 1H, J = 2.2 Hz, J = 8.9 Hz), 6.94 (d, 2H, J = 8.4 Hz), 6.77 (d, 2H, J = 8.4 Hz), 
6.50 (s, 1H), 6.48 (s, 1H), 4.81 (td, 1H, J = 5.6 Hz, J = 7.6 Hz), 3.95 (dd, 2H, J = 15.4 Hz, 
J = 52.7 Hz), 3.69 (s, 3H), 3.05 (dd, 1H, J = 5.6 Hz, J = 13.9 Hz), 2.97 (dd, 1H, J = 5.5 
Hz, J = 13.9 Hz), 1.61 (s, 9H).  13C NMR (75 MHz, CDCl3) δ ppm 171.6, 168.9, 150.6, 
135.6, 134.9, 134.3, 133.1, 130.6, 130.2, 128.9, 128.7, 124.7, 120.2, 117.2, 110.5, 85.7, 
53.2, 52.6, 38.1, 37.1, 28.2. 
 
(S)-tert-Butyl 2-(2-((3-(1H-indol-3-yl)-1-methoxy-1-oxopropan-2-yl) amino)-2-
oxoethyl)-5-chloro-1H-indole-1-carboxylate (2.76f).  Light yellow oil; yield, 93%. 1H 
NMR (500 MHz, Chloroform-d) δ ppm 7.99 (d, 1H, J = 9.0 Hz), 7.88 (s, 1H), 7.43 (d, 1H, 
J = 8.0 Hz), 7.41 (d, 1H, J = 2.0 Hz), 7.26 (m, 2H), 7.13 (t, 1H, J = 7.6 Hz), 6.99 (dt, 1H, 
J = 0.9 Hz, J = 7.5 Hz), 6.67 (d, 1H, J = 1.8 Hz), 6.33 (s, 1H), 6.23 (d, 1H, J = 7.6 Hz), 
4.87 (dd, 1H, J = 5.6 Hz, J = 13.2 Hz), 3.90 (q, 2H, J = 16.0 Hz), 3.65 (s, 3H), 3.23 (d, 
2H, J = 5.6 Hz), 1.54 (s, 9H).  13C NMR (125 MHz, CDCl3) δ ppm 172.3, 168.9, 150.2, 
136.2, 135.4, 135.2, 130.1, 128.7, 127.5, 124.5, 122.9, 122.4, 120.1, 119.8, 118.6, 117.0, 






propanamido)-4-oxobutanamido) pentanedioate (2.29).  Light yellow syrup; yield, 
86%.  1H NMR (300 MHz, Chloroform-d) δ ppm 8.01 (d, 1H, J = 9.0 Hz), 7.43 (d, 1H, J 
= 2.0 Hz), 7.28 (dd, 1H, J = 2.2 Hz, J = 9.0 Hz), 7.17 (dd, 1H, J = 3.1 Hz, J = 8.2 Hz), 6.76 
(d, 2H, J = 8.6 Hz), 6.43 (d, 2H, J = 8.6 Hz), 6.13 (d, 1H, J = 6.4 Hz), 4.73 (ddd, 1H, J = 
4.2 Hz, J = 6.1 Hz, J = 8.5 Hz), 4.50 (m, 2H), 3.92 (m, 2H), 3.71 (s, 3H), 3.66 (s, 3H), 2.93 
(m, 3H), 2.46 (dd, 1H, J = 6.3 Hz, J = 17.2 Hz), 2.27 (m, 2H), 2.13 (m, 1H), 1.94 (m, 1H), 
1.61 (s, 9H), 1.41 (s, 9H), 1.41 (s, 9H).  13C NMR (75 MHz, CDCl3) δ ppm 172.2, 172.0, 
171.8, 170.5, 170.3, 170.0, 158.8, 150.2, 135.1, 134.8, 130.1, 130.0, 128.9, 127.4, 124.7, 
120.1, 117.1, 114.2, 110.8, 85.8, 82.1, 80.8, 55.2, 55.0, 52.6, 52.1, 49.2, 38.2, 36.9, 36.4, 




oxobutanamido) pentanedioate (2.47a).  Light orange syrup; yield, 83%.  Two rotamers.  
1H NMR (500 MHz, Chloroform-d) δ ppm 8.08 (d, 0.6H, J = 8.3 Hz, major), 8.04 (d, 0.4H, 
96 
 
J = 8.3 Hz, minor), 7.47 (t, 1H, J = 8.6 Hz, major + minor), 7.27 (m, 0.8H, minor), 7.17 
(dd, 1H, J = 5.1 Hz, J = 8.3 Hz, major + minor), 7.10 (d, 0.4H, J = 8.7 Hz, minor), 6.83 
(d, 1H, J = 8.6 Hz, major), 6.72 (d, 1H, J = 8.6 Hz, major), 6.52 (m, 1H, minor), 6.48 (s, 
0.6H, major), 6.38 (d, 1H, J = 8.6 Hz, minor), 6.34 (d, 0.4H, J = 6.3 Hz, minor), 6.17 (d, 
0.6H, J = 6.3 Hz, major), 4.78 (m, 0.6H, major), 4.71 (m, 1H, major + minor), 4.49 (m, 
2H, major + minor), 4.33 (q, 0.4H, J = 7.1 Hz, minor), 3.91 (m, 2H, major + minor), 3.70 
(s, 1.8H, major), 3.69 (s, 1.2H, minor), 3.67 (s, 1.8H, major), 3.67 (s, 1.2H, minor), 3.62 
(s, 2H), 2.87 (m, 3H, major + minor), 2.54 (dd, 0.6H, J = 6.8 Hz, J = 17.1 Hz, major), 2.47 
(dd, 0.4H, J = 6.1 Hz, J = 17.2 Hz, minor), 2.32 (m, 1H, major + minor), 2.25 (m, 3H, 
major + minor), 2.13 (m, 1H), 1.93 (m, 1H), 1.60 (s, 9H), 1.40 (m, 18H, major + minor).  
13C NMR (125 MHz, CDCl3) δ ppm 172.3, 172.1, 172.0, 172.0, 171.9, 171.8, 171.6, 170.9, 
170.8, 170.5, 170.4, 170.4, 170.6, 170.3, 158.7, 158.7, 150.6, 136.7, 136.6, 133.6, 133.2, 
130.1, 120.0, 129.0, 128.9, 127.9, 127.5, 124.7, 124.5, 123.3, 123.2, 120.6, 116.1, 116.0, 
114.2, 111.8, 111.6, 85.3, 85.1, 82.1, 82.0, 81.0, 80.7, 56.0, 55.3, 55.2, 55.1, 52.6, 52.5, 
52.1, 49.3, 49.2, 38.2, 37.3, 36.9, 36.6, 36.4, 36.3, 31.6, 31.5, 31.4, 28.3, 28.2, 27.3, 27.2, 




oxobutanamido) pentanedioate (2.47b).  Light yellow syrup; yield, 83%.  1H NMR (500 
MHz, Chloroform-d) δ ppm 7.98 (d, 1H, J = 9.0 Hz), 7.60 (d, 1H, J = 2.0 Hz), 7.43 (dd, 
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1H, J = 2.0 Hz, J = 8.9 Hz), 7.26 (m (overlapped with CHCl3), 1H), 7.15 (d, 2H, J = 8.1 
Hz), 6.77 (d, 2H, J = 8.6 Hz), 6.44 (d, 2H, J = 8.6 Hz), 6.43 (s, 1H), 6.10 (d, 1H, J = 6.5 
Hz), 4.73 (ddd, 1H, J = 3.9 Hz, J = 6.0 Hz, J = 8.8 Hz), 4.51 (m, 2H), 3.93 (dd, 2H, J = 
16.5 Hz, J = 28.5 Hz), 3.72 (s, 3H), 3.67 (s, 3H), 3.00 (dd, 1H, J = 6.7 Hz, J = 14.1 Hz), 
2.92 (m, 3H), 2.46 (dd, 1H, J = 6.3 Hz, J = 17.2 Hz), 2.28 (m, 2H), 2.15 (m, 1H), 1.95 (m, 
1H), 1.62 (s, 9H), 1.42 (s, 9H), 1.42 (s, 9H).  13C NMR (125 MHz, CDCl3) δ ppm 172.1, 
171.9, 171.8, 170.5, 170.3, 170.1, 169.9, 158.8, 135.5, 134.7, 130.6, 130.4, 130.0, 127.5, 
127.4, 123.2, 117.5, 116.6, 114.3, 110.7, 85.9, 82.1, 55.3, 55.0, 52.6, 52.1, 49.2, 38.2, 36.9, 




propanamido)-4-oxobutanamido) pentanedioate (2.77a).  Light orange oil; yield, 76%.  
Two rotamers.  1H NMR (500 MHz, Chloroform-d) δ ppm 8.03 (d, 0.6H, J = 9.0 Hz, 
major), 7.99 (d, 0.4H, J = 9.0 Hz, minor), 7.47 (d, 0.4H, J = 2.1 Hz, minor), 7.44 (d, 0.6H, 
J = 2.0 Hz, major), 7.30 (m, 1H, major + minor), 7.15 (dd, 1.2H, J = 5.5 Hz, J = 8.2 Hz, 
major), 7.06 (dd, 0.8H, J = 8.6 Hz, J = 18.8 Hz, minor), 6.87 (d, 0.8H, J = 8.5 Hz, minor), 
6.75 (d, 1.2H, J = 8.5 Hz, major), 6.56 (d, 0.8H, J = 8.6 Hz, minor), 6.48 (s, 0.4H, mimor), 
6.43 (d, 1.2H, J = 5.6 Hz, major), 6.40 (s, 0.8H, major), 6.28 (d, 0.4H, J = 6.6 Hz, minor), 
6.12 (d, 0.6H, J = 6.4 Hz, major), 4.71 (m, 1H, major + minor), 4.50 (m, 2H, major + 
minor), 4.40 (m, 1H, major + minor), 4.33 (sept, 1H, J = 6.0 Hz), 3.93 (m, 2H, major + 
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minor), 3.72 (s, 2H, major), 3.69 (s, 1H, minor), 3.01 (dd, 1H, J = 6.5 Hz, J = 14.0 Hz), 
2.90 (m, 1H), 2.45 (dd, 1H, J = 6.3 Hz, J = 17.2 Hz), 2.29 (m, 3H), 2.13 (m, 1H), 1.94 (m, 
1H), 1.63 (s, 9H), 1.42 (s, 9H), 1.42 (s, 9H).  13C NMR (125 MHz, CDCl3) δ ppm 172.1, 
171.9, 171.8, 170.3, 170.0, 150.2, 130.2, 130.1, 130.0, 127.2, 124.7, 124.6, 120.2, 117.1, 
117.1, 116.2, 116.1, 110.9, 110.7, 85.8, 85.6, 82.1, 80.8, 69.8, 55.9, 54.9, 52.6, 52.2, 52.1, 
49.2, 38.2, 36.9, 36.5, 31.6, 28.3, 28.3, 28.2, 28.2, 28.2, 27.3, 27.2, 22.3, 22.2, 22.1.  MS 




propanamido)-4-oxobutanamido) pentanedioate (2.77d).  Orange syrup; yield, 82%.  
1H NMR (500 MHz, Chloroform-d) δ ppm 7.95 (d, 1H, J = 8.8 Hz), 7.46 (d, 1H, J = 1.6 
Hz), 7.28 (m, 2H), 7.19 (m, 2H), 6.92 (d, 2H, J = 8.1 Hz), 6.85 (d, 2H, J = 8.2 Hz), 6.45 
(s, 1H), 6.29 (d, 1H, J = 6.6 Hz), 4.71 (td, 1H, J = 6.9 Hz, J = 13.5 Hz), 4.52 (m, 2H), 3.91 
(s, 2H), 3.71 (s, 3H), 2.99 (m, 2H), 2.89 (dd, 1H, J = 3.9 Hz, J = 17.2 Hz), 2.51 (dd, 1H, J 
= 6.4 Hz, J = 17.2 Hz), 2.29 (m, 2H), 2.13 (m, 1H), 1.93 (m, 1H), 1.61 (s, 1H), 1.43 (s, 
9H), 1.42 (s, 9H).  13C NMR (125 MHz, CDCl3) δ ppm 172.2, 171.9, 171.7, 170.3, 170.2, 
169.9, 150.3, 134.9, 134.9, 134.5, 133.2, 130.5, 130.4, 130.0, 129.0, 129.0, 124.8, 120.2, 
117.1, 110.7, 85.8, 82.2, 80.9, 54.8, 52.6, 52.1, 49.4, 38.0, 37.1, 36.8, 31.6, 28.3, 28.2, 27.3.  





2-yl) acetamido)-3-(naphthalen-2-yl) propanamido)-4-oxobutanamido) 
pentanedioate (2.77e).  Orange syrup; yield, 86%.  1H NMR (500 MHz, Chloroform-d) δ 
ppm 9.52 (s, 0.5H), 9.31 (s, 0.5H), 7.74 (m, 1H), 7.64 (m, 1H), 7.46 (m, 6H), 7.33 (m, 2H), 
7.20 (m, 1H), 7.06 (m, 2H), 6.67 (d, 0.5H, J = 6.3 Hz), 6.44 (d, 0.5H, J = 6.3 Hz), 6.12 (s, 
1H), 4.73 (m, 2H), 4.53 (m, 2H), 3.72 (s, 0.3H), 3.69 (s, 1.7H), 3.66 (m, 3H), 3.16 (m, 2H), 
2.87 (m, 1H), 2.42 (dd, 0.5H, J = 6.3 Hz, J = 17.2 Hz), 2.26 (m, 2.5H), 2.12 (m, 2H), 1.92 
(m, 1H), 1.41 (s, 9H), 1.34 (s, 9H).  13C NMR (125 MHz, CDCl3) δ ppm 172.7, 172.6, 
172.5, 172.0, 171.6, 171.0, 170.7, 170.5, 170.4, 135.3, 135.2, 133.6, 133.5, 133.1, 132.9, 
132.8, 132.6, 129.5, 129.4, 128.7, 128.7, 128.1, 128.0, 127.9, 127.7, 127.1, 126.9, 126.6, 
126.2, 125.7, 125.4, 122.4, 122.1, 119.8, 119.6, 112.4, 112.3, 102.1, 101.8, 82.3, 82.1, 81.2, 
81.0, 56.1, 55.2, 52.7, 52.1, 52.0, 49.4, 49.3, 37.5, 37.3, 37.0, 36.4, 36.3, 36.0, 31.8, 31.6, 






propanamido)-4-oxobutanamido) pentanedioate (2.77f).  Light orange syrup; yield, 
78%.  1H NMR (500 MHz, Chloroform-d) δ ppm 8.14 (s, 1H), 7.99 (d, 1H, J = 8.9 Hz), 
7.59 (d, 1H, J = 7.9 Hz), 7.44 (d, 1H, J = 2.1 Hz), 7.28 (dd, 1H, J = 2.1 Hz, J = 8.9 Hz), 
7.25 (d, 1H, J = 8.2 Hz), 7.13 (t, 1H, J = 7.6 Hz), 6.99 (m, 2H), 6.84 (d, 1H, J = 8.4 Hz), 
6.76 (d, 1H, J = 2.3 Hz), 6.42 (s, 1H), 6.36 (d, 1H, J = 6.4 Hz), 4.67 (m, 2H), 4.48 (dt, 1H, 
J = 5.3 Hz, J = 8.3 Hz), 3.94 (m, 2H), 3.71 (s, 3H), 3.28 (dd, 1H, J = 5.6 Hz, J = 14.5 Hz), 
3.11 (dd, 1H, J = 7.7 Hz, J = 14.5 Hz), 2.82 (dd, 1H, J = 4.0 Hz, J = 17.2 Hz), 2.33 (dd, 
1H, J = 6.4 Hz, J = 17.2 Hz), 2.25 (m, 2H), 2.09 (m, 1H), 1.88 (m, 1H), 1.57 (s, 9H), 1.44 
(s, 9H), 1.36 (s, 9H).  13C NMR (125 MHz, CDCl3) δ ppm 172.5, 172.0, 171.5, 171.1, 
170.2, 169.8, 150.2, 136.5, 135.2, 135.1, 130.2, 128.8, 126.9, 124.6, 123.1, 122.7, 120.1, 
120.0, 118.9, 117.1, 111.5, 110.7, 110.1, 85.6, 82.0, 81.1, 54.2, 52.7, 51.9, 49.3, 38.3, 36.8, 
31.5, 29.9, 28.3, 28.3, 28.2, 27.5.  MS (ESI) m/e = 866.5 [M + H]+. 
General procedure for deprotection of tert-Butyl ester.  At 0 ˚ C degree, to a solution 
of tert-butyl ester in anhydrous dichloromethane (0.1 M 10mL) was added 10 mL of 
trifluoroacetic acid dropwise.  The reaction was kept at 0 ˚C for 4–6 h until TLC showed 
no starting material left. Upon completion, 10 mL of anhydrous toluene was added, and 




methoxyphenyl) propanamido) propanamido)-5-methoxy-5-oxopentanoic acid (2.12). 
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Light pink solid; yield, 93%; m.p., decompose at 118 ˚C.  1H NMR (500 MHz, DMSO) δ 
ppm 12.24 (br, 2H), 11.02 (s, 1H), 8.45 (t, 1H, J = 7.3 Hz), 8.19 (m, 2H), 7.41 (s, 1H), 7.28 
(d, 1H, J = 8.6 Hz), 7.04 (t, 2H, J = 7.9 Hz), 6.98 (dd, 1H, J = 1.5 Hz, J = 8.9 Hz), 6.65 
(dd, 2H, J = 2.4 Hz, J = 8.4 Hz), 6.00 (d, 1H, J = 18.6 Hz), 4.62 (m, 1H), 4.56 (m, 0.5H), 
4.45 (m, 1H), 4.24 (m, 1.5H), 3.63 (d, 3H, J = 2.9 Hz), 3.59 (m, 5H), 3.50 (m, 1H), 2.90 
(m, 1H), 2.64 (m, 2H), 2.41 (dd, 1H, J = 8.2 Hz, J = 16.3 Hz), 2.26 (m, 3H), 1.92 (m, 1H), 
1.78 (m, 1H).  13C NMR (500 MHz, DMSO) 174.4, 172.6, 172.2, 171.7, 171.5, 169.2, 
158.4, 136.3, 135.1, 130.9, 129.9, 139.6, 128.9, 123.9, 120.8, 119.1, 114.0, 113.0, 100.5, 
100.4, 55.5, 55.1, 52.6, 52.4, 52.0, 49.8, 37.5, 37.4, 36.9, 36.7, 35.9, 30.4, 26.7, 26.5. 
HRMS (ESI) m/e calcd. for C30H32ClN4O10 [M – H]– 643.1812, found 643.1819. 
 
(S)-4-((S)-2-((S)-2-(2-(1H-Indol-2-yl) acetamido)-3-(4-methoxyphenyl) 
propanamido)-3-carboxypropanamido)-5-methoxy-5-oxopentanoic acid (2.34). Light 
purple solid; yield, quantitative; m.p., decompose at 78 °C. 1H NMR (500 MHz, DMSO) 
δ ppm 12.25 (br, 2H), 10.79 (s, 1H), 8.44 (m, 1H), 8.16 (m, 2H), 7.37–6.92  (m, 6H), 6.65 
(d, 2H, J = 8 Hz), 6.03 (s, 1H), 4.57–4.47 (m, 2H), 4.27 (m, 1H), 3.70–3.52 (m, 8H), 2.92 
(m, 1H), 2.67 (d, 1H, J = 12 Hz), 2.29 (m, 2H), 1.94 (m, 1H), 1.80 (m, 1H).  13C NMR (125 
MHz, DMSO) δ ppm 174.4, 172.7, 172.3, 172.0, 171.4, 169.3, 158.4, 136.7, 134.3, 130.9, 
130.1, 129.6, 128.9, 128.8, 126.0, 121.0, 119.9, 119.3, 114.0, 111.5, 100.6, 55.5, 54.8, 52.6, 
52.0, 50.1, 37.5, 36.7, 36.0, 30.4, 26.7. HRMS (ESI) m/e calcd. for C30H33N4O10 [M – H]– 






acid (2.35). Light pink solid; yield, 97%; m.p., decompose at 166 ˚C.  1H NMR (500 MHz, 
DMSO) δ ppm 11.02 (s, 1H), 8.44 (d, 1H, J = 6.6 Hz), 8.19 (d, 1H, J = 7.7 Hz), 8.15 (d, 
1H, J = 6.9 Hz), 7.54 (s, 1H), 7.24 (d, 1H, J = 7.9 Hz), 7.09 (d, 1H, J = 8.6 Hz), 7.04 (d, 
2H, J = 7.8 Hz), 6.64 (d, 2H, J = 7.9 Hz), 5.97 (s, 1H), 4.55 (m, 1H), 4.44 (dd, 1H, J = 1.3 
Hz, J = 5.9 Hz), 4.26 (m, 1H), 3.62 (s, 3H), 3.59 (s, 3H), 2.93 (d, 2H, J = 14.6 Hz), 2.64 
(m, 1H), 2.25 (m, 1H), 1.91 (m, 1H), 1.76 (m, 1H).  13C NMR (125 MHz, DMSO) δ ppm 
174.4, 172.7, 172.2, 171.9, 136.1, 135.3, 130.9, 130.7, 130.1, 123.4, 122.1, 114.1, 114.0, 
113.5, 111.9, 100.3, 95.0, 55.4, 54.8, 54.7, 52.6, 52.0, 50.1, 37.5, 36.7, 35.9, 30.4, 26.7.  




(2.62).  Pink solid; yield, quantitative; m.p., decompose at 106 ˚C.  1H NMR (500 MHz, 
DMSO) δ ppm 12.24 (br, 2H), 11.05 (d, 1H, J = 9.6 Hz), 8.45 (t, 1H, J = 7.1 Hz), 8.26 
(dd, 1H, J = 8.1 Hz, J = 23.6 Hz), 8.18 (dd, 1H, J = 7.5 Hz, J = 18.9 Hz), 7.41 (s, 1H), 
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7.28 (d, 1H, J = 8.5 Hz), 7.23 (t, 1H, J = 7.5 Hz), 7.14 (dd, 1H, J = 7.2 Hz, J = 18.1 Hz), 
7.01 (m, 2H), 6.97 (dd, 1H, J = 1.3 Hz, J = 8.6 Hz), 6.60 (d, 2H, J = 7.7 Hz), 5.98 (d, 1H, 
J = 20.5 Hz), 4.62 (dt, 0.5H, J = 5.2 Hz, J = 8.3 Hz), 4.56 (dt, 0.5H, J = 5.3 Hz, J = 8.0 
Hz), 4.42 (m, 2H) 4.24 (m, 1H), 3.60 (s, 2H), 3.58 (s, 3H), 3.49 (dd, 2H, J = 11.4 Hz, J = 
15.1 Hz), 2.89 (ddd, 1H, J = 4.1 Hz, J = 13.8 Hz, J = 24.5 Hz), 2.64 (m, 2H), 2.40 (dd, 
1H, J = 8.5 Hz, J = 16.5 Hz), 2.26 (m, 3H), 1.91 (m, 1H), 1.77 (m, 1H), 1.20 (s, 3H), 1.19 
(s, 3H).  13C NMR (125 MHz, DMSO) δ ppm 174.5, 174.4, 172.7, 172.6, 172.3, 172.2, 
170.0, 171.7, 171.5, 171.4, 169.2, 169.0, 156.6, 156.5, 136.3, 136.3, 135.1, 130.9, 130.9, 
130.0, 129.9, 129.9, 129.7, 129.6, 128.9, 126.0, 123.9, 120.8, 119.1, 115.6, 115.6, 112.9, 
100.4, 100.4, 69.5, 69.5, 55.1, 54.8, 52.6, 52.6, 52.2, 52.0, 50.1, 49.8, 35.9, 30.5, 30.4, 26.7, 




chlorophenyl) propanamido) propanamido)-5-methoxy-5-oxopentanoic acid (2.65).  
Light orange solid; yield, 98%; m.p., decompose at 196 ˚C.  1H NMR (500 MHz, DMSO) 
δ ppm 12.25 (br, 2H), 11.02 (s, 1H) 8.48 (d, 1H, J = 7.6 Hz), 8.23 (dd, 2H, J = 8.0 Hz, J 
= 24.1 Hz), 7.42 (d, 1H, J = 1.4 Hz), 7.28 (d, 1H, J = 8.6 Hz), 7.15 (m, 4H), 6.98 (dd, 1H, 
J = 2.1 Hz, J = 8.6 Hz), 5.97 (s, 1H), 4.55 (m, 2H), 4.27 (m, 1H), 3.60 (s, 3H), 3.57 (d, 
2H, J = 14.0 Hz), 3.49 (d, 1H, J = 15.2 Hz), 2.99 (dd, 1H, J = 3.9 Hz, J = 13.9 Hz), 2.68 
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(m, 3H), 2.51 (d, 1H, J = 8.9 Hz), 2.27 (m, 2H), 1.93 (m, 1H), 1.77 (m, 1H).  13C NMR 
(125 MHz, DMSO) δ ppm 174.4, 172.7, 172.2, 171.6, 171.4, 169.0, 137.3, 136.3, 135.1, 
131.8, 131.6, 129.9, 128.5, 123.9, 120.8, 119.1, 112.9, 100.4, 95.0, 54.2, 52.6, 52.0, 50.2, 




(naphthalen-2-yl) propanamido) propanamido)-5-methoxy-5-oxopentanoic acid 
(2.66). Light pink solid; yield, quantitative;  m.p., decompose at 137 ˚C.  1H NMR (400 
MHz, DMSO) δ ppm 12.26 (br, 2H), 10.73 (s, 1H), 8.25(m, 3H), 6.88–7.86(m, 11H), 
6.03(s, 1H) 4.67(m, 2H), 4.32(m, 1H), 3.64(m, 5H), 2.95(m, 2H), 2.68(m, 2H), 2.30(m, 
4H), 1.94(m, 1H), 1.81(m, 1H).  13C NMR (125 MHz, DMSO) δ ppm 174.4, 172.7, 172.6, 
172.4, 172.0, 171.6, 171.0, 170.7, 170.5, 170.4, 135.3, 135.2, 133.6, 133.5, 133.1, 132.9, 
132.8, 132.6, 129.5, 129.4, 128.7, 128.7, 128.1, 128.0, 127.9, 127.7, 127.1, 126.9, 126.6, 
126.2, 125.7, 125.4, 122.4, 122.1, 119.8, 119.6, 112.4, 112.3, 102.1, 101.8, 56.1, 55.2, 52.7, 
52.1, 52.0, 49.4, 49.3, 37.5, 37.3, 37.0, 36.4, 36.3, 36.0, 31.8, 31.6, 26.5.  HRMS (ESI) m/e 





indol-3-yl) propanamido) propanamido)-5-methoxy-5-oxopentanoic acid (2.67).  
Light pink solid; yield, 96%; m.p., decompose at 128 ˚C.  1H NMR (500 MHz, DMSO) δ 
ppm 12.24 (br, 1H), 11.00 (m, 1H), 10.79 (s, 1H), 8.36 (m, 3H), 7.59 (dd, 1H, J = 7.2 Hz, 
J = 13.5 Hz), 7.39 (d, 1H, J = 11.0 Hz), 7.27 (m, 4H), 7.15 (m, 3H), 7.04 (t, 1H, J = 7.2 
Hz), 6.94 (m, 2H), 5.96 (m, 1H), 4.58 (m, 2H), 4.24 (m, 1H), 3.58 (m, 5H), 3.11 (dd, 1H, 
J = 10.0 Hz, J = 24.6 Hz), 2.92 (m, 1H), 2.64 (m, 2H), 2.30 (m, 2H), 1.91 (m, 1H), 1.77 
(m, 1H).  13C NMR (125 MHz, DMSO) δ ppm 174.4, 172.7, 172.6, 172.3, 172.2, 171.5, 
171.4, 169.2, 140.7, 138.0, 136.7, 136.7, 136.3, 135.1, 129.9, 129.6, 128.9, 128.0, 126.0, 
124.4, 123.8, 121.5, 120.8, 119.2, 119.1, 119.0, 118.8, 112.9, 112.9, 111.9, 110.6, 110.4, 
100.4, 54.2, 52.6, 52.5, 52.1, 52.0, 50.2, 49.8, 36.6, 35.7, 35.6, 30.4, 30.3, 28.5, 26.7, 26.5.  
HRMS (ESI) m/e calcd. for C31H3ClN5NaO9 [M – 2H + Na]– 674.1635, found 674.1654. 
 
(S)-5-Ethyl 1-methyl 2-((S)-2-((S)-2-(2-(5-chloro-1H-indol-2-yl) acetamido)-3-
(naphthalen-2-yl) propanamido)-4-ethoxy-4-oxobutanamido) pentanedioate (2.78).  
1H NMR (500 MHz, Chloroform-d) δ ppm 9.41 (s, 1H), 7.66 (m, 3H), 7.02-7.47 (m, 12H), 
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6.50 (m, 1H), 6.13 (s, 1H), 4.80 (ddd, 1H, J = 6.2 Hz, J = 10.5 Hz, J = 13.5 Hz), 4.50 (m, 
2H), 4.12 (m, 4H), 3.98 (m, 1H), 3.88 (m, 1H), 3.66 (s, 3H), 3.15 (m, 2H), 2.94 (dd, 1H, J 
= 4.6 Hz, J = 17.1 Hz), 2.49 (dd, 1H, J = 6.0 Hz, J = 17.2 Hz), 2.34 (m, 2H), 2.16 (m, 1H), 
1.95 (m, 1H), 1.20 (m, 6H).  13C NMR (125 MHz, CDCl3) 172.4, 170.6, 170.6, 135.3, 
133.4, 133.1, 132.8, 132.5, 129.5, 128.7, 128.1, 128.0, 127.8, 127.7, 126.9, 126.6, 126.1, 
125.6, 122.4, 119.8, 112.3, 102.1, 61.9, 61.4, 61.0, 55.2, 52.3, 49.2, 37.4, 36.3, 35.7, 30.7, 
27.3, 14.3, 14.2. HRMS (ESI): m/e calcd. for C37H42ClN4O9 [M + H]+ 722.2038, found 
722.2053. 
 
(S)-Methyl 2-(2-(3,4-dichlorophenyl) acetamido)-3-(4-methoxyphenyl) 
propanoate (2.49a).  Colorless oil; yield, 90%.  1H NMR (500 MHz, Chloroform-d) δ ppm 
7.36 (d, 1H, J = 8.2 Hz), 7.31 (d, 1H, J = 2.0 Hz), 7.03 (dd, 1H, J = 2.0 Hz, J = 8.2 Hz), 
6.82 (d, 2H, J = 8.6 Hz), 6.74 (d, 2H, J = 8.6 Hz), 6.03 (d, 1H, J = 7.8 Hz), 4.80 (td, 1H, 
J = 5.8 Hz, J = 7.8 Hz), 3.76 (s, 3H), 3.72 (s, 3H), 3.45 (d, 2H, J = 3.1 Hz), 3.02 (dd, 1H, 
J = 5.6 Hz, J = 14.1 Hz), 2.95 (dd, 1H, J = 6.0 Hz, J = 14.1 Hz).  13C NMR (125 MHz, 
CDCl3) δ ppm 172.1, 169.5, 158.9, 134.9, 132.9, 131.6, 131.4, 130.9, 130.3, 128.9, 127.4, 
114.2, 55.4, 53.4, 52.6, 42.6, 36.8. 
 
(S)-Methyl 2-(2-(3,4-dimethoxyphenyl) acetamido)-3-(4-methoxyphenyl) 
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propanoate (2.49b).  Colorless oil; yield, 93%.  1H NMR (500 MHz, Chloroform-d) δ ppm 
6.80 (d, 1H, J = 8.1 Hz), 6.77 (d, 2H, J = 8.5 Hz), 6.71 (m, 4H), 5.87 (d, 1H, J = 7.6 Hz), 
4.77 (td, 1H, J = 5.7 Hz, J = 7.6 Hz), 3.87 (s, 3H), 3.80 (s, 3H), 3.76 (s, 3H), 3.69 (s, 3H), 
3.48 (s, 3H), 2.98 (dd, 1H, J = 5.5 Hz, J = 14.0 Hz), 2.93 (dd, 1H, J = 5.8 Hz, J = 14.0 
Hz).  13C NMR (125 MHz, CDCl3) δ ppm 172.1, 171.1, 158.8, 149.5, 148.5, 130.3, 127.5, 
127.0, 121.8, 114.1, 112.5, 111.7, 56.1, 56.0, 55.3, 53.2, 52.5, 43.4, 36.9. 
 
(S)-5-tert-Butyl 1-methyl 2-((S)-4-(tert-butoxy)-2-((S)-2-(2-(3,4-
dichlorophenyl) acetamido)-3-(4-methoxyphenyl) propanamido)-4-oxobutanamido) 
pentanedioate (2.50a). White syrup; yield, 85%.  1H NMR (500 MHz, Chloroform-d) δ 
ppm 7.34 (d, 1H, J = 8.2 Hz), 7.30–7.15 (m, 3H), 7.00 (m, 2H), 6.88 (d, 1H, J = 8.0 Hz), 
6.75 (m, 2H), 6.36 (d, 0.4H, J = 6.3 Hz), 6.00 (d, 0.6H, J = 6.4 Hz), 4.71 (m, 1H), 4.54–
4.40 (m, 2H), 3.77 (s, 3H), 3.69 (d, 2H, J = 14.9 Hz), 3.49 (m, 2H), 2.94 (m, 3H), 2.46 (dd, 
0.5H, J = 6.2 Hz, J = 17.3 Hz), 2.28 (td, 2.5H, J = 6.3 Hz, J = 14.1 Hz), 2.13 (m, 1H), 1.92 
(m, 1H), 1.41 (m, 18H).  13C NMR (125 MHz, CDCl3) δ ppm 172.3, 172.2, 172.1, 171.9, 
171.6, 171.0, 170.7, 170.5, 170.3, 170.2, 159.0, 158.9, 134.8, 134.6, 133.1, 132.9, 131.9, 
131.6, 131.5, 131.1, 130.9, 130.3, 130.2, 129.1, 129.0, 127.9, 127.5, 114.4, 114.3, 82.3, 
82.2, 80.9, 77.5, 77.3, 77.0, 55.9, 55.4, 55.0, 52.7, 52.6, 52.1, 52.0, 49.3, 49.2, 42.6, 42.3, 






oxobutanamido) pentanedioate (2.50b). White syrup; yield, 87%.  1H NMR (500 MHz, 
Chloroform-d) δ ppm 7.33–7.15 (m, 2H), 6.90 (d, 1H, J = 7.0 Hz), 6.80 (m, 2H), 6.70 (m, 
3H), 6.60 (s, 1H), 6.00 (d, 0.5H, J = 5.9 Hz), 5.85 (d, 0.5H, J = 5.7 Hz), 4.80–4.67 (m, 1H), 
4.55–4.31 (m, 2H), 3.89 (d, 3H, J = 6.8 Hz), 3.78 (m, 6H), 3.70 (m, 3H), 3.48 (m, 2H), 
2.92 (m, 3H), 2.48 (m, 1H), 2.26 (m, 3H), 2.12 (m, 1H), 1.95 (m, 1H), 1.43 (m, 18H).  13C 
NMR (125 MHz, CDCl3) δ ppm 172.5, 172.3, 172.0, 171.7, 171.0, 170.6, 170.4, 170.3, 
158.9, 149.6, 149.5, 148.6, 130.2, 130.1, 127.9, 127.6, 126.8, 126.6, 122.0, 121.9, 114.3, 
112.6, 111.8, 111.7, 82.2, 82.1, 80.8, 80.7, 56.1, 55.9, 55.3, 52.6, 52.5, 52.1, 49.4, 49.2, 
43.3, 37.3, 36.7, 36.4, 31.6, 31.5, 28.3, 28.2, 27.4.  MS (ESI) m/e = 744.4 [M + H]+. 
 
(S)-4-((S)-3-carboxy-2-((S)-2-(2-(3,4-dichlorophenyl) acetamido)-3-(4-
methoxyphenyl) propanamido) propanamido)-5-methoxy-5-oxopentanoic acid (2.36).  
White solid; yield, 90%; m.p. 182.0–184.0 ˚C.  1H NMR (500 MHz, DMSO) δ ppm 12.21 
(br, 1H), 8.45 (m, 1H), 8.35 (m, 1H), 8.13 (t, 1H, J = 6.7 Hz), 7.45 (m, 1H), 7.36 (d, 1H, J 
= 11.0 Hz), 7.06 (m, 1H), 6.73 (dd, 1H, J = 5.7 Hz, J = 11.8 Hz), 4.58 (m, 1H), 4.43 (m, 
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1H), 4.24 (m, 1H), 3.68 (d, 1H, J = 1.2 Hz), 3.59 (d, 1H, J = 6.9 Hz), 3.45 (dd, 1H, J = 8.7 
Hz, J = 14.0 Hz), 3.33 (m, 1H), 2.89 (m, 1H), 2.63 (m, 1H), 2.41 (m, 1H), 2.23 (m, 1H), 
1.92 (dq, 1H, J = 7.5 Hz, J = 12.9 Hz), 1.76 (ddd, 1H, J = 9.1 Hz, J = 16.2 Hz, J = 24.1 
Hz).  13C NMR (125 MHz, DMSO) δ ppm 174.4, 172.6, 172.2, 172.0, 171.8, 171.5, 170.0, 
169.7, 168.5, 158.4, 138.0, 131.7, 131.2, 130.9, 130.8, 130.2, 130.1, 130.0, 129.6, 128.9, 
114.0, 95.0, 55.5, 55.2, 54.6, 52.6, 52.1, 52.0, 50.1, 49.7, 41.6, 41.4, 37.4, 36.8, 30.4, 26.7, 
26.5.  HRMS (ESI) m/e calcd. for C28H30Cl2N3O10 [M – H]– 638.1314, found 638.1335. 
 
(S)-4-((S)-3-carboxy-2-((S)-2-(2-(3,4-dimethoxyphenyl) acetamido)-3-(4-
methoxyphenyl) propanamido) propanamido)-5-methoxy-5-oxopentanoic acid (2.37).  
Off-white solid; yield, 96%; m.p. 77.6–79.2 ˚C. 1H NMR (500 MHz, DMSO) δ ppm 12.24 
(br, 1H), 8.40 (t, 0.5H, J = 8.3 Hz), 8.23–8.06 (m, 1H), 7.23 (t, 0.5H, J = 7.5 Hz), 7.16–
7.06 (m, 2.5H), 6.74 (m, 3.5H), 6.58 (ddd, 1H, J = 1.5 Hz, J = 8.1 Hz, J = 15.5 Hz), 4.64–
4.51 (m, 1H), 4.42–4.18 (m, 2H), 3.68 (m, 6H), 3.65 (m, 3H), 3.59 (d, 3H, J = 9.5 Hz), 
3.33 (dd, 1H, J = 10.8 Hz, J = 13.7 Hz), 3.25 (dd, 1H, J = 7.7 Hz, J = 13.9 Hz), 2.88 (m, 
1H), 2.63 (m, 2H), 2.41 (m, 1H), 2.25 (m, 2H), 1.91 (m, 1H), 1.78 (m, 1H).  13C NMR (125 
MHz, DMSO) δ ppm 174.4, 172.6, 172.3, 171.9, 171.5, 171.0, 158.4, 149.0, 148.0, 138.0, 
130.9, 130.3, 130.0, 129.6, 129.2, 128.9, 126.0, 121.7, 121.6, 114.0, 113.5, 112.3, 56.1, 
55.5, 52.6, 52.5, 52.1, 50.1, 42.4, 42.3, 37.3, 36.8, 36.7, 30.4, 26.7. HRMS (ESI) m/e calcd. 





amino)-2-oxoethyl)-1H-indole-1-carboxylate (2.60b). Colorless oil; yield, 95%.  1H 
NMR (300 MHz, Chloroform-d) δ ppm 8.21 (d, 1H, J = 7.8 Hz), 7.55 (s, 1H), 7.49 (d, 1H, 
J = 7.7 Hz), 7.39 (dt, 1H, J = 1.1 Hz, J = 7.8 Hz), 7.27 (t, 1H, J = 7.5 Hz), 6.66 (d, 2H, J 
= 8.7 Hz), 6.59 (d, 2H, J = 8.8 Hz), 6.12 (d, 1H, J = 8.0 Hz), 4.85 (td, 1H, J = 5.6 Hz, J = 
8.0 Hz), 3.74 (s, 3H), 3.70 (s, 3H), 3.67 (s, 2H), 2.95 (d, 2H, J = 5.7 Hz), 1.71 (s, 9H).  13C 
NMR (75 MHz, CDCl3) δ ppm 171.9, 169.e8, 158.6, 149.5, 135.7, 130.0, 129.8, 127.2, 




oxobutanamido) pentanedioate (2.61b).  Light orange oil; yield, 87%.  1H NMR (500 
MHz) 8.97 (s, 0.5H), 8.69 (s, 0.5H), 7.49 (d, 0.5H, J = 8.0 Hz), 7.46 (d, 0.5H, J = 7.9 Hz), 
7.40 (m, 1H), 7.31 (t, 1H, J = 8.8 Hz), 7.23 (m, 2H), 7.11 (m 1.5H), 7.01 (m, 0.5H), 6.90 
(d, 0.5H, J = 8.1 Hz), 6.68 (d, 1H, J = 8.6 Hz), 6.52 (m, 3H), 6.28 (m, 0.5H), 6.17 (d, 0.5H, 
J = 6.0 Hz), 4.80 (dt, 0.5H, J = 4.4 Hz, J = 7.3 Hz), 4.69 (m, 1H), 4.52 (m, 1.5H), 4.45 (m, 
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1H), 3.70 (m, 8H), 3.06–2.75 (m, 3H), 2.77 (dd, 0.5H, J = 6.8 Hz, J = 13.8 Hz), 2.57 (m, 
0.5H), 2.30 (m, 2H), 2.14 (m, 1H), 1.91 (m, 1H), 1.42 (m, 27H). 13C NMR (75 MHz, 
CDCl3) δ ppm 173.0, 172.6, 172.6, 172.4, 172.3, 172.2, 172.0, 171.9, 171.8, 171.7, 171.2, 
170.9, 170.7, 170.5, 170.4, 170.2, 167.5, 167.3, 158.6, 158.6, 136.7, 136.6, 130.2, 130.0, 
127.9, 127.6, 127.2, 127.1, 124.4, 124.3, 122.8, 122.6, 120.4, 120.2, 118.7, 114.2, 114.1, 
111.7, 108.2, 108.1, 99.2, 82.5, 82.1, 81.4, 81.1, 81.1, 80.8, 55.4, 55.3, 55.3, 54.6, 52.6, 
52.2, 52.1, 51.9, 49.4, 49.2, 39.4, 37.3, 36.7, 36.5, 36.2, 33.2, 33.1, 32.1, 31.8, 31.6, 31.5, 
31.3, 29.8, 29.6, 28.3, 28.2, 27.5, 27.4, 27.3, 23.4, 22.9. MS (ESI) m/e = 822.5 [M + H]+. 
 
(S)-5-tert-Butyl 1-methyl 2-((S)-2-((S)-2-(1H-indole-3-carboxamido)-3-(4-
methoxyphenyl) propanamido)-4-(tert-butoxy)-4-oxobutanamido) pentanedioate 
(2.61c). Light orange syrup; yield, 85%.  1H NMR (500 MHz, Chloroform-d) δ ppm 9.83 
(s, 1H), 7.75 (d, 1H, J = 2.9 Hz), 7.66 (d, 1H, J = 7.8 Hz), 7.59 (d, 1H, J = 8.4 Hz), 7.43 
(d, 1H, J = 8.0 Hz), 7.32 (d, 1H, J = 8.1 Hz), 7.12 (m, 5H), 6.86 (d, 1H, J = 6.0 Hz), 6.79 
(d, 2H, J = 8.6 Hz), 4.80 (m, 2H), 4.50 (dt, 1H, J = 5.3 Hz, J = 8.2 Hz), 3.70 (s, 3H), 3.65 
(s, 3H), 3.21 (dd, 1H, J = 6.0 Hz, J = 14.0 Hz), 3.14 (dd, 1H, J = 7.6 Hz, J = 14.0 Hz), 
3.00 (dd, 1H, J = 3.2 Hz, J = 17.3 Hz), 2.90 (dd, 1H, J = 4.7 Hz, J = 17.2 Hz), 2.60 (ddd, 
1H, J = 7.9 Hz, J = 13.1 Hz, J = 17.2 Hz), 2.38 (t, 1H, J = 7.3 Hz), 2.24 (m, 2H), 2.14 (m, 
1H), 1.92 (m, 1H), 1.36 (s, 9H), 1.31 (s, 9H).  13C NMR (125 MHz, CDCl3) δ ppm 172.4, 
172.1, 171.8, 171.4, 170.6, 166.3, 159.0, 136.5, 130.5, 129.6, 128.5, 124.8, 123.0, 121.8, 
120.0, 114.6, 112.3, 111.2, 82.0, 80.8, 55.6, 55.4, 52.6, 52.2, 49.5, 39.5, 37.0, 31.6, 28.3, 
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28.2, 27.3.  MS (ESI) m/e = 709.3 [M + H]+. 
 
(S)-4-((S)-2-((S)-2-(1H-Indole-2-carboxamido)-3-(4-methoxyphenyl) 
propanamido)-3-carboxypropanamido)-5-methoxy-5-oxopentanoic acid (2.38). Light 
yellow solid; yield, quantitative; m.p. decompose at 107 ˚C.  1H NMR (500 MHz, DMSO) 
δ ppm 12.24 (br, 2H), 11.39 (s, 1H), 8.52 (ddd, 2H, J = 8.6 Hz, J = 15.5 Hz, J = 26.1 Hz), 
8.19 (dd, 1H, J = 7.3 Hz, J = 18.5 Hz), 7.60 (d, 3H, J = 7.4 Hz), 7.38 (t, 1H, J = 7.7 Hz), 
7.24 (t, 2H, J = 8.1 Hz), 7.19 (s, 1H), 7.15 (m, 1H), 7.01 (m, 1H), 6.78 (dd, 2H, J = 2.3 
Hz, J = 8.7 Hz), 4.64 (m, 2H), 4.26 (m, 1H), 3.64 (s, 3H), 3.60 (s, 3H), 3.57 (m, 2H), 3.03 
(m, 1H), 2.88 (m, 1H), 2.66 (dt, 1H, J = 5.1 Hz, J = 16.7 Hz), 2.27 (m, 2H), 1.96 (m, 1H), 




propanamido)-3-carboxypropanamido)-5-methoxy-5-oxopentanoic acid (2.39).  Light 
brown solid; yield, 96%; m.p. decompose at 92 ˚C.  1H NMR (500 MHz, Chloroform-d) δ 
ppm 12.22 (br, 2H), 10.80 (s, 1H), 8.42 (m, 1H), 8.14 (m, 2H), 6.62 – 7.38 (m, 7H), 4.57 
(m, 1H), 4.22 (m, 2H), 3.44 – 3.70 (m, 8H), 2.87 (dt, 0.5H, J = 4.6Hz, J = 13.7Hz), 2.62 
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(m, 1.5H) 2.38 (m, 1H) 2.25 (m, 2H) 1.93 (m, 1H) 1.75 (m, 1H) 13C NMR (125 MHz, 
DMSO) δ ppm 174.9, 174.4, 174.4, 172.7, 172.6, 172.6, 172.3, 172.3, 172.1, 171.8, 171.4, 
170.0, 168.4, 168.3, 158.4, 136.7, 130.9, 130.2, 129.9, 127.8, 124.5, 119.4, 118.9, 114.0, 
111.8, 109.2, 55.5, 52.6, 52.0, 51.5, 49.9, 36.9, 36.7, 30.4, 26.5.  HRMS (ESI) m/e calcd. 
for C30H33N4O10 [M – H]– 609.2197, found 609.2222. 
 
(S)-4-((S)-2-((S)-2-(1H-Indole-3-carboxamido)-3-(4-methoxyphenyl) 
propanamido)-3-carboxypropanamido)-5-methoxy-5-oxopentanoic acid (2.40). 
Yellow solid; yield, 95%; m.p. decompose at 104˚C. 1H NMR (500 MHz, DMSO) δ ppm 
12.23 (br, 2H), 11.53 (d, 1H, J = 2.4 Hz), 8.44 (d, 1H, J = 7.8 Hz), 8.11 (m, 3H), 7.97 (d, 
1H, J = 7.8 Hz), 7.91 (d, 1H, J = 7.9 Hz), 7.39 (d, 1H, J = 8.1 Hz), 7.23 (t, 3H, J = 8.4 
Hz), 7.12 (ddd, 3H, J = 4.5 Hz, J = 13.2 Hz, J = 15.1 Hz), 7.04 (m, 1H), 6.78 (d, 3H, J = 
8.7 Hz), 4.59 (m, 2H), 4.28 (m, 1H), 4.15 (t, 0.5H, J = 4.8 Hz), 3.95 (t, 0.5H, J = 5.4 Hz), 
3.65 (s, 3H), 3.60 (s, 3H), 3.03 (dd, 1H, J = 3.6 Hz, J = 13.8 Hz), 2.87 (dd, 1H, J = 10.4 
Hz, J = 13.7 Hz), 2.70 (dd, 1H, J = 5.3 Hz, J = 16.6 Hz), 2.63 (dd, 1H, J = 3.0 Hz, J = 5.2 
Hz), 2.54 (dd, 1H, J = 8.0 Hz, J = 16.6 Hz), 2.26 (m, 1H), 1.94 (m, 1H), 1.78 (m, 1H). 13C 
NMR (125 MHz, DMSO) δ ppm 179.8, 179.4, 177.8, 177.6, 177.4, 177.1, 176.5, 173.3, 
170.3, 163.4, 141.7, 136.0, 135.9, 134.6, 134.1, 133.9, 131.6, 131.0, 127.5, 126.5, 126.0, 
119.1, 117.5, 115.7, 95.0, 60.5, 60.1, 58.8, 57.6, 57.0, 56.5, 55.2, 42.0, 41.8, 41.6, 35.3, 





Fmoc-L-Hex-OMe (2.71c). Colorless oil; yield, 95%. 1H NMR (300 MHz, 
Chloroform-d) δ ppm 7.76 (d, 2H, J = 7.6 Hz), 7.60 (m, 2H), 7.40 (t, 2H, J = 7.5 Hz), 7.31 
(t, 2H, J = 7.2 Hz), 5.18 (d, 1H, J = 8.8 Hz), 4.41 (m, 3H), 4.24 (t, 1H, J = 7.1 Hz), 3.74 
(s, 3H), 1.84–0.83(m, 13H).  13C NMR (75 MHz, CDCl3) δ ppm 174.0, 156.2, 144.0, 141.5, 
127.9, 127.3, 125.3, 120.2, 67.2, 52.6, 52.0, 47.4, 40.4, 34.2, 33.8, 32.6, 26.6, 26.4, 26.2. 
 
H-L-Hex-OMe (2.72c). Colorless oil; yield, 87%. 1H NMR (300 MHz, 
Chloroform-d) δ ppm 3.66 (s, 3H), 3.46 (dd, 1H, J = 5.3 Hz, J = 8.5 Hz), 1.73–0.78 (m, 
13H).  13C NMR (75 MHz, CDCl3) δ ppm 177.4, 52.3, 52.1, 42.8, 34.2, 33.9, 32.6, 26.7, 
26.4, 26.2. 
H-L-Hex-OMe hydrochloride salt (2.69c). At 0 ˚C, to a stirred solution of H-L-
Hex-OMe (2.72c) in anhydrous dichloromethane was added 1.2 equiv of 1 M HCl in 
MeOH. After 10 min, the solvent was evaporated under reduced pressure to yield the 






2-oxoethyl)-1H-indole-1-carboxylate (2.76b).  Colorless oil; yield, 96%.  1H NMR (500 
MHz, Chloroform-d) δ ppm 8.00 (d, 1H, J = 8.9 Hz), 7.45 (d, 1H, J = 2.1 Hz), 7.25 (dd, 
1H, J = 2.1 Hz, J = 8.9 Hz), 7.11 (t, 1H, J = 6.8 Hz), 7.02 (t, 2H, J = 7.6 Hz), 6.88 (d, 2H, 
J = 7.7 Hz), 6.44 (s, 1H), 6.32 (d, 1H, J = 7.7 Hz), 4.84 (td, 1H, J = 5.8 Hz, J = 7.7 Hz), 
3.94 (dd, 2H, J = 15.8 Hz, J = 42.2 Hz), 3.68 (s, 3H), 3.05 (dd, 1H, J = 5.6 Hz, J = 13.8 
Hz), 3.01 (dd, 1H, J = 5.8 Hz, J = 13.8 Hz), 1.61 (s, 9H).  13C NMR (125 MHz, CDCl3) δ 
ppm 171.8, 168.8, 150.4, 135.8, 135.5, 135.1, 130.2, 129.2, 128.8, 128.7, 127.2, 124.5, 
120.1, 117.1, 110.4, 85.6, 53.3, 52.5, 38.2, 37.9, 28.3. 
 
(S)-tert-Butyl 5-chloro-2-(2-((3-cyclohexyl-1-methoxy-1-oxopropan-2-
yl)amino)-2-oxoethyl)-1H-indole-1-carboxylate (2.76c).  Colorless oil; yield, 80%.  1H 
NMR (300 MHz, Chloroform-d) δ ppm 7.99 (d, 1H, J = 8.9 Hz), 7.46 (dd, 1H, J = 0.4 Hz, 
J = 2.1 Hz), 7.22 (dd, 1H, J = 2.2 Hz, J = 8.9 Hz), 6.52 (d, 1H, J = 0.6 Hz), 6.18 (d, 1H, 
J = 8.2 Hz), 4.62 (dt, 1H, J = 5.4 Hz, J = 8.8 Hz), 3.97 (s, 2H), 3.67 (s, 3H), 1.67 (s, 9H), 
1.63–0.75 (m, 13H).  13C NMR (75 MHz, CDCl3) δ ppm 173.6, 169.1, 150.4, 135.6, 135.2, 
130.2, 128.8, 124.5, 120.1, 117.1, 110.5, 85.5, 52.5, 50.5, 40.2, 38.3, 34.3, 33.6, 32.7, 28.4, 
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oxobutanamido) pentanedioate (2.77b).  Light orange oil; yield, 86%.  Two rotamers. 1H 
NMR (500 MHz) ppm 7.95 (t, 1H, J = 8.4 Hz, major + minor), 7.45 (d, 1H, J = 9.5 Hz, 
major + minor), 7.26 (m, 2H, major + minor), 7.10 (m, 4H, major + minor), 6.98 (m, 2H, 
major + minor), 6.92 (s, 0.6H, major), 6.91 (s, 0.4H, minor), 6.46 (s, 0.4H, minor), 6.42 (s, 
0.6H, major) 6.38 (d, 0.4H, J = 6.2 Hz, minor), 6.23 (d, 0.6H, J = 6.0 Hz, major), 4.70 (m, 
1H, major + minor), 4.49 (m, 1.6H, major + minor), 4.41 (q, 0.4H, J = 6.7 Hz, minor), 3.91 
(m, 2H, major + minor), 3.70 (s, 1.6H, major), 3.67 (s, 1.4H, minor), 3.00 (m, 2H, major + 
minor), 2.88 (m, 1H, major + minor), 2.48 (dd, 0.4H, J = 6.4 Hz, J = 17.3 Hz, major + 
minor), 2.27 (m, 2.6H, major + minor), 2.11 (m, 1H, major + minor), 1.92 (m, 1H, major 
+ minor), 1.60 (m, 9H, major + minor), 1.41 (s, 18H, major + minor).  13C NMR (125 MHz, 
CDCl3) δ ppm 172.2, 172.1, 172.0, 171.9, 171.7, 171.6, 170.7, 170.5, 170.4, 170.3, 170.0, 
150.3, 136.1, 135.9, 135.1, 135.1, 135.0, 134.8, 130.1, 130.1, 129.1, 129.0, 128.9, 128.8, 
127.3, 124.7, 124.5, 120.1, 117.1, 110.8, 110.6, 95.0, 85.7, 85.5, 82.1, 82.0, 80.8, 55.9, 






oxobutanamido) pentanedioate (2.77c). Orange syrup; yield, 72%.  1H NMR (500 MHz, 
Chloroform-d) δ ppm 7.94 (d, 0.5H, J = 3.5 Hz), 7.93 (d, 0.5H, J = 3.5 Hz), 7.46 (s, 1H), 
7.38 (d, 0.5H, J = 8.0 Hz), 7.27 (d, 0.5H, J = 8.9 Hz), 7.25 (d, 0.5H, J = 3.5 Hz), 7.22 (m, 
1.5H), 6.54 (d, 1H, J = 6.5 Hz), 6.29 (dd, 1H, J = 2.6 Hz, J = 6.5 Hz), 4.76 (m, 0.5H), 4.72 
(m, 0.5H), 4.50 (dq, 1H, J = 5.1 Hz, J = 8.0 Hz), 4.37 (td, 0.5H, J = 5.9 Hz, J = 9.7 Hz), 
4.26 (dd, 0.5H, J = 6.6 Hz, J = 14.9 Hz), 3.97 (m, 2H), 3.70 (s, 1.7H), 3.68 (s, 1.3H), 3.00 
(dd, 0.4H, J = 4.2 Hz, J = 17.3 Hz), 2.90 (dd, 0.6H, J = 4.3 Hz, J = 17.2 Hz), 2.53 (m, 
1H), 2.26 (m, 1H), 2.11 (m, 2H), 1.93 (m, 1H), 1.67 (s, 9H), 1.54–1.63 (m, 5H), 1.42 (m, 
18H), 0.79–1.31 (m, 8H).  13C NMR (125 MHz, CDCl3) δ ppm 172.2, 172.0, 171.9, 171.7, 
170.5, 170.1, 150.6, 150.5, 135.4, 135.3, 135.0, 134.9, 130.2, 128.9, 128.8, 124.6, 124.5, 
120.2, 120.1, 117.0, 110.8, 110.7, 85.7, 85.5, 82.1, 82.0, 80.8, 52.6, 52.4, 52.2, 52.1, 49.3, 
39.5, 38.8, 38.1, 37.9, 37.0, 36.8, 34.4, 33.8, 33.5, 32.9, 32.6, 31.6, 31.5, 29.9, 28.4, 28.2, 





phenylpropanamido) propanamido)-5-methoxy-5-oxopentanoic acid (2.63).  Pink 
solid; yield, quantitative; m.p. decompose at 103˚C. 1H NMR (500 MHz, DMSO) δ ppm 
12.24 (br, 2H), 11.03 (s, 1H), 8.47 (dd, 1H, J = 4.3 Hz, J = 7.9 Hz), 8.31 (dd, 1H, J = 7.6 
Hz, J = 21.2 Hz), 8.18 (dd, 1H, J = 7.6 Hz, J = 12.6 Hz), 7.41 (s, 1H), 7.28 (d, 1H, J = 8.6 
Hz), 7.23 (t, 1H, J = 7.5 Hz), 7.15 (m, 8H), 6.97 (dd, 1H, J = 1.9 Hz, J = 8.6 Hz), 6.02 
(dd, 1H, J = 0.9 Hz, J = 18.1 Hz), 4.62 (m, 0.5H), 4.53 (m, 2H), 4.23 (m, 1.5H), 3.60 (s, 
3H), 3.58 (s, 2H), 3.53 (m, 2H), 2.98 (ddd, 1H, J = 4.4 Hz, J = 13.8 Hz, J = 18.8 Hz), 2.74 
(m, 1H), 2.63 (ddd, 1H, J = 5.0 Hz, J = 16.6 Hz, J = 31.2 Hz), 2.39 (dd, 1H, J = 8.3 Hz, J 
= 16.5 Hz), 2.25 (m, 4H), 1.91 (m, 1H), 1.77 (m, 1H).  13C NMR (125 MHz, DMSO) δ 
ppm 174.4, 172.7, 172.2, 171.9, 171.6, 171.5, 169.2, 169.1, 138.4, 138.1, 136.3, 136.2, 
135.1, 129.9, 129.9, 129.6, 128.9, 128.6, 128.6, 126.8, 126.0, 123.8, 120.8, 119.0, 112.9, 
100.4, 100.4, 54.9, 54.6, 52.6, 52.5, 52.1, 52.0, 50.2, 49.8, 35.8, 30.5, 30.4, 26.7.  HRMS 
(ESI) m/e calcd. for C29H30ClN4O9 [M – H]– 613.1707, found 613.1712. 
 
(S)-4-((S)-3-Carboxy-2-((S)-2-(2-(5-chloro-1H-indol-2-yl) acetamido)-3-
cyclohexyl propanamido) propanamido)-5-methoxy-5-oxopentanoic acid (2.64).  Pink 
solid; yield, 98%; m.p. decompose at 82 ˚C.  1H NMR (500 MHz, DMSO) δ ppm 11.07 (s, 
0.6H), 11.01 (s, 0.4H), 9.52 (s, 1H), 8.32 (m, 1H), 8.05 (dd, 1H, J = 7.6 Hz, J = 27.0 Hz), 
7.42 (t, 1H, J = 2.6 Hz), 7.29 (dd, 1H, J = 3.8 Hz, J = 8.6 Hz), 7.22 (t, 1H, J = 7.3 Hz), 
7.13 (dd, 1H, J = 7.4 Hz, J = 18.3 Hz), 6.97 (td, 1H, J = 2.1 Hz, J = 8.5 Hz), 6.19 (s, 1H), 
4.58 (m, 0.5H), 4.49 (m, 1H), 4.23 (m, 1.5H), 3.58 (m, 2H), 3.55 (s, 3H), 2.67 (ddd, H, J 
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= 4.8 Hz, J = 9.4 Hz, J = 16.6 Hz), 2.44 (m, 1H), 2.21 (m, 2H), 1.88 (m, 1H), 1.74 (m, 
1H), 0.71–1.63 (m, 13H).  13C NMR (125 MHz, DMSO) δ ppm 174.5, 174.4, 173.0, 172.6, 
172.3, 172.2, 171.6, 171.4, 169.6, 169.4, 136.5, 136.4, 135.2, 135.1, 129.9, 129.6, 128.9, 
126.0, 123.9, 120.9, 119.0, 113.0, 112.9, 100.4, 52.6, 52.5, 52.1, 52.0, 51.8, 51.2, 50.1, 
49.9, 36.4, 35.9, 35.7, 34.0, 33.9, 33.8, 32.4, 30.4, 30.3, 30.2, 26.7, 26.4, 26.2, 26.1.  HRMS 
(ESI) m/e calcd. for C29H36ClN4O9 [M – H]– 619.2176, found 619.2181. 
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The interfaces between proteins have emerged as a popular therapeutic target. 
However, finding small-molecule drugs that can disrupt protein-protein interactions is 
challenging not only because of the flat and featureless surfaces with shallow pockets that 
are on the protein,1 but also the complicated thermodynamics involved in the process of 
protein-protein interactions and ligand binding.2 Within the past decade, the 
thermodynamics of molecular binding to guide medicinal chemistry has gained increased 
attention.3-7 This chapter focuses on the optimization of the inhibitors of β-catenin/T-cell 
factor 4 (Tcf4) protein-protein interactions (PPIs) using a thermodynamics-guided strategy. 
 
3.1.1 Thermodynamics of Ligand-Protein Interactions 
When a drug-like molecule binds to a protein, it becomes less mobile.8 The 
resulting loss in entropy, which works against the attractive forces that favor binding, is 
called the entropic penalty.  
The thermodynamic plots of the measured free binding energy (ΔGobs), the 
measured binding enthalpy (ΔHobs), and the calculated entropic contribution (−TΔSobs) are
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used to demonstrate the driving forces of the process when small-molecule inhibitors bind 
to a protein. The sum of ΔHobs and −TΔSobs, ΔGobs, gives a quick assessment of their 
individual contributions to the binding affinity. 
 
ΔGobs = ΔHobs − TΔSobs            (1) 
 
Ligand binding enthalpy mostly arises from specific target-ligand interactions such 
as hydrogen bonds, salt bridges, or directed van-der-Waals contacts, while nonspecific 
lipophilic interactions cause entropy.9-12 Typically, a large negative value for ΔHobs is 
considered to be favorable as it indicates the formation of noncovalent bonds during the 
binding process. On the other hand, a large negative value for TΔSobs (nonspecific 
hydrophobic effects) is often regarded as disadvantageous. Thus, a balanced 
thermodynamic profile (larger enthalpic and smaller entropic contributions) has become 
an important factor in thermodynamics-guided drug design, which often includes the 
identification of hits having a large enthalpic advantage with a small entropic penalty. 
One common effort in entropy management is adding conformational constraints 
during the synthetic design of the compounds (Figure 3.1).13 As a flexible ligand often 
exists as multiple conformations, such preorganization attempts to restrain its dynamic 
motion minimize the unfavorable conformations and hence avoid the unfavorable change 
in entropy, leading to a more ordered binding configuration. 
Within native peptides and peptidomimetics, conformational constraints are widely 
used to help improve target selectivity,14-18 favoring the binding to one protein over others 




Figure 3.1. Theoretical behavior of conformational entropy in the case of a flexible ligand 




to peptide and peptidomimetic structures include increased resistance to proteases and in 
vivo metabolic stability,24-31 along with improved cell membrane permeability.32-36 
 
3.1.2 Protein Surface Adaptability 
Many protein-protein interaction surfaces are shared with more than one binding 
partner, and hence the binding surface can be flexible or “plastic”.37 Studies have shown 
that these interaction surfaces are typically less shaped but adaptable for their binding 
partners.38-40 As a result, this adaptability often leads to the opening up of new pockets that 
could be available for the binding of inhibitors. This effect is consistently observed in the 
co-crystallized structures of proteins with small molecules,41, 42 where the small molecule 
induced new conformations of protein surfaces that were not seen in the native crystal 
structures of the apoprotein or the protein-protein complex. Inhibitors utilizing this 
adaptability of protein surface often exhibit a better potency and selectivity. An example is 
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shown in Figure 3.2.41 However, locating such sites can be difficult. Even if the protein 
structural information is available, conformational adaptation is required for binding the 
ligand. Therefore, these “plastic” sites may not be detectable in the unbound receptors.37 
 
3.1.3 Previous Work 
Previously, peptidomimetic small molecules 3.1 and 3.2 (Figure 3.3) were 
identified as potent and selective inhibitors of the β-catenin/Tcf4 PPIs by maintaining the 
“hot spot interactions” and utilizing the unexploited interactions around the “hot spot”. 
Compound 3.2 has a Kd value of 0.418 μM for binding to β-catenin and a Ki value of 1.36 
μM to disrupt β-catenin/Tcf interactions completely.44 It also exhibits dual selectivity for 
β-catenin/Tcf over β-catenin/cadherin and β-catenin/APC interactions.  
However, the further optimization of this compound towards a more drug-like 
molecule was hampered due to several problematic features, mainly coming from the 
peptide-like structure and the instability of the 2-(1H-indol-2-yl)acetate. Therefore, we 
searched for more potent and more promising drug candidates. Efforts were made to 
change the inhibitor from a flexible and peptide-like structure to a rigid, more drug-like 
molecule. 
 
3.2 Results and Discussion 
3.2.1 Replacing the Flexible Peptide Backbone with a Rigid Ring Core 
Inspection of the docking modes of compound 3.1 gave rise to the proposed 
structure with a biphenyl core 3.3 shown in Figure 3.4. Connectivities of the side chains 




Figure 3.2. An example of surface adaptability.41 MDM2 (surface is shown in blue)  
a. MDM2 surface with no ligands, PDB id: 3LBK.43 b. MDM2 with YH-300, an MDM2-
p53 inhibitor. PDB id: 4MDQ.41 The small molecule induced a new hydrophobic pocket 











Figure 3.4. a. Structural modification from 3.1 to 3.4.  b. AutoDock predicted 




were examined using AutoDock 4.2.45 Docking results suggested a 1, 3, 5-trisubsituted 
pattern for the core phenyl ring with an oxygen linker to the 6-position of indole. From the 
proposed docking mode, this new structure maintains the hydrophobic interactions at 
pocket B and the indole can still form cation-π interaction with R515 (parallel). 
Additionally, with the oxygen linker in proximity (2.36 Å to N-H of R474) with A474, a 
weak H-bond is likely to form and hence adds to the binding affinity.  
The synthesis of compound 3.4 is shown in Figure 3.5. Using 3-bromo-5-
iodobenzoic acid and (4-chlorophenyl) boronic acid as a starting material, this synthesis 
employed a selective Suzuki coupling followed by an Ullman coupling to assemble the key 
intermediate 3.9, which was then coupled with the dipeptide 3.10 reported in the previous 
chapter.46-47 Deprotection of the tert-butyl esters and Boc group in one pot yielded 3.4.  
Fluorescence polarization (FP) assay was used to determine the potency of 





Figure 3.5. Synthesis of compound 3.4 
 
 
Table 3.1. The FP competitive inhibition assay results of β-catenin/Tcf4 PPIs inhibitors 
Entry Ki ± SD (μM) 
3.1 5.74 ± 0.7644 
3.2 1.36 ± 0.1244 
3.4 0.21 ± 0.05 





3.4 exhibited a Ki of 0.2 ± 0.1 μM toward the inhibition of β-catenin/Tcf4 PPIs, which was 
a 6-fold enhancement to the previously best small molecule inhibitor 3.2. 
 
3.2.2 Exploration of Arginine Channel (Pocket C) 
The synthetic route featuring Ullmann coupling allows the facilitation of different 
phenols. Therefore it is possible to install various heterocyclic rings onto the scaffold to 
examine the structural-activity relationship for pocket C.  Indazole and benzimidazole were 
chosen to replace indole for two reasons: 1. they are geometrically similar to indole; 2. they 
are chemically more stable than indole. Furthermore, pocket C exhibited a hydrophobic 
area that can potentially be used to increase the binding affinity (Figure 3.6).  
Following the similar synthesis of 3.4, a Boc-protected 6-hydroxyl indazole was 
prepared (Figure 3.7). However, the Ullman coupling failed to proceed with the indazole 
due to the strong electron withdrawing effect of the two nitrogen atoms together with the 
Boc group. Therefore, benzyl groups were used for both heterocyclic rings. 3.23a-b were 
synthesized using a reported method.50 
Benzyl protected benzimidazoles were synthesized by reducing the nitro group 
using iron powder in the presence of formic acid followed by ring formation to give 3.26 
(Figure 3.8).51  Substituting formic acid with acetic acid in the hope of yielding the 2-
methyl benzimidazole resulted in product decomposition upon contact with air, which 
significantly complicated the purification and lowered the yield. It was then found that 
protecting the phenol as an acetate could minimize the decomposition and allow the 
separation and purification of the product. The acetyl group was then hydrolyzed using 
acidic/basic washes, yielding 3.27. 
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.    
Figure 3.6. Compounds for exploring pocket C. 
 
 
Figure 3.7. Attempts for the synthesis of indazole compounds. 
 
 




Compound 3.26 (1-benzyl-6-hydroxyl benzimidazole) was subjected to Ullman 
coupling conditions (Figure 3.9). The reaction proceeded in moderate yields. After 
coupling with the dipeptide 3.10, the benzyl group was found inert to mild hydrogenation. 
In order to prevent the racemization of the peptides, harsher conditions were not examined. 
Removal of the tert-butyl esters from 3.30 gave 3.31. 
Oxidative debenzylation turned out to be an effective means of removing the benzyl 
groups on the heterocyclic rings (Figure 3.10).52 Debenzylation on 3.29 was successfully 
carried out using this condition 85% yield. Interestingly, the reaction rate was found to 
have a direct dependence on the concentration of potassium tert-butyl oxide (tBuOK). The 
reaction proceeded very slowly when the concentration of the base was lower than 0.1 
g/mL. Additional base was needed in order to achieve higher conversion. 
With the key steps worked out for 3.31 and 3.32, compounds 3.12-3.15 were 
synthesized (Figure 3.11). The efficiency of the peptide coupling reaction was 
significantly lowered when protecting groups were absent on the heterocyclic rings. 
The AlphaScreen assay was used to evaluate the inhibitory activity of the newly 
synthesized inhibitors.48 The results are shown in Figure 3.12.  In accordance with the 
AutoDock results, indazole-containing compounds (3.12 and 3.13) showed elevated 
inhibitory activity than 3.4. Compared to the methyl group on the indazole contributed to 
a lower Ki presumably from the additional hydrophobic interaction with I579 and L519. 
On the other hand, benzimidazole adversely affected the Ki of 3.14 and 3.15 due to the 
hydrophobicity of benzimidazole. A methyl group in the 2 position of the benzimidazole 
further created an unfavorable steric interaction to fit 3.15 into the pocket. However, the 




Figure 3.9. Attempted synthesis of benzimidazole compound. 
 
 




Figure 3.11. Completed synthesis of compounds 3.12-3.15. 
  
 
Figure 3.12. AlphaScreen competitive inhibition assay results. 
Compound Ki ± SD (nM) 
3.4 200.3 ± 3.4 
3.12 96.7 ± 13.9 
3.13 77.7 ± 15.5 
3.14 436.0 ± 29.3 
3.15 572.2 ± 129.6 
3.31 13.2 ± 1.7 
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To investigate the rationale for the exceptional result of 3.31, a molecular dynamics 
(MD) simulation study was run by Jonathan Leon Catrow. The R612 adjacent to the 
arginine channel was discovered to be flexible and uncapped a “hidden” hydrophobic 
pocket which might contribute to adapting the additional benzyl group from 3.31 (Figure 
3.13). While this pocket was present to a lesser degree in several crystal structures, MD 
simulation predicted its accessibility. 
Pocket C’ is a hydrophobic pocket with H-bond donors consisted of R612, V613, 
L579 and the backbone of H578 (Figure 3.14). In most crystal structures, this pocket is 
covered with R612 and therefore unavailable. The unveiling of this pocket offers the 
possibility of utilizing the surface adaptability of β-Catenin to design potent inhibitors for 
β-Catenin/Tcf PPIs. 
Encouraged by the discovery, a variety of N-alkylated benzimidazoles containing 
compounds were screened by AutoDock 4.2. Some of them were selected to explore the 
structure-activity relationship (SAR) of the new pocket following the benzimidazole 
synthesis (Figure 3.15). 1-(2-(pyridin-2-yl)ethyl)-1H-benzo[d]imidazol-6-ol (3.40f) was 
used to synthesize compound 3.43 (Figure 3.16) . 
Unfortunately, this direction was not further pursued due to a major change in the 
results of the previously tested compounds (Table 3.2). The highly concentrated protein 
stock solution was stored in pH 7.4 buffer, which can cause aggregation of β-catenin, 
leading to the false positive results. Newly expressed proteins (by Dr. Min Zhang) were 
stored in pH 8.8 buffer, in which the highly concentrated β-catenin was stabilized. 
Additionally, a modification of the assay conditions done by Dr. Min Zhang and Jack 




Figure 3.13. β-Catenin is shown as a space-filled model. Compound 3.31 is shown in 
yellow stick model. a. 3.13 in the active site of the 2GL7 crystal structure with R612 
blocking the benzyl group. b. 2GL7 apo simulation cluster 2 from the MD simulation 





Figure 3.14. Residues of pocket C’. 3.31 is shown in yellow; β-Catenin residues are 





Figure 3.15. Synthesis of N-alkylated benzimidazole-6-ols. 
 
 
Figure 3.16. Synthesis of compound 3.43. 
 
Table 3.2 Revised inhibitory activity. 
 Ki (μM) 
Compound AlphaScreen FP Originally by AlphaScreen 
3.4 0.37 ± 0.10 2.84 ± 0.59 0.20 ± 0.03 
3.12 2.03 ± 0.21 5.17 ± 0.84 0.097 ± 0.014 
3.13 0.79 ± 0.20  3.04 ± 0.62 0.078 ± 0.016 
3.14 16.58 ± 4.93 42.95 ± 1.72 0.436 ± 0.029 
3.15 24.67 ± 2.98 45.58 ± 2.12 0.572 ± 0.130 
3.31 2.77 ± 0.85  13.28 ± 1.27 0.013 ± 0.002 
3.43 24.10 ± 3.24 47.03 ± 2.25 N/A 
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In the new structure-activity relationship based on the revised inhibitory activities, 
compound 3.4 remains the most potent inhibitor. The others followed an opposite trend. 
Indazole containing compounds 3.12 and 3.13 have slightly decreased activity when 
compared to 3.4. The 3-methyl group in 3.13 contributed to a better activity. Benzimidazole 
compounds (3.14 and 3.15) exhibit a higher Ki, and the addition of methyl negatively 
affected the binding affinity. Similar to previous results, with the benzyl group on 
imidazole, the Ki of 3.31 is lower by 4-fold than that of 3.14. 
 
3.2.3 Binding Mode Investigation Using Site-Directed Mutagenesis 
Site-directed mutagenesis studies were performed by Dr. Min Zhang to determine 
the importance of each pocket to the binding of the small molecules. 
 As is shown in Table 3.3, none of the compounds responded to any of the mutants. 
Mutations in the arginine channel had no effect on the inhibitory activity in all cases, and 
the mutations in the hydrophobic pocket even led to lower Ki’s. The results raised the 
suspicion that the compounds were not in this binding site possibly due to the rigidity of 
the scaffold.  
 
Table 3.3. Site-directed mutagenesis studies using the FP assay. 
 Ki (μM) 
β-catenin 3.4 3.13 3.31 
Wild type 2.84 ± 0.59 3.04 ± 0.62 13.28 ± 1.27 
V511S 0.62 ± 0.12 1.52 ± 0.21 6.29 ± 0.76 
V511S/I569S 1.37 ± 0.19 2.29 ± 0.69 7.22 ± 0.91 
R474A 1.61 ± 0.21 4.15 ± 1.09 10.34 ± 0.88 
R515A 2.17 ± 0.69 4.50 ± 0.58 10.04 ± 0.90 




Therefore, compounds 3.44 and 3.45 each with one missing side chain were 
synthesized in the hope of putting this scaffold back into the pocket and revealing the 
problematic site of this scaffold (Figure 3.17). The inhibitory activities of 3.44 and 3.55 
on the wild-type β-catenin/Tcf4 and mutant β-catenin/Tcf4 interactions are shown in Table 
3.4. As expected, the loss of function has a significant impact on the Ki’s of compound 3.44 
and 3.45. However, both compounds displayed better inhibition activities with the mutants, 
suggesting that this series of molecules completely deviated from the targeted binding site. 
ITC studies further proved that the compound 3.4 was not binding to the proposed pocket 
(the Kd of 3.4 binding to wild-type β-catenin is 530 nM, and 590 nM to K435A/K508A 
mutant.) 
 
Figure 3.17. Synthesis of 3.44 and 3.45. 
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Table 3.4. Site-directed mutagenesis studies and the FP assay to evaluate the binding 
mode of 3.4, 3.44 and 3.45. 
 Ki (μM) 
Compound Wild-type R474A/R515A I511S/I569S 
3.4 2.84 ± 0.59 2.18 ± 0.55 1.37 ± 0.19 
3.44 163.4 ± 6.47 71.75 ± 6.21 58.42 ± 5.33 




3.2.4 Attempts to Validate an Alternative Binding Site  
 As previously reported, there are three “hot regions” on the β-catenin/Tcf4 protein-
protein interaction surface.49 Hot-spot 2 is adjacent to the hot-spot 1 and contains lysine 
residues (K312 and K345) as key interaction element (Figure 3.18a). Besides the similar 
two residues for charge-charge interactions, the surface area around hot-spot 2 is also 
equipped with hydrophobic residues I303 and V349, as well as hydrogen bond 
donor/acceptor T306, W338, and R342 to make it a reasonable site for ligand binding, 
Therefore, it is likely that the designed inhibitor can bind to the hot-spot 2 in the case of 
failing to fit in hot-spot 1. Docking studies confirmed that the ligand can bind to the hot-
spot 2 area with reasonable conformation (Figure 3.18b). The two carboxylic acids can 
form charge-charge interactions with lysine residues, and the 4-chlorophenyl group stacks 
with R342 for a cation-π interaction. The indole sits in the hydrophobic pocket formed by 
I303 and T306, and possibly forming hydrogen bonding interaction with the backbone of 
Q302. 
Four β-catenin mutants (K312A, K345A, Y306A and W338A) were made by Dr. 





Figure 3.18.49  Hot spots of the -catenin/Tcf complex. a. “Hot-spots” on the structure of 
the -catenin/Tcf complex (PDB id: 2GL754). -Catenin: surface model (gray), and Tcf: 
stick model.  “Hot-spot” 1: K435 and K508 of -catenin.  “Hot-spot” 2: K312 and K345 
of -catenin.  b. Proposed docking mode for ligand at the active site from AutoDock 4.2. 




(Y306A and W338A) interactions were tested (Table 3.5). The Ki’s for the mutant proteins 
are indeed higher than the wild-type, indicating a decrease in the binding affinity after the 
lost-of-function of the key amino acid side chains. Although a 4-fold difference is hardly 
significant, this preliminary study suggested that the inhibitors are very likely to bind to 
this hot-spot 2 area for its more open pockets as compared to the deep and narrow ones at 
hot-spot 1.  
More studies need to be performed for the further validation of the binding mode. 
Moreover, the K312A mutation causes a substantial drop of the binding affinity between 
β-catenin and Tcf4. Because of this decrease in the association constant (KA), it  makes the 
FP assay no longer suitable for evaluating the inhibitory activity of the ligands. Therefore, 
ITC experiments are recommended for the validation of the hot-spot 2 binding. 
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Table 3.5. The FP assay for β-catenin/TCF interaction. 
 Ki (μM) 
Compound Wild-type Y306A W338A 




3.2.5 Inhibitor Selectivity Studies 
The selectivity assay was established in the Ji laboratory using FP to quantify 
inhibitor selectivity between -catenin/Tcf, β-catenin/E-cadherin, and β-catenin/APC 
interactions.55 The results are shown in Table 3.6. The selectivities of 3.4 for -catenin/Tcf 
over β-catenin/E-cadherin interactions and -catenin/APC interactions are 10- and 16-fold, 
respectively. Comparing to the previously reported best inhibitor 3.2,44 compound 3.4 
shows significantly decreased selectivities, which on the other hand proves that the 
inhibitors targeting the hot-spot 1 region can indeed achieve higher selectivities. 
 
3.2.6 Rationale of the Off-Target Outcome 
 To investigate the cause of the off-target binding of the newly designed inhibitors, 
the docking modes of the previously designed (3.2) and newly designed (3.4) inhibitors 
were extracted and overlapped shown in Figure 3.19. 
 Prominently, compound 3.4 reaches deeper in pocket B than compound 3.2 but 
comes short in pocket C. The rigidity of compound 3.4 does not allow the free adjustment 
of side chains. Therefore, the hydrophobic biphenyl core has to stay elevated from the 
protein surface in order to allow the side-chains to fit into the pockets and hence be exposed 
to the aqueous solution. Taking off either side chain does not increase the likelihood of 
placing the core or the other side-chain in a more favorable position due to the lack of  
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Table 3.6.   The FP selectivity assay to determine inhibitor selectivity of the -
catenin/Tcf4 inhibitors. 










3.4 2.84 ± 0.59 30.69 ± 2.62 46.81 ± 3.22 10.8 16.5 
3.2 1.36 ± 0.12 238.1 ± 2.3  86.63 ± 0.64 175.1 63.7 
 
 
   
Figure 3.19. Comparison of the two scaffolds. a. Structures of the previously designed 
inhibitor 3.2 and the inhibitor 3.4 designed in this chapter. b. Overlapped docking mode of 






rotatable bonds. On the other hand, pocket B is a narrow hydrophobic area. Attempting to 
insert additional hydrophobic groups into the narrow pocket can possibly cause increased 
entropy (protein structure change), which disfavors the thermodynamics of the binding. 
 
3.3 Conclusion 
Proteins have large surfaces and interact dynamically with a complicated network 
of other partners. Hence the discovery of small-molecule inhibitors of PPIs is challenging. 
In this chapter, we attempted to use the thermodynamics of protein-ligand interactions as 
a guideline to modify the known inhibitors. A new series of inhibitors with rigid core 
structures were synthesized (Figure 3.20). Unfortunately, the overly rigid structure was 
unable to fit into the target binding site. Preliminary results suggest binding to hot-spot 2. 
The binding of the newly designed inhibitors relies largely on the heterocyclic ring and 
leads to a disruption of β-catenin/Tcf interaction with low micromolar Ki’s. The selectivity 
of compound 3.4 was lower than that of 3.2 due to the fact that hot-region 2 is not selective. 
 
3.4 Future Directions 
3.4.1 Synthesis of New Compound with a Pyridine Core 
The inhibitors designed in this chapter resulted in the disruption of β-catenin/Tcf4 
interactions. This unexpected result provided a starting point to for the exploration of the 
hot-spot 2 binding site. Compared to the deep cleft present in hot-spot 1, hot-spot 2 is 
flatter in shape and solvent exposed. Therefore, replacing the benzene core with a less 
hydrophobic structure will stabilize the inhibitor on the surface of protein. Also, the 








side chains and/or backbone. On the choice of heterocyclic rings, the 1-benzyl protected 
3-methyl indazole derivative is given a high hope for this new compound because of its 
enhanced chemical stability compared to indole.  Additionally, the benzyl group will add 
to the inhibitory activity according to the SAR of the benzimidazoles. The synthesis of 
the new pyridine containing compound is shown in Figure 3.21.   
The key intermediate 3.55 was synthesized through a stepwise functionalization of 
4-chloropyridine (3.50) to install the cyano group and chloride with moderate yields. The 
indazole was installed by Ullman coupling reaction, and hydrolysis of the cyano group 
yielded the carboxylic acid 3.57, which was then coupled with the dipeptide 3.10. The tert-
butyl esters were deprotected in trifluoroacetic acid to afford compound 3.59. To date, the 
inhibitory activity of this compound has not been investigated. 
 
3.4.2 Benzodiazepines as New Core Structures 
As previously discussed, we believed that the overly rigid structure disfavored the 
placement of the side chains in the active site. Thus, an ideal new core structure should 
possess both rigidity as well as a certain degree of flexibility. 
Based on the docking mode of 3.2, the 7-membered diazepine in 3.60 is proposed 
to meet those requirements (Figure 3.22). The 7-member ring keeps both side chains in 
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Figure 3.21. Synthesis of the inhibitor with pyridine core. 
 
    
Figure 3.22. Structure and overlapped docking mode of the diazepine containing 





close proximity to their original position after minimization and possesses both the degree 
of rigidity and the flexibility to adapt to the active site. 
Other forms of diazepine-containing structures were also screened, and compound 
3.61 was chosen as a potential starting molecule (Figure 3.23).  The 7-member ring is also 
capable of mimicking the peptide conformation, and the amide groups add to the 
hydrophobicity of the compound, facilitating the surface binding.  
A proposed synthesis is shown in Figure 3.24. The Ugi reaction would be used to 
assemble the precursor 3.67 as a racemic mixture for the diazepine. The removal of the 
Boc group would trigger the ring-closing in one pot. Following peptide coupling to give 
3.70, the racemic mixture would be converted to a mixture of diastereomers. 
 
3.5 Methods and Experiments 
3.5.1 Ligand Docking Using AutoDock 4.245  
In AutoDock studies, only the polar hydrogen atoms remained on the protein 
structure, and Kollman united atom charges were assigned. The 3D structures of the ligands 
were built, and the partial atomic charges were calculated using the Gasteiger–Marsili 
method.  The rotatable bonds in the ligands were defined using AutoTors, which also 
united the nonpolar hydrogens and partial atomic charges to the bonded carbon atoms. The 
grid maps were calculated using AutoGrid. The AutoDock area was defined to include all 
the residues of the Tcf4 G13ANDE17 binding site, and the grid spacing was set to 0.375 Å. 
Docking was performed using the Lamarckian genetic algorithm, and the pseudo-Solis and 
Wets method were applied to the local search. Each docking experiment was performed 
100 times, yielding 100 docked conformations. Other settings were the standard default  
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Figure 3.23. Structure and the docking mode of compound 3.61 (shown in red)  








parameters. All of the ligands followed the same docking protocol. The results of the 
docking experiments were evaluated by the auxiliary clustering analysis and a visual 
inspection to match the proposed binding elements. 
 
3.5.2 FP Competitive Inhibition Assay48, 55 
Experiments were performed in 96-well Microfluor 2 black plates on a Synergy 2 
plate reader (Biotek). The polarization was measured at room temperature with an 
excitation wavelength at 485 nm and an emission wavelength at 535 nm. The FP 
experiments were performed in an assay buffer of 137 mM NaCl, 2.7 mM KCl, 10 mM 
Na2HPO4, 2 mM KH2PO4, 100 μg/mL of bovine gamma globulin, and 0.01% Triton-X 
100. The final reaction volume was set to 100 μL. For the β-catenin/Tcf assay, 10 nM of 
β-catenin (residues 142–686) was incubated with 2.5 nM of C-terminally fluorescein-
labeled human Tcf4 (residues 7–51) for 30 min at 4 °C, and then different concentrations 
of the tested peptides and compounds in assay buffer were added. The negative control 
(equiv to 0% inhibition) refers to 2.5 nM Tcf4 fluorescence tracer and 10 nM β-catenin in 
assay buffer without the tested compound. The positive control (equiv to 100% inhibition) 
refers to only 2.5 nM Tcf4 fluorescence tracer in assay buffer. For the β-catenin/cadherin 
assay, 150 nM human β-catenin (residues 138−686) was incubated with 5 nM of C-
terminally fluorescent-labeled human E-cadherin (residues 819−873) in assay buffer for 30 
min at 4 °C. The negative control refers to 5 nM E-cadherin fluorescence tracer and 150 
nM β-catenin in assay buffer with no inhibitor presenting. The positive control refers to 5 
nM E-cadherin fluorescence tracer in assay buffer. For the β-catenin/APC-R3 assay, 2000 
nM human β-catenin (residues 138−686) was incubated with 5 nM of C-terminally 
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fluorescent-labeled human APC-R3 (residues 1477−1519) in assay buffer for 30 min at 4 
°C. The negative control refers to 5 nM APC-R3 fluorescence tracer and 2000 nM β-catenin 
in assay buffer without the tested compound.  The positive control refers to 5 nM APC-R3 
fluorescence tracer in assay buffer. Each assay plate was covered black and gently mixed 
on an orbital shaker at 4 °C for 2.5 h to reach equilibrium before the polarization values 
were read. The background of the tested inhibitors was corrected by subtracting the raw 
intensity values of the sample background well (all components except probe) from the 
raw intensity values of the corresponding test wells (all components). The IC50 values were 
determined by GraphPad Prism 5.0. The Ki values were derived from the IC50 values.55 All 
of the experiments were performed in triplicate and carried out in the presence of 1% 
DMSO for small-molecule inhibitors. The results were expressed as mean ± standard 
deviation. The Tcf/cadherin selectivity ratios were calculated based on the respective Ki 
value of β-catenin/E-cadherin interactions over that of β-catenin/Tcf4 interactions. The 
Tcf/APC selectivity ratios were calculated based on the respective Ki value of β-
catenin/APC-R3 interactions over that of β-catenin/Tcf4 interactions. 
 
3.5.3 AlphaScreen Assay48 
Experiments were performed in white opaque 384-well plates from PerkinElmer 
(Waltham, MA), and the samples were read on a Synergy 2 plate reader (Biotek, Winooski, 
VT) with a sensitivity setting of 200 using AlphaScreen protocol with excitation at 680 nm 
and emission at 570 nm.   All dilutions were made in 1 × assay buffer containing 25 mM 
HEPES (pH 7.4), 100 mM NaCl and 0.1% BSA to minimize nonspecific interactions.   In 
the AlphaScreen competitive inhibition assay, 20 nM of N-terminal His6-tagged β-catenin 
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(residues 142-686) was incubated with 5 nM of C-terminal biotinylated Tcf4 45-mer 
(residues 7-51) for 30 min at 4 °C, and then different concentrations of the tested inhibitors 
in the assay buffer were added to make a final volume of 20 μL.  The mixture was incubated 
at 4 °C for 2 h.   Donor and acceptor beads were added to a final concentration of 10 μg/mL 
in 25 μL of assay buffer.  The mixture was incubated at 4 °C for 1 h. The IC50 value was 
determined by nonlinear least-square analysis of GraphPad Prism 5.0.  The Ki values were 
derived from the IC50 values by a reported method.56  Experiments were performed in 
triplicate and carried out in the presence of 1 % DMSO. 
 
3.5.4 ITC Experiments 
ITC measurements were performed at 30 °C using a VP-ITC (Microcal, GE 
Healthcare Life Sciences).  The concentrations of inhibitor and β-catenin were set to 80 
μM and 8 μM, respectively, in a buffer of 20 mM HEPES, pH 7.5, 200 mM NaCl, 1mM 
TCEP, 0.01% Triton X-100, and 8% glycerol.  Each titration experiment was initiated by 
a 2 μL injection, followed by 30–35 injections with 8 μL per injection.  Blank titrations, 
which were carried out by injecting the compound into the buffer, were subtracted from 
each data set.  The association constant KA, enthalpy change (ΔH), and stoichiometry N 
were obtained from fitting the data using the Origin software package (Microcal).  The Kd, 
the free energy change ΔG, and the entropy change ΔS were obtained from the basic 






3.5.5 Site-Directed Mutagenesis Studies 
β-Catenin mutants V511S, V511S/I569S, R474A, R515A, R474A/R515A, K312A, 
K345A, T306A and W338A were generated using the overlapping PCR technique. The 
template for the mutagenesis reactions was the full-length wild-type β-catenin in pET-28a. 
KOD Hot start DNA polymerase (Novagen) was used for all the experiments. Mutants 
were confirmed by direct sequencing (Core Facility, University of Utah). The templates 
used for β-catenin double mutation were V511S for V511S/I569S and R474A for 
R474A/R515A, respectively. The double mutants were again confirmed by direct 
sequencing. Following the confirmation of the sequence, β-catenin mutants were cloned 
into a pET-28 vector and transformed into E. coli BL21 DE3.  
 
3.5.6 Chemistry 
All experiments were conducted under anhydrous conditions in an atmosphere of 
argon, using flame-dried apparatus and employing standard techniques in handling air-
sensitive materials.  Dichloromethane (CH2Cl2), acetonitrile (CH3CN), tetrahydrofuran 
(THF), dimethylformamide (DMF) were degassed with nitrogen and passed through JC 
Meyer solvent systems.  All reagents were purchased from Sigma-Aldrich and used as 
received.  Aqueous solutions of sodium bicarbonate (NaHCO3), sodium chloride (brine), 
and ammonium chloride (NH4Cl) were saturated.  Analytical thin layer chromatography 
was visualized by ultraviolet light. Flash chromatography was performed on SilicaFlash@ 
F60 silica gel (230–400 mesh).  1H NMR spectra were recorded using a Varian Unity Inova 
500 (500 MHz) or a Varian Unity Inova 300 (300 MHz).  13C NMR spectra were recorded 
using a Varian Unity Inova 500 (125 MHz) or Varian Unity Inova 300 (75 MHz).  The 1H 
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and 13C NMR spectra were referenced to the residual solvent signals (7.26 ppm for 1H and 
77.0 ppm for 13C in CDCl3; 2.50 ppm for 1H and 39.5 ppm for 13C in DMSO-d6).  All 
melting points were determined on a Büchi M560 melting point apparatus and uncorrected.  
Low (MS) and high (HRMS) mass spectra were determined on a Micromass Quattro II 
(ESI/APCI-TOF) at the University of Utah, Department of Chemistry Mass Spectrometry 
Facility. Optical rotation of final compounds was determined on a Perkin-Elmer PE-343 
polarimeter. 
 
3.5.7 Synthetic Routes, Procedures and Characterizations 
 
6-((tert-Butyldimethylsilyl)oxy)-1H-indazole (3.17). To a stirred solution of 5-
hydroxyl-1H-indazole (0.5 g, 3.727 mmol) in 10 mL DMF under room temperature was 
added TBSCl (0.674 g, 4.472 mmol) and imidazole (0.38g, 5.59 mmol). The reaction was 
left to react overnight. Upon completion, the reaction mixture was poured into 30 mL 1 M 
HCl, and extracted with ethyl acetate (40 mL). The organic layer was washed with 2 M 
HCl (aq) (30 mL), saturated NaHCO3 (aq) (30 mL), brine (2× 30 mL) and then dried over 
Na2SO4. The solvent was evaporated under reduced pressure to afford 0.89 g product as 
colorless oil (96%). 1H NMR (500 MHz, Chloroform-d) δ 7.99 (s, 1H), 7.59 (dd, J = 8.6, 
0.7 Hz, 1H), 6.92 – 6.86 (m, 1H), 6.75 (dd, J = 8.7, 2.0 Hz, 1H), 1.01 (s, 9H), 0.23 (s, 6H). 
13C NMR (126 MHz, CDCl3) δ 155.7, 141.5, 134.8, 121.6, 118.7, 117.1, 99.2, 25.9, 18.5, 




tert-Butyl 6-((tert-butyldimethylsilyl)oxy)-1H-indazole-1-carboxylate (3.18). 
To a stirred solution of 6-((tert-butyldimethylsilyl)oxy)-1H-indazole (3.17) (0.265 g, 1.07 
mmol) in 15 mL dichloromethane at room temperature was added Boc2O (0.26 g, 1.2 
mmol) and N, N-dimethyl-4-aminopyridine (10 mg, 0.08 mmol). The reaction was 
completed in 5 min. The reaction mixture was poured to 2 M HCl (aq) (30 mL) and 
extracted with dichloromethane (2 × 20 mL). The organic layers were combined and 
concentrated under reduced pressure. The residue was purified by column chromatography 
(hexanes : ethyl acetate =10:1) to yield 0.15g 3.18 (40%) and 0.16g 3.19 (45%).  1H NMR 
(500 MHz, Chloroform-d) δ 8.50 (d, J = 1.1 Hz, 1H), 7.47 (dd, J = 9.2, 0.8 Hz, 1H), 6.98 
(dt, J = 1.9, 0.9 Hz, 1H), 6.72 (dd, J = 9.1, 2.0 Hz, 1H), 1.69 (s, 9H), 1.51 (s, 3H), 0.98 (s, 
9H), 0.23 (s, 6H). 13C NMR (126 MHz, CDCl3) δ 156.5, 152.4, 148.5, 124.6, 123.4, 122.1, 
118.6, 103.9, 86.5, 28.1, 27.6, 25.9, 18.5, -4.2. MS (ESI) m/z = 349.3 [M+H]+. 
 
tert-Butyl 6-((tert-butyldimethylsilyl)oxy)-2H-indazole-2-carboxylate (3.19). 
1H NMR (500 MHz, Chloroform-d) δ 8.04 (s, 1H), 7.60 (s, 2H), 7.53 (dd, J = 8.6, 0.7 Hz, 
2H), 6.83 (dd, J = 8.6, 2.1 Hz, 1H), 4.09 (q, J = 7.2 Hz, 1H), 1.69 (s, 10H), 0.99 (s, 10H), 
0.23 (s, 5H). 13C NMR (126 MHz, CDCl3) δ 157.3, 149.5, 141.3, 139.6, 121.8, 120.8, 118.6, 




tert-Butyl 6-hydroxy-1H-indazole-1-carboxylate (3.20). To a stirred solution of 
tert-butyl 6-((tert-butyldimethylsilyl)oxy)-1H-indazole-1-carboxylate (3.18) (0.136 g, 
0.39 mmol) in 10 mL anhydrous THF at 0˚C, was added TBAF solution (1 M in THF, 0.58 
mL, 0.58 mmol) dropwise. The reaction was allowed to warm to room temperature 
overnight. The reaction mixture was poured into 20 mL saturated NH4Cl (aq) and then 
extracted with ethyl acetate (2 × 20 mL). The organic layers were combined and 
concentrated in vacuo. The residue was purified by column chromatography (hexanes : 
ethyl acetate = 7:3) to yield 82 mg product as a white solid (90%). 1H NMR (500 MHz, 
Chloroform-d) δ 8.09 (s, 1H), 7.68 (s, 1H), 7.54 (d, J = 8.6 Hz, 1H), 6.96 (dd, J = 8.6, 2.1 
Hz, 1H), 1.61 (s, 6H). 13C NMR (126 MHz, CDCl3) δ 159.0, 149.5, 141.4, 139.8, 122.3, 
119.7, 115.2, 100.3, 85.5, 28.3. MS (ESI) m/z = 234.9 [M+H]+. 
 
1-Benzyl-3-methyl-1H-indazol-6-ol (3.23b).  To a stirred solution of 1.0 g 1-(2-
fluoro-4-hydroxyphenyl)ethan-1-one (6.5 mmol, 1 eq) in 20 mL xylenes was added 3.1 g 
BnNHNH2•HCl (19.5 mmol, 3 eq) and 3.2 g KOAc (32.5 mmol, 5 eq). The reaction was 
heated at 140˚C for 10 d. The reaction was cooled to room temperature and poured into 50 
mL 2 M HCl (aq) and extracted with ethyl acetate (2 × 30 mL). The organic layers were 
combined and concentrated under reduced pressure. Crude product was purified by column 
chromatography (hexanes : ethyl acetate = 8:2) to afford 0.8 g product as a light brown 
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solid (52%).1H NMR (500 MHz, Chloroform-d) δ 7.48 (d, J = 8.7 Hz, 1H), 7.28 – 7.21 (m, 
3H), 7.18 – 7.11 (m, 2H), 6.69 (dd, J = 8.6, 2.0 Hz, 1H), 6.59 (d, J = 2.0 Hz, 1H), 5.38 (s, 
2H), 2.52 (s, 3H). 13C NMR (125 MHz, CDCl3) δ ppm 173.3, 156.0, 142.2, 142.0, 137.2, 
128.9, 127.3, 127.3, 121.9, 111.8, 93.8, 52.7, 12.0. MS (ESI) m/z = 239.4 [M+H]+. 
General procedure for 3-alkylamino-4-nitrophenols. To a sealed vial was added 
3-fluoro-4-nitrophenol (1 eq.), amine (1.5 eq) and 10 mL EtOH. The reaction was heated 
at 75˚C for 24 h. Upon completion, the reaction mixture was cooled to room temperature 
and then poured into 50 mL cold 2 M HCl (aq) while stirring. Yellow to orange precipitate 
was formed. The mixture was cooled in an ice bath and the product was collected by 
filtration. 
 
3-(Benzylamino)-4-nitrophenol (3.25). Orange solid; yield 98%; m.p. 184.2-
188.0˚C. 1H NMR (500 MHz, DMSO) δ ppm 10.75 (s, 1H), 8.77 (t, J=5.8 Hz, 1H), 7.99 
(d, J=10 Hz, 1H), 7.34 (m, 4H), 7.24 (m, 1H), 6.16 (dd, J=2.3 Hz, J=9.8 Hz, 1H), 6.11 (d, 
J=2 Hz, 1H), 4.53 (d, J=6 Hz, 2H). 13C NMR (125 MHz, DMSO) δ ppm 165.4, 148.3, 
139.0, 129.7, 129.3, 127.8, 127.6, 125.7, 107.1, 98.4, 46.5, 40.2. MS (ESI) m/z = 245.0 
[M+H]+. 
 
4-Nitro-3-(phenylamino)phenol (3.39a). Orange solid; yield 46%, m.p. 165.3—
167.0˚C. 1H NMR (500 MHz, DMSO-d6) δ 10.72 (s, 1H), 9.56 (s, 1H), 8.03 (d, J = 9.4 Hz, 
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1H), 7.43 (t, J = 7.9 Hz, 2H), 7.36 – 7.30 (m, 2H), 7.26 – 7.19 (m, 1H), 6.44 (d, J = 2.4 Hz, 
1H), 6.28 (dd, J = 9.4, 2.4 Hz, 1H). 13C NMR (126 MHz, DMSO) δ 200.9, 165.0, 145.7, 
139.2, 130.0, 129.5, 126.6, 125.8, 125.1, 108.5, 99.5. MS (ESI) m/z = 230.9 [M+H]+. 
 
3-((2-Chlorobenzyl)amino)-4-nitrophenol (3.39b). Orange solid; yield 78%, m.p. 
202.2—203.1˚C. 1H NMR (500 MHz, DMSO-d6) δ 10.70 (s, 1H), 8.73 (t, J = 6.1 Hz, 1H), 
8.00 (dd, J = 9.5, 1.8 Hz, 1H), 7.48 (dq, J = 7.9, 2.7 Hz, 1H), 7.37 (s, 0H), 7.30 (s, 2H), 
7.30 (s, 1H), 6.16 (dd, J = 9.3, 2.3 Hz, 1H), 5.98 (d, J = 2.4 Hz, 1H), 4.59 (d, J = 6.1 Hz, 
2H), 2.06 (d, J = 2.0 Hz, 2H). 13C NMR (126 MHz, DMSO) δ 165.3, 147.7, 135.6, 132.5, 
129.9, 129.6, 129.3, 128.8, 127.9, 125.7, 107.0, 97.9, 44.3, 31.1. MS (ESI) m/z = 279.0 
[M+H]+. 
 
3-((3-Chlorobenzyl)amino)-4-nitrophenol (3.39c). Orange solid, yield 82%, m.p. 
208.1-209.2˚C. 1H NMR (500 MHz, DMSO-d6) δ 10.71 (s, 1H), 8.77 (t, J = 6.1 Hz, 1H), 
7.98 (d, J = 9.4 Hz, 1H), 7.42 – 7.33 (m, 2H), 7.33 – 7.27 (m, 2H), 6.15 (dd, J = 9.4, 2.4 
Hz, 1H), 6.05 (d, J = 2.4 Hz, 1H), 4.54 (d, J = 6.1 Hz, 2H). 13C NMR (126 MHz, DMSO) 
δ 165.2, 147.8, 141.7, 133.7, 130.9, 129.5, 127.5, 127.2, 125.9, 125.6, 106.9, 98.1, 45.7. 





3-((4-Fluorobenzyl)amino)-4-nitrophenol (3.39d). Orange solid, yield 67%; m.p. 
198.7—199.7˚C. 1H NMR (500 MHz, DMSO-d6) δ 10.70 (s, 1H), 8.73 (t, J = 6.0 Hz, 1H), 
7.97 (d, J = 9.4 Hz, 1H), 7.41 – 7.34 (m, 2H), 7.20 – 7.12 (m, 2H), 6.15 (dd, J = 9.4, 2.4 
Hz, 1H), 6.08 (d, J = 2.4 Hz, 1H), 4.50 (d, J = 5.9 Hz, 2H). 13C NMR (126 MHz, DMSO) 
δ 165.2, 162.7, 160.8, 147.9, 135.0, 134.9, 129.5, 129.4, 129.3, 125.6, 115.8, 115.7, 106.8, 
98.1, 45.5, 31.1. MS (ESI) m/z = 263.9 [M+H]+. 
 
3-((3,5-Bis(trifluoromethyl)benzyl)amino)-4-nitrophenol (3.39e). Yellow solid; 
yield 74%; m.p. 184.0-184.8˚C. 1H NMR (500 MHz, DMSO-d6) δ 10.71 (s, 1H), 8.86 (t, J 
= 6.4 Hz, 1H), 8.05 (s, 2H), 8.02 – 7.96 (m, 2H), 6.17 (dd, J = 9.2, 2.4 Hz, 1H), 6.06 (d, J 
= 2.4 Hz, 1H), 4.72 (d, J = 6.4 Hz, 2H). 13C NMR (126 MHz, DMSO) δ 165.2, 147.5, 
143.1, 130.9, 130.7, 129.6, 128.2, 125.8, 124.9, 122.7, 121.3, 106.9, 98.1, 45.4. MS (ESI) 
m/z = 381.4 [M+H]+. 
 
4-Nitro-3-((2-(pyridin-2-yl)ethyl)amino)phenol (3.39f). Dark purple solid; yield 
42%; m.p.  decomposes >220˚C. 1H NMR (500 MHz, DMSO-d6) δ 11.00 (s, 1H), 8.81 – 
8.76 (m, 1H), 8.43 (td, J = 7.9, 1.6 Hz, 1H), 8.27 (s, 1H), 7.94 (dd, J = 8.8, 2.3 Hz, 2H), 
7.85 (t, J = 6.8 Hz, 1H), 6.39 (d, J = 2.4 Hz, 1H), 6.23 (dd, J = 9.4, 2.3 Hz, 1H), 3.74 (t, J 
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= 6.9 Hz, 2H), 3.37 (t, J = 6.8 Hz, 2H). 13C NMR (126 MHz, DMSO) δ 165.7, 154.9, 147.6, 
145.6, 142.6, 129.4, 127.7, 125.5, 125.3, 107.0, 97.7, 41.8, 32.8. MS (ESI) m/z = 259.9 
[M+H]+. 
 
3-(([1,1'-Biphenyl]-2-ylmethyl)amino)-4-nitrophenol (2.39g). Orange solid, 
yield 79%; m.p. 197.3—197.9˚C. 1H NMR (500 MHz, DMSO-d6) δ 10.68 (s, 1H), 8.44 (t, 
J = 5.7 Hz, 1H), 7.94 (d, J = 9.4 Hz, 1H), 7.48 – 7.41 (m, 2H), 7.43 – 7.32 (m, 5H), 7.29 – 
7.21 (m, 1H), 6.13 (dd, J = 9.4, 2.3 Hz, 1H), 5.88 (d, J = 2.4 Hz, 1H), 4.41 (d, J = 5.7 Hz, 
2H). 13C NMR (126 MHz, DMSO) δ 165.2, 147.7, 141.5, 140.6, 135.4, 130.5, 129.4, 129.2, 
128.9, 128.2, 127.8, 127.8, 125.5, 106.8, 97.8, 44.9. MS (ESI) m/z = 321.5 [M+H]+. 
 
3-(Benzylamino)-4-nitrophenyl acetate (3.28). To stirred solution of 3-
(benzylamino)-4-nitrophenol (3.25) (0.2 g, 0.892 mmol) in 10 mL pyridine at room 
temperature was added acetic anhydride (0.1 mL, 1.07 mmol) dropwise. The reaction was 
completed after 3 h. The reaction mixture was poured into 100 mL 2 M HCl aqueous 
solution and extracted with ethyl acetate (50 mL × 2). The organic layers were combined, 
washed with saturated NaHCO3 and brine (50 mL each) and dried over Na2SO4. The 
solvent was removed in vacuo to afford the product as yellow solid (0.224g, 88%). m.p. 
109.3—110.5˚C. 1H NMR (500 MHz, DMSO-d6) δ 8.70 (t, J = 6.1 Hz, 1H), 8.13 (d, J = 
9.3 Hz, 1H), 7.37 – 7.30 (m, 4H), 7.30 – 7.21 (m, 1H), 6.68 (d, J = 2.3 Hz, 1H), 6.48 (dd, 
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J = 9.3, 2.4 Hz, 1H), 4.58 (d, J = 6.1 Hz, 2H), 2.22 (s, 2H). 13C NMR (126 MHz, DMSO) 
δ 169.0, 157.3, 146.9, 138.8, 129.7, 129.3, 128.8, 127.8, 127.6, 110.8, 107.5, 46.4, 21.6. 
MS (ESI) m/z = 287.7 [M+H]+. 
General procedure for the synthesis of benzo[d]imidazols. To a sealed tube was 
added 3-(R-amino)-4-nitrophenol (1 eq), NH4Cl (10 eq) and iron powder (10 eq). An equal 
volume of HCOOH (88%) and i-PrOH was added as a solvent. The reaction was heated at 
82˚C for 16 h and turned milky white. The excess HCOOH was neutralized with aqueous 
2 M NaOH (aq) to pH 7. After extracting with ethyl acetate (50 mL × 2), the aqueous layer 
was discarded. The organic layers were combined and extracted with 2 M HCl (aq) (3 × 30 
mL). The aqueous layers were combined and neutralized to pH 7 by adding 2 M NaOH 
(aq). A precipitate was formed, and the aqueous solution was extracted with ethyl acetate 
(3 × 30 mL). Organic layers were combined, washed with brine (50 mL), dried over 
Na2SO4, and evaporated under reduced pressure to afford the product as off-white to light 
brown solids. 
 
1-Benzyl-1H-benzo[d]imidazol-6-ol (3.26). Light brown solid; yield 70%. 1H 
NMR (500 MHz, DMSO) δ ppm 8.16 (s, 1H), 7.47 (d, J=9 Hz, 1H), 7.28-7.34 (m, 3H), 
7.24 (m, 2H), 6.79 (dd, J=2 Hz, J=9 Hz, 1H), 6.74 (d, J=2.5 Hz), 5.38 (s, 2H), 4.88 (s, 2H). 
13C NMR (125 MHz, DMSO) δ ppm 154.6, 142.4, 136.3, 136.0, 134.5, 128.8, 127.9, 127.2, 




  1-Benzyl-2-methyl-1H-benzo[d]imidazol-6-ol (3.27). Off-white solid; yield 35%; 
m.p.253.2—254.3˚C. 1H NMR (500 MHz, DMSO) δ ppm 7.40 (d, J=9 Hz, 1H), 7.25-7.33 
(m, 3H), 7.11 (m, 2H), 6.78 (dd, J=8.5 Hz, J=2.5 Hz, 1H), 6.75 (d, J=2 Hz, 1H), 5.362 (s, 
2H), 2.53 (s, 3H). 13C NMR (125 MHz, DMSO) δ ppm 154.4, 150.9, 136.1, 135.8, 133.5, 
128.9, 127.8, 126.4, 117.6, 112.3, 95.9, 46.8, 12.0. MS (ESI) m/z = 239.3 [M+H]+. 
 
1-Phenyl-1H-benzo[d]imidazol-6-ol (3.40a). Light brown solid; yield 84%; m.p. 
191.8—198.6˚C. 1H NMR (500 MHz, DMSO-d6) δ 9.38 (s, 1H), 8.30 (s, 1H), 7.64 – 7.56 
(m, 4H), 7.53 (d, J = 8.7 Hz, 1H), 7.46 (tt, J = 5.5, 3.1 Hz, 1H), 6.91 (d, J = 2.2 Hz, 1H), 
6.77 (dd, J = 8.7, 2.3 Hz, 1H). 13C NMR (126 MHz, DMSO) δ 155.0, 142.1, 137.6, 136.7, 
134.4, 130.5, 128.0, 123.9, 120.8, 112.6, 96.0. MS (ESI) m/z = 211.2 [M+H]+. 
 
1-(2-Chlorobenzyl)-1H-benzo[d]imidazol-6-ol (3.40b). Light brown solid; yield 
72%; m.p. decomposes >218˚C. 1H NMR (500 MHz, DMSO-d6) δ 9.24 (s, 1H), 8.11 (s, 
1H), 7.50 (d, J = 7.9 Hz, 1H), 7.44 (d, J = 8.4 Hz, 1H), 7.32 (td, J = 7.6, 1.8 Hz, 1H), 7.27 
(t, J = 7.3 Hz, 1H), 6.96 (dd, J = 7.6, 1.8 Hz, 1H), 6.69 (s, 2H), 6.72 – 6.65 (m, 1H), 5.46 
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(s, 2H). 13C NMR (126 MHz, DMSO) δ 154.3, 143.6, 137.4, 135.0, 134.4, 132.6, 130.1, 
130.0, 129.5, 128.0, 120.3, 112.0, 96.1, 45.9. MS (ESI) m/z = 258.5 [M+H]+. 
 
1-(3-Chlorobenzyl)-1H-benzo[d]imidazol-6-ol (2.40c). Light brown sold; yield 
79%; m.p. decomposes >252˚C. 1H NMR (500 MHz, DMSO-d6) δ 9.30 (s, 1H), 8.17 (s, 
1H), 7.41 (d, J = 8.6 Hz, 1H), 7.39 – 7.30 (m, 1H), 7.17 (d, J = 6.6 Hz, 1H), 6.74 (d, J = 
2.3 Hz, 1H), 6.67 (dd, J = 8.6, 2.3 Hz, 1H), 5.39 (s, 2H). 13C NMR (126 MHz, DMSO) δ 
154.3, 143.3, 140.0, 137.5, 134.8, 133.7, 131.0, 128.1, 127.5, 126.4, 120.3, 112.0, 96.1, 
47.2. MS (ESI) m/z = 258.4 [M+H]+. 
 
1-(4-Fluorobenzyl)-1H-benzo[d]imidazole-6-ol (3.40d). Light brown solid; yield 
72%; m.p. decomposes >183˚C. 1H NMR (500 MHz, DMSO-d6) δ 9.21 (s, 1H), 8.15 (s, 
1H), 7.41 (d, J = 8.6 Hz, 1H), 7.30 (dd, J = 8.4, 5.4 Hz, 2H), 7.15 (t, J = 8.7 Hz, 2H), 6.74 
(d, J = 2.2 Hz, 1H), 6.66 (dd, J = 8.6, 2.2 Hz, 1H), 5.35 (s, 2H).  13C NMR (126 MHz, 
DMSO) δ 163.0, 161.0, 154.2, 143.2, 137.6, 134.8, 133.7, 133.7, 129.8, 129.8, 120.2, 




1-(3,5-Bis(trifluoromethyl)benzyl)-1H-benzo[d]imidazol-6-ol (3.40e). Brown 
solid; yield 58%; m.p. >250˚C. 1H NMR (500 MHz, DMSO-d6) δ 9.29 (s, 1H), 8.26 (s, 
1H), 8.04 (s, 1H), 7.97 (s, 2H), 7.43 (d, J = 8.6 Hz, 1H), 6.80 (s, 1H), 6.68 (d, J = 8.7 Hz, 
1H), 5.59 (s, 2H). 13C NMR (126 MHz, DMSO) δ 154.6, 143.5, 141.3, 137.7, 135.0, 131.6, 
131.4, 131.1, 130.8, 128.9, 127.1, 124.9, 122.8, 122.3, 120.6, 112.4, 96.2, 47.0. MS (ESI) 
m/z = 360.8 [M+H]+. 
 
 
1-(2-(Pyridin-2-yl)ethyl)-1H-benzo[d]imidazol-6-ol (3.40f). Dark purple solid; 
yield 40%; m.p. decomposes >156˚C. 1H NMR (500 MHz, DMSO-d6) δ 9.29 (s, 1H), 8.53 
– 8.48 (m, 2H), 7.82 (s, 1H), 7.63 (td, J = 7.7, 1.9 Hz, 1H), 7.37 (d, J = 8.6 Hz, 1H), 7.20 
(dd, J = 6.5, 4.8 Hz, 0H), 7.15 (d, J = 7.8 Hz, 1H), 6.85 (d, J = 2.2 Hz, 1H), 6.67 (dd, J = 
8.6, 2.3 Hz, 1H), 4.50 (t, J = 7.1 Hz, 2H), 3.21 (t, J = 7.1 Hz, 2H). 13C NMR (126 MHz, 
DMSO) δ 158.5, 154.4, 149.8, 143.1, 137.5, 137.3, 135.2, 124.1, 122.5, 120.3, 112.0, 96.0, 




1-([1,1'-Biphenyl]-2-ylmethyl)-1H-benzo[d]imidazol-6-ol (3.40g). Light brown 
solid; yield 66%; m.p. 199.5—203.3˚C. 1H NMR (500 MHz, DMSO-d6) δ 9.16 (s, 1H), 
7.69 (s, 1H), 7.51 – 7.44 (m, 1H), 7.45 – 7.31 (m, 5H), 7.32 – 7.24 (m, 1H), 6.91 (d, J = 
7.6 Hz, 1H), 6.63 (dt, J = 8.7, 1.8 Hz, 1H), 6.42 (t, J = 1.8 Hz, 1H), 5.31 (d, J = 2.3 Hz, 
2H). 13C NMR (126 MHz, DMSO) δ 154.1, 143.2, 141.3, 140.3, 137.4, 134.9, 134.1, 130.6, 
129.4, 129.0, 128.2, 128.2, 128.0, 127.7, 120.2, 111.9, 96.0, 46.3. MS (ESI) m/z = 301.3 
[M+H]+. 
 
5-Bromo- 4'-chloro-[1,1'-biphenyl]-3-carboxylic acid (3.7). To a sealed tube 
with a magnetic stirrer was added 3-iodo-5-bromo-benzoic acid (1.514 g mg, 4.647 mmol), 
(4-chlorophenyl)boronic acid (0.707 g, 4.647 mmol), Cs2CO3 (1.651 mg, 5.112 mmol) and 
Pd(PPh3)4 (0.268 g, 0.232 mmol.). A mixed solvent (toluene : ethanol : water = 9:3:1, 50 
mL) was added. The reaction was heated at 80 ̊C for 24 h. Upon completion, the reaction 
mixture was poured into 100 mL 2 M HCl and extracted with ethyl acetate (50 mL × 2). 
The organic layers were combined and filtered through a cotton plug, concentrated under 
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reduced pressure. The residue was purified by column chromatography (hexanes : ethyl 
acetate = 8:2) to afford the product as off-white to light orange solid (0.93 g, 64%). 1H 
NMR (500 MHz, DMSO) δ ppm 8.12 (s, 2H), 8.01 (s, 1H), 7.76 (d, J = 8.5 Hz, 2H), 7.52 
(d, J = 8.5 Hz, 2H). 13C NMR (125 MHz, DMSO) δ ppm 166.5, 142.2, 137.2, 134.2, 134.1, 
131.5, 129.8, 138.6, 127.0, 123.2. MS (ESI) m/z = 311.2 [M + H]+. 
General procedure for Ullman reaction. To a sealed vial under argon was added 
aryl bromide (1.0 eq.), phenol (1.2 eq.), Cs2CO3 (3 eq.), CuI (0.1 eq.), N,N-dimethyl 
glycine hydrochloride (0.3 eq.) and 10 mL anhydrous dioxane. The reaction was heated at 
95 ̊C for 16 h. Upon completion, the solvent was evaporated under reduced pressure. The 
residue was broken up in 20 mL 2 M HCl (aq) and extracted with ethyl acetate (15 mL × 
2). The organic layers were combined and washed with saturated Na2CO3 (aq) and brine 
(20 mL each). The organic layer was then evaporated under reduced pressure. Crude 
product was purified by column chromatography (hexanes : ethyl acetate = 8:2) or 
crystalized from adding hexanes to ethyl acetate solution to afford desired product. 
 
5-((1-(tert-Butoxycarbonyl),-1H-indol-6-yl),oxy),-4'-chloro-[1,1'- biphenyl]-3-
carboxylic acid (3.9). as off-white solid (0.15 g,  65%). 1H NMR (500 MHz, DMSO) δ 
ppm 7.93 (br, 1H), 7.62-7.71 (m, 6H), 7.49 (d, 2H, J = 7.5 Hz), 7.43 (s, 1H), 7.08 (d, 1H, 
J = 8.5 Hz), 6.70 (d, 1H, J = 3.5 Hz), 1.47 (s, 9H), 13C NMR (125 MHz, DMSO) δ ppm 
167.2, 158.8, 154.3, 149.6, 142.0, 138.0, 135.7, 134.1, 133.9, 129.7, 129.4, 128.3, 127.4, 
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(3.33a). Off-white solid; yield 58%. 1H NMR (500 MHz, DMSO-d6) δ 13.22 (s, 1H), 8.10 
(d, J = 1.0 Hz, 1H), 7.93 (t, J = 1.6 Hz, 1H), 7.81 (d, J = 8.7 Hz, 1H), 7.72 – 7.66 (m, 2H), 
7.58 (t, J = 2.1 Hz, 1H), 7.55 – 7.44 (m, 3H), 7.41 (dd, J = 2.4, 1.3 Hz, 1H), 7.27 – 7.15 
(m, 5H), 6.95 (dd, J = 8.7, 2.1 Hz, 1H), 5.58 (s, 2H). 13C NMR (126 MHz, DMSO) δ 166.9, 
158.5, 155.2, 141.7, 140.5, 137.8, 133.9, 133.6, 129.5, 129.1, 128.9, 127.9, 123.2, 122.6, 
121.3, 121.1, 117.6, 114.8, 100.2, 52.2. MS (ESI) m/z = 455.0 [M+H]+. 
 
5-((1-Benzyl-3-methyl-1H-indazol-6-yl)oxy)-4'-chloro-[1,1'-biphenyl]-3-
carboxylic acid (3.33b). Off-white solid; yield 60%. 1H NMR (500 MHz, Chloroform-d) 
δ 8.03 (t, J = 1.6 Hz, 1H), 7.66 (dd, J = 2.4, 1.4 Hz, 1H), 7.64 (d, J = 8.7 Hz, 1H), 7.49 – 
7.46 (m, 2H), 7.42 – 7.38 (m, 3H), 7.25 – 7.12 (m, 5H), 6.89 (dd, J = 8.7, 2.0 Hz, 1H), 6.86 
(d, J = 1.9 Hz, 1H), 5.45 (s, 2H), 2.59 (s, 3H). 13C NMR (125 MHz, CDCl3) δ ppm 170.0, 
158.3, 156.1, 142.4, 142.4, 141.4, 137.9, 136.9, 134.6, 132.0, 129.4, 128.9, 128.6, 127.9, 
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carboxylic acid (3.29). Off-white solid; yield 67%.  1H NMR (500 MHz, DMSO-d6) δ 
7.93 (d, J = 1.7 Hz, 1H), 7.73 – 7.66 (m, 2H), 7.55 (d, J = 2.1 Hz, 1H), 7.52 (d, J = 8.2 Hz, 
3H), 7.36 (q, J = 2.4, 1.9 Hz, 4H), 7.26 (dt, J = 20.0, 7.4 Hz, 5H), 5.60 (s, 2H). 13C NMR 
(126 MHz, DMSO) δ 167.1, 158.9, 153.6, 141.9, 138.0, 136.0, 134.1, 134.0, 133.9, 129.7, 
129.4, 129.4, 129.4, 128.9, 128.5, 122.8, 121.1, 117.6, 49.5. MS (ESI) m/z = 455.5 [M+H]+. 
 
5-((1-Benzyl-2-methyl-1H-benzo[d]imidazol-6-yl)oxy)-4'-chloro-[1,1'-
biphenyl]-3-carboxylic acid (3.36). Off-white solid; yield 52%. 1H NMR (500 MHz, 
DMSO-d6) δ 7.94 (dt, J = 2.9, 1.4 Hz, 1H), 7.84 (d, J = 9.0 Hz, 1H), 7.69 (dd, J = 8.5, 2.5 
Hz, 2H), 7.65 (d, J = 3.1 Hz, 1H), 7.57 (qd, J = 2.7, 1.8, 1.2 Hz, 1H), 7.52 (dd, J = 8.6, 2.5 
Hz, 2H), 7.36 (dp, J = 2.4, 1.2 Hz, 1H), 7.35 – 7.22 (m, 6H), 5.64 (d, J = 2.4 Hz, 2H), 2.81 
(d, J = 2.4 Hz, 3H). 13C NMR (126 MHz, DMSO) δ 167.1, 158.7, 154.1, 142.0, 137.9, 
135.1, 134.2, 133.9, 129.7, 129.5, 129.4, 128.9, 128.0, 123.0, 121.3, 118.9, 117.7, 116.9, 
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104.4, 48.2, 12.8. MS (ESI) m/z = 469.4 [M+H]+. 
 
3-((1-(tert-Butoxycarbonyl)-1H-indol-6-yl)oxy)benzoic acid (3.48). White solid; 
yield 63%. 1H NMR (500 MHz, Chloroform-d) δ 11.47 (s, 1H), 7.82 (dt, J = 7.8, 1.2 Hz, 
1H), 7.74 – 7.70 (m, 1H), 7.59 (d, J = 3.7 Hz, 1H), 7.53 (d, J = 8.4 Hz, 1H), 7.42 (t, J = 7.9 
Hz, 1H), 7.32 – 7.27 (m, 1H), 6.99 (dd, J = 8.4, 2.2 Hz, 1H), 6.56 (dd, J = 3.7, 0.9 Hz, 1H), 
1.60 (s, 9H). 13C NMR (126 MHz, CDCl3) δ 171.9, 158.7, 154.0, 149.8, 131.2, 130.0, 




(3.32). To a stirred solution of 150 mg 5-((1-benzyl-1H-benzo[d]imidazol-6-yl)oxy)-4'-
chloro-[1,1'-biphenyl]-3-carboxylic acid (0.33 mmol, 1eq) in 2 mL DMSO, was added 296 
mg potassium tert-butyl oxide (2.638 mmol, 8 eq) in small portions. Oxygen (or air) is 
bubbled to the solution through a needle. Upon completion (monitored by TLC, approx. 20 
min), the reaction mixture was poured to 20 mL ice cooled 1 M HCl aqueous solution. The 
resulting milky solution was further stirred in ice bath for 10 min allowing full 
precipitation. The off-white solid was filtered and dried in oven (120˚C) for 1 h to afford 
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the title compound as light brown solid; yield 85%. 1H NMR (500 MHz, DMSO-d6) δ 13.16 
(s, 1H), 8.40 (s, 1H), 7.87 (s, 1H), 7.70 (d, J = 8.0 Hz, 2H), 7.56 (s, 1H), 7.50 (d, J = 7.8 
Hz, 2H), 7.34 (d, J = 12.5 Hz, 2H), 7.05 (d, J = 7.3 Hz, 1H). 13C NMR (126 MHz, DMSO) 
δ 166.9, 159.6, 151.5, 141.5, 137.9, 133.7, 133.5, 129.5, 129.1, 122.0, 120.5, 116.7, 116.0. 
MS (ESI) m/z = 365.3 [M+H]+. 
Oxidative debenzylation for the synthesis of 3.34a-b and 3.37. The procedure 
was adopted from the synthesis of 3.32. Starting materials decomposed rapidly under room 
temperature. Therefore a mixture of solvents was used (THF : DMSO = 1:1) to allow the 
reactions to run at 10˚C. The reactions showed no further conversion after 30 min. A 
mixture of product and starting material was isolated and was used without further 
purification. 
General procedure for peptide coupling:  At 0 ˚C, to a suspension of carboxylic 
acid (1 equiv), amine (HCl salt, 1 equiv), EDC•HCl (1.2 equiv), and HOAt (1 equiv) in 
anhydrous dichloromethane was added triethylamine (2.5 equiv) dropwise.  A clear yellow 
solution was formed.  The reaction was kept at 0 ˚C for 4–6 h until TLC showed no starting 
material left.  The reaction was concentrated under reduced pressure.  Residue was broken 
up in ethyl acetate and ice-cold 2 M HCl (aq).  The organic layer was washed with equal 
volume of saturated NaHCO3 (aq) and brine.  The organic layer was dried over Na2SO4 
and then evaporated under reduced pressure.  Column chromatography was used to purify 




(S),-5-tert-Butyl 1-methyl 2-((S),-4-(tert-butoxy),-2-(5- ((1-(tert-
butoxycarbonyl),-1H-indol-6-yl),oxy),-4'- chloro-[1,1'-biphenyl]-3-ylcarboxamido),-
4- oxobutanamido),pentanedioate (3.11). Colorless syrup, yield, 90%. 1H NMR (500 
MHz, DMSO) δ ppm 7.87 (br, 1H), 7.69 (d, 1H, J = 1.5 Hz), 7.63 (d, 1H, J = 7.5 Hz), 7.56 
(s, 1H), 7.52 (dd, 1H, J = 9.0 Hz, J = 3 Hz), 7.48 (m, 2H), 7.45 (s, 1H), 7.43 (s, 1H), 7.37 
(m, 2H), 7.32 (s, 1H), 6.99 (td, 1H, J = 8.0 Hz, J = 2.5 Hz), 6.54 (d, 1H, J = 3.0 Hz), 4.98 
(m, 1H), 4.55 (m, 1H), 3.71 (s, 3H), 3.00 (dd, 1H, J = 17.0 Hz, J = 4.0 Hz), 2.65 (dd, 1H, 
J = 17.3 Hz J = 7.3 Hz), 2.28 (m, 2H), 2.13 (m, 1H), 1.96 (m, 1H), 1.56 (s, 9H), 1.43 (s, 
9H), 1.34 (s, 9H). 13C NMR (125 MHz, DMSO) δ ppm 172.2, 172.0, 171.9, 170.8, 166.6, 
159.4, 153.8, 148.7, 142.4, 138.3, 136.2, 134.4, 129.3, 128.7, 127.4, 126.4, 122.1, 120.2, 
120.0, 116.1, 115.7, 107.3, 107.2, 84.2, 82.3, 81.0, 52.7, 52.3, 49.8, 37.3, 31.5, 28.3, 28.2, 






Colorless syrup; yield 40%. 1H NMR (500 MHz, Chloroform-d) δ 8.03 (s, 1H), 7.83 (d, J 
= 7.7 Hz, 1H), 7.77 (t, J = 1.6 Hz, 1H), 7.72 (d, J = 8.7 Hz, 1H), 7.52 – 7.47 (m, 2H), 7.45 
(d, J = 7.8 Hz, 1H), 7.41 – 7.37 (m, 2H), 7.04 (d, J = 2.0 Hz, 1H), 6.97 (dd, J = 8.7, 2.0 Hz, 
1H), 5.00 (td, J = 7.4, 4.1 Hz, 1H), 4.52 (td, J = 7.9, 5.2 Hz, 1H), 3.72 (s, 3H), 2.98 (dd, J 
= 17.1, 4.1 Hz, 1H), 2.66 (dd, J = 17.1, 7.1 Hz, 1H), 2.34 – 2.20 (m, 2H), 2.18 – 2.09 (m, 
1H), 1.99 – 1.87 (m, 1H), 1.43 (s, 9H), 1.38 (s, 9H). 13C NMR (126 MHz, CDCl3) δ 172.2, 
172.0, 171.9, 170.9, 166.5, 158.1, 156.7, 142.7, 138.0, 136.3, 134.6, 129.3, 128.6, 121.1, 
121.0, 116.9, 115.1, 95.0, 82.4, 81.2, 60.6, 52.7, 52.2, 49.9, 37.3, 31.5, 28.2, 28.2, 27.3, 




(3.35b). Colorless syrup; yield 34%. 1H NMR (500 MHz, CDCl3) δ ppm 7.82 (d, J=7.7 Hz, 
1H) 7.76 (t, J=1.4 Hz, 1H) 7.62 (d, J=8.7 Hz, 1H) 7.49 (m, 3H) 7.44 (d, J=7.7 Hz, 1H) 7.38 
(d, J=8.5 Hz, 2H) 7.36 (m, 1H) 6.98 (d, J=1.9 Hz, 1H) 6.92 (dd, J=1.9 Hz, J=8.7 Hz, 1H) 
5.00 (dq, J=4.4 Hz, J=7.3 Hz, 1H) 4.54 (m, 1H) 3.71 (s, 3H) 2.98 (dd, J=4.1 Hz, J=17.1 
Hz, 1H) 2.66 (dd, J=7.2 Hz, J=17.1 Hz, 1H) 2.56 (s, 3H) 2.26 (m, 2H) 2.13 (m, 1H) 1.94 
(m, 1H) 1.43 (s, 9H) 1.38 (s, 9H). 13C NMR (125 MHz, CDCl3) δ ppm 172.2, 172.0, 171.9, 
170.9, 166.5, 158.2, 156.8, 142.7, 138.0, 136.3, 134.6, 129.3, 128.6, 122.1, 121.0, 120.7, 
116.8, 114.3, 99.0, 82.4, 81.1, 52.7, 52.2, 49.9, 37.3, 31.5, 28.2, 27.3, 14.4, 12.0. MS (ESI) 
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(3.30). Colorless syrup; yield 62%. 1H NMR (500 MHz, Chloroform-d) δ 8.14 (s, 1H), 7.70 
(dt, J = 3.2, 1.6 Hz, 1H), 7.66 (dd, J = 7.7, 4.6 Hz, 1H), 7.49 – 7.39 (m, 3H), 7.39 – 7.34 
(m, 2H), 7.31 – 7.24 (m, 3H), 7.21 (ddd, J = 4.0, 2.3, 1.6 Hz, 1H), 7.19 – 7.15 (m, 2H), 
7.05 (dd, J = 8.7, 2.2 Hz, 1H), 7.00 (s, 1H), 5.32 (s, 2H), 4.98 (td, J = 7.3, 4.0 Hz, 1H), 
4.55 (m, 1H), 3.72 (d, J = 1.3 Hz, 3H), 3.01 (dd, J = 17.1, 3.9 Hz, 1H), 2.66 (dd, J = 17.2, 
7.3 Hz, 1H), 2.36 – 2.21 (m, 2H), 2.18 – 2.09 (m, 1H), 2.00 – 1.89 (m, 1H), 1.44 (s, 9H), 
1.37 (s, 9H). 13C NMR (126 MHz, CDCl3) δ 172.1, 172.0, 171.9, 170.8, 166.5, 159.1, 
153.0, 142.5, 138.1, 138.1, 136.4, 134.9, 134.5, 129.4, 129.3, 128.7, 128.6, 128.6, 127.5, 
127.5, 121.3, 120.4, 119.7, 116.1, 116.0, 101.6, 82.4, 82.3, 81.1, 52.7, 52.7, 52.3, 52.2, 






Colorless syrup; yield 27%. 1H NMR (500 MHz, Chloroform-d) δ 8.05 (s, 1H), 7.84 (d, J 
= 7.8 Hz, 1H), 7.66 (q, J = 1.7 Hz, 1H), 7.60 (d, J = 8.5 Hz, 1H), 7.51 (d, J = 8.0 Hz, 1H), 
7.45 – 7.38 (m, 3H), 7.36 – 7.33 (m, 2H), 7.29 – 7.24 (m, 1H), 7.20 (s, 1H), 6.99 (dd, J = 
8.8, 2.2 Hz, 1H), 4.99 (td, J = 7.3, 4.3 Hz, 1H), 4.52 (ddd, J = 13.0, 9.2, 5.3 Hz, 1H), 3.69 
(s, 3H), 2.97 (dd, J = 17.2, 4.1 Hz, 1H), 2.67 (dd, J = 17.1, 7.1 Hz, 1H), 2.34 – 2.21 (m, 
2H), 2.16 – 2.07 (m, 1H), 1.93 (ddd, J = 12.3, 8.1, 6.2 Hz, 1H), 1.41 (s, 9H), 1.36 (s, 9H). 
13C NMR (126 MHz, CDCl3) δ 172.3, 172.2, 172.1, 172.0, 171.7, 170.9, 166.9, 159.5, 
152.3, 142.5, 142.4, 141.8, 138.1, 136.1, 134.4, 129.3, 128.6, 120.1, 119.9, 116.1, 115.6, 




glutamate (3.38b). Colorless syrup; yield 32%. 1H NMR (300 MHz, CDCl3) δ ppm 7.89 
(d, J=7.7 Hz, 1H) 7.67 (t, J=1.4 Hz, 1H) 7.46 (m, 4H) 7.37 (m, 3H) 7.28 (m, 1H) 7.12 (d, 
J=1.9 Hz, 1H) 6.92 (dd, J=2.2 Hz, J=8.6 Hz, 1H) 4.98 (dt, J=4.3 Hz, J=7.4 Hz, 1H) 4.52 
(dt, J=4.8 Hz, J=7.9 Hz, 1H) 3.71 (s, 3H) 2.97 (dd, J=4.1 Hz, J=17.3 Hz, 1H) 2.66 (dd, 
J=7.0 Hz, J=16.8 Hz, 1H) 2.57 (s, 3H) 2.27 (m, 2H) 2.15 (m, 1H) 1.94 (ddd, J=6.1 Hz, 
J=7.9 Hz, J=14.3 Hz, 1H) 1.42 (s, 9H) 1.37 (s, 9H). 13C NMR (75 MHz, CDCl3) δ ppm 
172.3, 172.0, 171.8, 170.9, 166.9, 159.8, 152.1, 141.6, 142.5, 138.2, 135.9, 134.4, 129.3, 
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128.6, 119.9, 119.8, 115.6, 115.1, 98.8, 82.4, 81.2, 52.7, 52.3, 49.9, 37.2, 31.5, 29.9, 28.2, 




oxobutanoyl)-L-glutamate (3.42). Colorless syrup. 53%. 1H NMR (500 MHz, 
Chloroform-d) δ 8.54 (ddd, J = 4.9, 1.8, 0.9 Hz, 1H), 7.77 (s, 1H), 7.74 (d, J = 8.7 Hz, 1H), 
7.70 (t, J = 1.6 Hz, 1H), 7.67 (d, J = 7.6 Hz, 1H), 7.51 – 7.42 (m, 5H), 7.41 – 7.36 (m, 2H), 
7.10 (ddd, J = 7.6, 4.9, 1.1 Hz, 1H), 7.07 (d, J = 2.3 Hz, 1H), 7.01 (dd, J = 8.7, 2.3 Hz, 1H), 
6.87 (d, J = 7.8 Hz, 1H), 4.98 (td, J = 7.4, 3.9 Hz, 1H), 4.60 (t, J = 6.8 Hz, 2H), 4.55 (td, J 
= 7.9, 5.1 Hz, 1H), 3.72 (s, 3H), 3.28 (t, J = 6.7 Hz, 2H), 3.00 (dd, J = 17.2, 3.9 Hz, 1H), 
2.66 (dd, J = 17.2, 7.3 Hz, 1H), 2.37 – 2.19 (m, 2H), 2.14 (dtd, J = 14.9, 7.5, 5.1 Hz, 1H), 
1.94 (dtd, J = 14.3, 8.1, 6.3 Hz, 1H), 1.44 (s, 9H), 1.37 (s, 9H). 13C NMR (126 MHz, CDCl3) 
δ 172.1, 172.0, 171.9, 170.8, 166.6, 159.6, 157.1, 152.6, 149.7, 143.9, 142.5, 138.2, 137.2, 
137.1, 136.3, 134.5, 129.3, 128.6, 124.1, 124.1, 122.4, 121.5, 120.1, 119.6, 115.8, 115.6, 
101.3, 82.4, 81.1, 52.7, 52.7, 52.3, 49.8, 44.7, 38.2, 37.4, 31.5, 28.3, 28.2, 27.3. MS (ESI) 





carboxamido)-4-(tert-butoxy)-4-oxobutanoyl)-L-glutamate (3.46). Colorless syrup; 
yield 83%. 1H NMR (500 MHz, Chloroform-d) δ 7.92 (dt, J = 5.2, 1.6 Hz, 2H), 7.83 (t, J 
= 1.7 Hz, 1H), 7.64 (dd, J = 7.6, 4.3 Hz, 1H), 7.52 (dd, J = 8.5, 2.2 Hz, 2H), 7.48 (d, J = 
7.8 Hz, 1H), 7.46 – 7.40 (m, 2H), 5.00 (tt, J = 7.5, 3.9 Hz, 1H), 4.57 (tdd, J = 7.9, 5.0, 2.8 
Hz, 1H), 3.74 (s, 3H), 3.04 (dd, J = 17.2, 3.7 Hz, 1H), 2.67 (dd, J = 17.2, 7.4 Hz, 1H), 2.38 
– 2.21 (m, 2H), 2.17 (ddd, J = 14.6, 7.3, 5.1 Hz, 1H), 2.06 – 1.91 (m, 1H), 1.48 (s, 9H), 
1.38 (s, 9H). 13C NMR (126 MHz, CDCl3) δ 172.2, 171.9, 170.7, 170.4, 165.6, 142.7, 137.4, 
136.3, 134.9, 133.4, 129.4, 129.3, 129.2, 128.7, 124.8, 123.5, 82.5, 81.1, 52.7, 52.3, 49.8, 
37.1, 31.5, 28.2, 27.2. MS (ESI) m/z = 681.5 [M+H]+. 
 
5-(tert-Butyl) 1-methyl ((S)-4-(tert-butoxy)-2-(3-((1-(tert-butoxycarbonyl)-1H-
indol-6-yl)oxy)benzamido)-4-oxobutanoyl)-L-glutamate (3.49). Colorless syrup; yield 
86%. 1H NMR (500 MHz, Chloroform-d) δ 7.82 (s, 1H), 7.58 (dd, J = 12.0, 5.7 Hz, 2H), 
7.53 – 7.43 (m, 3H), 7.43 – 7.34 (m, 2H), 7.18 – 7.13 (m, 1H), 6.96 (dt, J = 8.5, 2.0 Hz, 
1H), 6.54 (d, J = 3.6 Hz, 1H), 4.96 (td, J = 7.2, 3.6 Hz, 1H), 4.60 – 4.51 (m, 1H), 3.72 (d, 
176 
 
J = 1.6 Hz, 3H), 3.01 (dd, J = 17.1, 3.8 Hz, 1H), 2.62 (dd, J = 17.1, 7.0 Hz, 1H), 2.36 – 
2.20 (m, 2H), 2.20 – 2.09 (m, 1H), 1.99 – 1.88 (m, 1H), 1.60 (s, 9H), 1.44 (s, 10H), 1.40 
(s, 9H). 13C NMR (126 MHz, CDCl3) δ 172.2, 172.0, 172.0, 170.8, 166.8, 153.9, 135.6, 
130.1, 127.3, 126.3, 122.0, 121.3, 107.3, 84.1, 82.3, 81.0, 52.7, 52.2, 49.7, 37.2, 31.5, 28.3, 
28.2, 27.3, 21.3. MS (ESI) m/z = 724.6 [M+H]+. 
General procedure for deprotection of tert-Butyl ester. To a stirred solution of 
tert-butyl ester in anhydrous dichloromethane (5 mL) at 0 ̊C was added trifluoroacetic acid 
(5 mL) dropwise. The reaction was kept at 0 ̊C for 4-6 h until TLC showed no starting 
material left. Anhydrous toluene (5 mL) was added to the reaction. The solvent was 
removed under reduced pressure to afford the product. 
 
(S)-4-((S)-2-(5-((1H-indol-6-yl)oxy)-4'-chloro-[1,1'-biphenyl]-3-
carboxamido)-3-carboxypropanamido)-5-methoxy-5-oxopentanoic acid (2.4). Off-
white to light pink solid; yield, 98%; m.p. decomposes at 126.1˚C. [α]D20 -10.4˚ (c 14.36, 
MeOH). 1H NMR (500 MHz, DMSO-d6) δ 12.18 (s, 2H), 11.01 (s, 1H), 8.62 (d, J = 7.7 
Hz, 1H), 8.30 (d, J = 7.6 Hz, 1H), 7.57 (d, J = 7.8 Hz, 1H), 7.54 (d, J = 8.5 Hz, 1H), 7.48 
– 7.45 (m, 1H), 7.42 (t, J = 7.9 Hz, 1H), 7.30 (t, J = 2.7 Hz, 1H), 7.11 (dd, J = 8.0, 2.5 Hz, 
1H), 7.00 (d, J = 2.1 Hz, 1H), 6.75 (dd, J = 8.6, 2.2 Hz, 1H), 6.41 (t, J = 2.4 Hz, 1H), 4.77 
(td, J = 8.5, 5.0 Hz, 1H), 4.25 (td, J = 8.4, 5.4 Hz, 1H), 3.59 (s, 3H), 2.72 (dd, J = 16.7, 4.8 
Hz, 1H), 2.65 (dd, J = 16.7, 9.2 Hz, 1H), 2.26 (t, J = 8.0 Hz, 3H), 1.94 (dq, J = 13.4, 7.4 
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Hz, 1H), 1.84 – 1.73 (m, 1H). 13C NMR (126 MHz, DMSO) δ 174.1, 172.5, 172.1, 171.5, 
166.0, 158.7, 151.6, 136.7, 136.2, 130.1, 129.3, 128.6, 126.1, 125.7, 125.0, 122.0, 121.5, 
121.0, 117.2, 112.5, 102.3, 101.6, 52.3, 51.8, 50.5, 36.4, 30.2, 26.4. HRMS (ESI) m/z calcd. 
for C31H28ClN3O9Na+ [M + Na]+ 644.1412, found 644.1417. 
 
(S)-4-((S)-2-(5-((1H-Indazol-6-yl)oxy)-4'-chloro-[1,1'-biphenyl]-3-
carboxamido)-3-carboxypropanamido)-5-methoxy-5-oxopentanoic acid (3.12). White 
solid; yield, 99%; m.p. decomposes at 124.5˚C. [α]D20 -21.0˚ (c 3.02, MeOH). 1H NMR 
(500 MHz, DMSO-d6) δ 12.23 (s, 2H) 8.82 (d, J = 7.8 Hz, 1H), 8.37 (d, J = 7.5 Hz, 1H), 
8.05 (s, 1H), 8.00 – 7.95 (m, 2H), 7.79 (d, J = 8.8 Hz, 1H), 7.79 – 7.73 (m, 3H), 7.58 – 7.53 
(m, 1H), 7.57 – 7.50 (m, 2H), 7.49 (dd, J = 2.4, 1.4 Hz, 1H), 7.09 – 7.04 (m, 1H), 6.92 (dd, 
J = 8.6, 2.1 Hz, 1H), 4.86 – 4.78 (m, 1H), 4.26 (dd, J = 13.3, 8.7 Hz, 1H), 3.59 (s, 3H), 
2.75 (dd, J = 16.7, 5.0 Hz, 1H), 2.64 (dd, J = 16.4, 8.9 Hz, 1H), 2.28 (t, J = 7.5 Hz, 2H), 
2.01 – 1.87 (m, 1H), 1.86 – 1.74 (m, 1H). 13C NMR (126 MHz, DMSO) δ 174.3, 172.7, 
172.3, 165.8, 158.1, 156.0, 141.5, 138.2, 137.3, 133.8, 129.7, 129.4, 122.9, 121.5, 120.5, 
117.7, 114.5, 99.3, 52.6, 52.1, 30.5, 26.6. HRMS (ESI) m/z calcd. for C30H27ClN4O9Na+ 





biphenyl]-3-carboxamido)propanamido)-5-methoxy-5-oxopentanoic acid. White 
solid; yield, 99%; m.p. decomposes at 113.1˚C. [α]D20 -15.6˚ (c 5.62, MeOH). 1H NMR 
(500 MHz, DMSO) δ ppm 12.25 (brs, 2H), 8.84 (d, J=8 Hz, 1H), 8.41 (d, J=7.5 Hz, 1H), 
7.97 (s, 1H), 7.74 (m, 3H), 7.53 (m, 3H), 7.47 (s, 1H), 6.99 (s, 1H), 6.87 (d, J=8.5 Hz, 1H), 
5.74 (s, 1H), 4.82 (m, 1H), 4.25 (m, 1H), 3.59 (s, 3H), 2.75 (dd, J=16.5 Hz, J=4.5 Hz, 1H), 
2.64 (dd, J=16.8 Hz, J=9.3 Hz, 1H), 2.46 (s, 3H), 2.28 (m, 2H), 1.95 (m, 1H), 1.79 (m, 
1H). 13C NMR (125 MHz, DMSO) δ ppm 174.4, 172.8, 172.4, 471.7, 165.8, 158.3, 156.0, 
142.2, 141.9, 141.5, 137.2, 137.2, 133.8, 129.7, 129.4, 122.4, 121.4, 120.4, 119.8, 117.6, 
113.6, 99.4, 55.6, 52.6, 52.1, 50.7, 36.7, 30.5, 28.3, 26.5, 12.3. HRMS (ESI) m/z calcd. for 




(3.31). Off-white solid; yield, 99%; m.p. decomposes at 65˚C. [α]D20 -16.8˚ (c 20.0, 
MeOH). 1H NMR (500 MHz, DMSO-d6) δ 9.21 (s, 1H), 8.84 (d, J = 7.5 Hz, 1H), 8.43 (d, 
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J = 7.6 Hz, 1H), 7.95 (d, J = 15.3 Hz, 1H), 7.82 (s, J = 8.8 Hz, 1H), 7.71 (d, J = 8.1 Hz, 
2H), 7.54 (m, 2H), 7.43 (d, J = 19.8 Hz, 1H), 7.36 (m, 2H), 7.32 – 7.09 (m, 3H), 5.59 (s, 
2H), 4.82 (m, 1H), 4.25 (m, 1H), 3.60 (s, 3H), 2.80 – 2.70 (m, 1H), 2.66 (dd, J = 16.7, 9.3 
Hz, 1H), 2.27 (m, 2H), 1.97 (m, 1H), 1.81 (m, 1H). 13C NMR (126 MHz, DMSO) δ 174.4, 
172.8, 172.3, 171.7, 168.5, 165.8, 158.6, 154.0, 144.3, 141.5, 138.2, 137.2, 135.9, 133.8, 
129.7, 129.6, 129.5, 129.5, 129.4, 128.9, 128.9, 128.6, 128.5, 126.0, 121.3, 119.7, 119.2, 
117.9, 117.0, 103.6, 52.6, 52.1, 50.8, 49.5, 36.7, 30.5, 26.5. HRMS (ESI) m/z calcd. for 
C37H33ClN4O9Na+ [M + Na]+ 735.1834, found 735.1831. 
 
(S)-4-((S)-2-(5-((1H-Benzo[d]imidazol-6-yl)oxy)-4'-chloro-[1,1'-biphenyl]-3-
carboxamido)-3-carboxypropanamido)-5-methoxy-5-oxopentanoic acid (3.14). White 
solid; yield, 99%; m.p. decomposes at 123.3˚C. [α]D20 -10.4˚ (c 8.94, MeOH). 1H NMR 
(500 MHz, DMSO-d6) δ 12.25 (s, 2H), 9.07 (s, 1H), 8.81 (dd, J = 12.0, 7.7 Hz, 1H), 8.36 
(d, J = 7.6 Hz, 1H), 7.97 (t, J = 1.5 Hz, 1H), 7.81 (d, J = 8.8 Hz, 1H), 7.76 (m, 2H), 7.58 – 
7.49 (m, 4H), 7.47 – 7.40 (m, 1H), 7.25 (dd, J = 8.8, 2.3 Hz, 1H), 4.87 – 4.76 (m, 1H), 4.25 
(td, J = 8.2, 5.0 Hz, 1H), 3.59 (s, 3H), 2.76 (dd, J = 16.7, 5.0 Hz, 1H), 2.65 (dd, J = 16.6, 
9.3 Hz, 1H), 2.30 – 2.19 (m, 2H), 1.95 (dq, J = 13.2, 7.2 Hz, 1H), 1.85 – 1.72 (m, 1H). 13C 
NMR (126 MHz, DMSO) δ 174.3, 174.3, 172.7, 172.3, 171.7, 165.9, 158.6, 154.2, 141.5, 
138.2, 137.3, 133.8, 129.7, 129.6, 129.4, 128.9, 121.3, 118.1, 117.0, 105.4, 52.6, 52.1, 50.8, 







acid (3.15). White solid; yield, 99%; m.p. decomposes at 133.3˚C. [α]D20 -16.6˚ (c 5.82, 
MeOH). 1H NMR (500 MHz, DMSO-d6) δ 12.21 (s, 2H) 8.81 (d, J = 7.8 Hz, 1H), 8.37 (d, 
J = 7.6 Hz, 1H), 7.94 (s, 1H), 7.77 – 7.73 (m, 2H), 7.71 (d, J = 8.9 Hz, 1H), 7.57 – 7.49 
(m, 3H), 7.43 – 7.35 (m, 2H), 7.26 – 7.09 (m, 1H), 4.87 – 4.76 (m, 1H), 4.32 – 4.16 (m, 
1H), 3.59 (s, 3H), 2.75 (dd, J = 16.7, 4.7 Hz, 1H), 2.67 (m, 4H), 2.29 – 2.23 (m, 2H), 2.01 
– 1.88 (m, 1H), 1.85 – 1.73 (m, 1H). 13C NMR (126 MHz, DMSO) δ 174.1, 172.5, 172.1, 
171.4, 165.6, 158.7, 152.8, 141.2, 138.0, 137.0, 133.6, 129.4, 129.3, 129.1, 128.6, 120.9, 
116.5, 52.3, 51.9, 50.5, 36.4, 30.2, 26.3, 13.6. HRMS (ESI) m/z calcd. for C31H30ClN4O9+ 




benzo[d]imidazol-1-yl)ethyl)pyridin-1-ium 2,2,2-trifluoroacetate (3.43). Light purple 
solid; yield, 99%; m.p. decomposes at 60.0˚C. [α]D20 -9.4˚ (c 29.22, MeOH). 1H NMR (500 
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MHz, DMSO-d6) δ 12.25 (s, 2H), 9.10 (s, 1H), 8.84 (d, J = 7.8 Hz, 1H), 8.45 (d, J = 5.1 
Hz, 1H), 8.39 (d, J = 7.5 Hz, 1H), 8.01 – 7.92 (m, 1H), 7.85 – 7.72 (m, 3H), 7.62 – 7.46 
(m, 3H), 7.40 (t, J = 2.1 Hz, 1H), 7.35 (d, J = 7.7 Hz, 2H), 7.30 – 7.08 (m, 4H), 4.87 – 4.80 
(m, 1H), 4.78 (t, J = 6.8 Hz, 2H), 4.25 (ddd, J = 9.3, 7.4, 5.1 Hz, 1H), 3.59 (d, J = 4.7 Hz, 
3H), 3.38 (t, J = 6.8 Hz, 2H), 2.76 (dd, J = 16.7, 4.8 Hz, 1H), 2.66 (dd, J = 16.6, 9.4 Hz, 
1H), 2.31 – 2.21 (m, 4H), 2.00 – 1.89 (m, 1H), 1.86 – 1.73 (m, 1H). 13C NMR (126 MHz, 
DMSO) δ 174.1, 172.5, 172.1, 171.5, 165.6, 158.8, 158.5, 156.7, 153.9, 148.1, 141.3, 138.0, 
137.8, 137.0, 133.6, 133.3, 129.4, 129.3, 129.2, 128.6, 125.7, 124.9, 123.1, 121.0, 119.6, 
118.3, 118.2, 116.7, 103.6, 52.3, 51.9, 50.6, 45.4, 36.4, 36.4, 30.2, 26.3, 21.5. HRMS (ESI) 
m/z calcd. for C37H35ClN5O9+ [M + H]+ 728.2123, found 728.2130. 
 
(S)-4-((S)-2-(5-Bromo-4'-chloro-[1,1'-biphenyl]-3-carboxamido)-3-
carboxypropanamido)-5-methoxy-5-oxopentanoic acid (3.44). White solid; yield, 99%; 
m.p. 187.8—188.3˚C. [α]D20 -12.3˚ (c 24.98, MeOH). 1H NMR (500 MHz, DMSO-d6) δ 
12.22 (s, 2H), 8.89 (d, J = 7.7 Hz, 1H), 8.40 (d, J = 7.6 Hz, 1H), 8.12 (t, J = 1.6 Hz, 1H), 
8.06 – 7.99 (m, 2H), 7.81 – 7.76 (m, 2H), 7.58 – 7.52 (m, 2H), 4.83 (ddd, J = 9.3, 7.8, 4.8 
Hz, 1H), 4.34 – 4.23 (m, 1H), 3.61 (s, 3H), 2.77 (dd, J = 16.6, 4.7 Hz, 1H), 2.66 (dd, J = 
16.6, 9.3 Hz, 1H), 2.29 (t, J = 7.5 Hz, 2H), 2.02 – 1.91 (m, 1H), 1.82 (ddd, J = 13.6, 9.3, 
6.9 Hz, 1H). 13C NMR (126 MHz, DMSO) δ 174.1, 172.5, 172.1, 171.3, 165.0, 141.5, 
137.2, 137.1, 133.8, 132.3, 129.9, 129.5, 129.3, 125.2, 122.8, 52.3, 51.9, 50.6, 36.4, 30.2, 
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methoxy-5-oxopentanoic acid (3.45). Light pink solid; yield, 99%; m.p. decomposes at 
90˚C. [α]D20 -22.6˚ (c 8.54, MeOH). 1H NMR (500 MHz, DMSO-d6) δ 12.18 (s, 2H), 11.01 
(s, 1H), 8.62 (d, J = 7.7 Hz, 1H), 8.30 (d, J = 7.6 Hz, 1H), 7.57 (d, J = 7.8 Hz, 1H), 7.54 
(d, J = 8.5 Hz, 1H), 7.48 – 7.45 (m, 1H), 7.42 (t, J = 7.9 Hz, 1H), 7.30 (t, J = 2.7 Hz, 1H), 
7.11 (dd, J = 8.0, 2.5 Hz, 1H), 7.00 (d, J = 2.1 Hz, 1H), 6.75 (dd, J = 8.6, 2.2 Hz, 1H), 6.41 
(t, J = 2.4 Hz, 1H), 4.77 (td, J = 8.5, 5.0 Hz, 1H), 4.25 (td, J = 8.4, 5.4 Hz, 1H), 3.59 (s, 
3H), 2.72 (dd, J = 16.7, 4.8 Hz, 1H), 2.65 (dd, J = 16.7, 9.2 Hz, 1H), 2.26 (t, J = 8.0 Hz, 
2H), 1.94 (dq, J = 13.4, 7.4 Hz, 1H), 1.85 – 1.73 (m, 1H). 13C NMR (126 MHz, DMSO) δ 
174.1, 172.5, 172.1, 171.5, 166.0, 158.7, 151.6, 136.7, 136.2, 130.1, 129.3, 128.6, 126.1, 
125.0, 122.0, 121.5, 121.0, 117.2, 112.5, 102.3, 101.6, 52.3, 51.8, 50.5, 36.4, 30.2, 26.4. 
HRMS (ESI) m/z calcd. for C25H26N3O9+ [M + H]+ 512.1669, found 512.1670. 
 
4-(4-Chlorophenyl)pyridine (3.51). To a sealed tube with a magnetic stirrer was 
added 4-chloropyridine hydrochloride (0.75 g, 5 mmol), (4-chlorophenyl)boronic acid 
(0.86 g, 5.5 mmol), Pd(PPh4)3 (0.288 g, 0.25 mmol) and K2CO3 (4.3 g, 25 mmol). 
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Anhydrous dioxane (25 mL) was added. The reaction was heated at 90˚C for 16 h. The 
reaction mixture was poured into 50 mL saturated NaHCO3 (aq) and extracted with ethyl 
acetate (50 mL × 2). The organic layers were combined and concentrated in vacuo, and the 
residue was purified by column chromatography (hexanes : ethyl acetate = 1:1) to yield the 
0.38 g title compound as a white solid (40%). 1H NMR (300 MHz, Chloroform-d) δ 8.70 
– 8.62 (m, 2H), 7.62 – 7.53 (m, 2H), 7.49 – 7.43 (m, 3H). 13C NMR (75 MHz, CDCl3) δ 
150.6, 136.8, 135.5, 129.6, 129.3, 128.5, 127.9, 127.7, 121.6. 
 
4-(4-Chlorophenyl)picolinonitrile (3.53). To a stirred solution of 4-(4-
chlorophenyl)pyridine 1-oxide (3.51) (0.28 g, 1.362 mmol) in 20 mL anhydrous 
dichloromethane at 0˚, was added TMSCN (204 μL, 1.634 mmol). Dimethylcarbamic 
chloride (150 μL, 1.634 mmol) was then added dropwise. The reaction was allowed to 
warm to room temperature and stirred overnight. Upon completion, the reaction was 
evaporated to dryness under reduced pressure, and the residue was purified by column 
chromatography (hexanes : ethyl acetate = 10:1) to afford 0.173 g product as light a yellow 
solid (59%). 1H NMR (500 MHz, Chloroform-d) δ 8.75 (d, J = 5.2 Hz, 1H), 7.87 (dd, J = 
1.8, 0.9 Hz, 1H), 7.68 (ddd, J = 5.2, 1.9, 0.8 Hz, 1H), 7.60 – 7.55 (m, 2H), 7.53 – 7.48 (m, 






4-(4-Chlorophenyl)-2-cyanopyridine 1-oxide (3.54). To a stirred solution of 4-
(4-chlorophenyl)picolinonitrile (3.53) (170 mg, 0.792 mmol) in 5 mL chloroform at room 
temperature, was added mCPBA solution (213 mg, 0.95 mmol in 20 mL chloroform) 
through an addition funnel over 4 h. The reaction was stirred at room temperature overnight. 
Upon completion, the reaction mixture was diluted by 20 mL dichloromethane and washed 
with saturated Na2CO3 (aq) (2 × 20 mL). The organic layer was concentrated in vacuo. The 
residue was purified by flash chromatography (MeOH : DCM = 1:20) to afford 110 mg 
product as a white solid (60%). 1H NMR (500 MHz, Chloroform-d) δ 8.31 (dd, J = 7.0, 0.6 
Hz, 1H), 7.85 (d, J = 2.8 Hz, 1H), 7.64 (dd, J = 7.0, 2.7 Hz, 1H), 7.54 – 7.47 (m, 4H). 13C 
NMR (126 MHz, CDCl3) δ 140.5, 136.7, 136.6, 133.2, 130.2, 128.7, 127.8, 126.7, 111.9. 
 
6-Chloro-4-(4-chlorophenyl)picolinonitrile (3.55). To a stirred solution of 5 mL 
POCl3 at room temperature was added 4-(4-chlorophenyl)-2-cyanopyridine 1-oxide (3.54) 
(150 mg, 0.65 mmol). The reaction was heated at 80˚C for 10 h. Upon completion, the 
reaction mixture was diluted in 20 ethyl acetate and 30 mL saturated NaHCO3 (aq) was 
added slowly while stirring to quench the unreacted POCl3. The mixture was extracted with 
20 mL ethyl acetate. The organic layer was washed with 30 mL brine and concentrated in 
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vacuo. The residue was purified by column chromatography (hexanes : ethyl acetate = 8:2) 
to afford 102 mg product as a white solid (63%).  1H NMR (500 MHz, Chloroform-d) δ 
7.80 (s, 1H), 7.71 (d, J = 1.8 Hz, 1H), 7.56 (d, J = 8.5 Hz, 2H), 7.54 – 7.48 (m, 2H). 13C 




(3.56). Procedure from Ullman coupling. White solid, 55%. 1H NMR (500 MHz, 
Chloroform-d) δ 7.67 (dt, J = 8.7, 0.9 Hz, 1H), 7.58 (t, J = 1.3 Hz, 1H), 7.55 – 7.48 (m, 
2H), 7.50 – 7.46 (m, 2H), 7.31 – 7.27 (m, 2H), 7.27 – 7.22 (m, 2H), 7.22 – 7.17 (m, 2H), 
7.11 – 7.06 (m, 1H), 6.92 (ddd, J = 8.6, 2.0, 1.1 Hz, 1H), 5.49 (s, 2H), 2.60 (d, J = 1.1 Hz, 
3H). 13C NMR (126 MHz, CDCl3) δ 164.9, 152.3, 152.3, 142.4, 141.2, 137.0, 136.9, 134.5, 




(3.57).  To a stirred solution of 6-((1-benzyl-3-methyl-1H-indazol-6-yl)oxy)-4-(4-
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chlorophenyl)picolinonitrile (3.56) (30 mg, 0.067 mmol) in MeOH (2 mL) and dioxane (2 
mL) was added 6 M NaOH aqueous solution (4 mL). The reaction was heated to reflux for 
2 h until no starting material was left. The reaction was cooled to room temperature and 
neutralized by adding 2 M HCl (aq). The mixture was extracted with ethyl acetate (2 × 20 
mL). The organic layers were combined, washed with brine (40 mL) and dried over Na2SO4. 
The solvent was evaporated in vacuo to yield 30 mg product, which was used without 
further purification (96%). 1H NMR (500 MHz, DMSO-d6) δ 12.84 (s, 2H), 8.06 (d, J = 
1.5 Hz, 1H), 7.90 – 7.84 (m, 2H), 7.72 (d, J = 8.6 Hz, 1H), 7.59 – 7.55 (m, 3H), 7.30 – 7.18 




General peptide coupling procedure. Colorless syrup, 58%. 1H NMR (500 MHz, 
Chloroform-d) δ 8.54 (d, J = 8.4 Hz, 1H), 8.14 (d, J = 1.5 Hz, 1H), 7.69 (d, J = 8.6 Hz, 
1H), 7.56 (d, J = 8.3 Hz, 2H), 7.45 (d, J = 8.5 Hz, 2H), 7.31 – 7.13 (m, 7H), 7.08 (d, J = 
1.9 Hz, 1H), 7.00 (dd, J = 8.7, 1.9 Hz, 1H), 5.49 (s, 2H), 4.95 – 4.87 (m, 1H), 4.53 (td, J = 
7.7, 5.2 Hz, 1H), 3.71 (s, 3H), 2.88 (dd, J = 17.1, 4.6 Hz, 1H), 2.62 (d, J = 6.7 Hz, 1H), 
2.59 (s, 3H), 2.36 – 2.18 (m, 2H), 2.11 (m, 1H), 1.89 (tt, J = 14.6, 7.0 Hz, 1H), 1.37 (s, 9H), 
1.34 (s, 9H). 13C NMR (126 MHz, CDCl3) δ 172.1, 172.1, 170.8, 170.4, 164.1, 163.5, 153.0, 
152.6, 148.2, 142.3, 141.3, 137.1, 136.3, 135.7, 129.7, 128.9, 128.6, 127.9, 127.4, 121.9, 
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121.6, 116.0, 114.9, 111.9, 100.9, 99.9, 81.9, 80.9, 52.9, 52.6, 52.1, 49.6, 37.1, 31.4, 29.9, 




acid (3.59). General procedure for tert-butyl ester deprotection. White solid; yield, 99%; 
m.p. decomposes at 85.2˚C. [α]D20 -4.8˚ (c 6.98, MeOH). 1H NMR (500 MHz, DMSO-d6) 
δ 12.15 (s, 2H), 8.55 (d, J = 8.4 Hz, 1H), 8.37 (d, J = 7.6 Hz, 1H), 8.05 (t, J = 1.2 Hz, 1H), 
7.77 (dd, J = 12.1, 8.5 Hz, 3H), 7.58 – 7.51 (m, 3H), 7.35 (d, J = 1.3 Hz, 1H), 7.25 – 7.14 
(m, 5H), 7.01 (dt, J = 8.3, 1.3 Hz, 1H), 5.50 (s, 2H), 4.80 (q, J = 6.7 Hz, 1H), 4.27 (q, J = 
7.5 Hz, 1H), 3.59 (d, J = 1.0 Hz, 3H), 2.71 (d, J = 6.2 Hz, 2H), 2.51 (s, 3H, with DMSO), 
2.26 (t, J = 7.6 Hz, 2H), 1.96 (dt, J = 13.0, 6.4 Hz, 1H), 1.79 (dq, J = 15.1, 7.8 Hz, 1H). 
13C NMR (126 MHz, DMSO) δ 174.1, 172.3, 172.1, 170.7, 163.3, 163.3, 153.3, 151.9, 
149.4, 141.7, 141.3, 138.1, 135.5, 135.3, 129.7, 129.4, 128.9, 127.8, 127.8, 122.3, 121.0, 
115.6, 114.4, 111.6, 100.8, 52.3, 51.9, 51.8, 49.9, 31.1, 30.2, 26.4, 12.1. HRMS (ESI) m/z 
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